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Background. Infectious diseases societies recommend that hospitals risk-
adjust their antimicrobial use before comparing it to their peers, a process 
called benchmarking. The purpose of this investigation is to apply and 
compare 3 risk-adjustment procedures for benchmarking hospital 
antibacterial consumption (AbC). Two standardization of rates procedures, 
  
direct and indirect standardization, are compared with one another as well 
as with regression modeling.  
Methods. Total aggregate adult AbC for 52 systemic antibacterial agents 
was measured in 70 hospitals that subscribed to the University 
HealthSystem Consortium Clinical Resource Manager database in 2009 and 
expressed as days of therapy (DOTs) per either 1000 patients days (PDs) or 
1000 discharges. The two AbC rates served the role of the outcome while 
several known risk factors for AbC served the role of potential predictor 
variables in the linear regression models. Selection criteria were applied to 
select a model that represented the first rate (Model I) and another that 
represented the second (Model II), respectively, and outliers were identified. 
Adult discharges in each hospital were then stratified into 35 clinical service 
lines based upon their Medicare Severity-Diagnosis Related Group (MS-
DRG) assignment. Direct and indirect standardization were applied to this 
set and the expected-to-observed (E/O) and observed-to-expected (O/E) 
ratios, respectively, for AbC were determined. The agreement of the different 
methods in ranking hospitals according to their risk-adjusted rates and in 
identifying outliers was determined. 
Results. The mean total AbC rate was 821.2 DOTs/1000 PDs or 4487.6 
DOTs/1000 discharges. Model I explained 31% of the variability in AbC 
  
measured in DOTs/1000 PDs while Model II explained 64% of the variability 
in AbC measured in DOTs/1000 discharges. The E/O ratios ranged from 
0.76-1.44 while the O/E ratios ranged from 0.73-1.45. The comparison of 
the risk-adjustment methods revealed a very good agreement between the 
two regression models as well as between the two standardization methods 
whereas the agreement of Model II with either standardization method was 
moderate. 
 
Conclusion. Standardization provides a viable alternative to regression for 
benchmarking hospital AbC rates. Direct standardization appears to be 
especially useful for benchmarking purposes since it allows the direct 
comparison of risk-adjusted rates.  
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Chapter I 
Introduction 
 
 
 
1.1 Brief Overview 
The Infectious Diseases Society of America (IDSA) and Society for Healthcare 
Epidemiology of America (SHEA) guidelines for developing antimicrobial 
stewardship programs (ASPs) recommend that hospitals measure their 
antimicrobial use and compare it, after risk-adjustment, with that of other 
institutions [1,2]. This process of interinstitutional comparison for the 
purpose of quality improvement is known as “benchmarking”. More 
specifically, interinstitutional comparison is known as “external 
benchmarking” while intrainstitutional comparison is known as “internal 
benchmarking”.   
The need for hospitals to measure and monitor their antimicrobial use 
is becoming an increasingly pressing issue given the ever-increasing 
antimicrobial resistance rates. Antimicrobial use increases the rate by 
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which resistant microorganisms emerge by exerting selective pressure on 
these microorganisms [3,4]. Many hospitals have adopted ASPs as a means 
of overseeing the quality and quantity of their antimicrobial prescribing. In 
particular, ASPs strive to identify and minimize inappropriate antimicrobial 
therapy. A validated benchmarking model for antimicrobial use should be 
another useful tool for hospitals to assess their antimicrobial consumption 
as it will help them determine whether this consumption is consistent with 
their “risk” profile. Such benchmarks can work in tandem with ASPs to help 
guide and improve antimicrobial prescribing practices.   
In the absence of standardized national antimicrobial use rates, 
hospitals often evaluate the performance of their ASPs by comparing their 
antimicrobial use internally, before and after the adoption of such 
programs. Such internal benchmarking, while undoubtedly useful, does not 
provide hospitals with a tool to compare their antimicrobial use and ASPs 
with their counterparts that set the standard in these areas. This makes 
setting target goals for these quality control measures an often obscure 
proposition. By comparing their risk-adjusted antimicrobial use with their 
peers, hospitals may be able to make a more informative assessment of their 
antimicrobial use and the effectiveness of their ASPs. However, the direct 
comparison of antimicrobial use between hospitals may be flawed due to 
differences in characteristics pertaining to the hospitals themselves as well 
as the patients attending them. Accordingly, in order for this comparison to 
be meaningful, it is necessary to take these differences between hospitals 
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into account by risk-adjusting their antimicrobial use before actually 
comparing it. 
1.2 Study Rationale  
There are no details in the previously mentioned IDSA/SHEA guidelines, 
and very little guidance elsewhere, on how to risk-adjust antimicrobial use 
within or across hospitals. Regression modeling has been the standard 
methodology employed to risk-adjust and compare antimicrobial use in 
hospitals [5-7] with indirect standardization recently emerging as a viable 
alternative [8,9]. However, direct standardization has not been previously 
used for this purpose. The current investigation will apply, compare and 
assess the usefulness of direct and indirect standardization in risk-
adjusting antibacterial consumption (AbC) in hospitals. This investigation 
will also risk-adjust AbC in hospitals using regression modeling and will 
compare this strategy with the standardization procedures.    
This study assumes that the variability in antimicrobial use can be 
modeled and predicted.  While antimicrobial use is not an outcome from a 
clinical perspective, but rather a resource utilization measure, it can be 
modeled and benchmarked in a similar manner to clinical outcomes (e.g., 
infection rates). Differences in antimicrobial use between hospitals can be 
attributed to modifiable (e.g., effectiveness of ASPs) and non-modifiable 
factors (e.g., severity of illness (SOI) and type of hospital); and by having a 
tool that adjusts for the latter, hospitals can compare their antimicrobial 
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use with that of peer institutions knowing that they can focus their efforts 
on the modifiable factors when evaluating their antimicrobial use. 
1.3 Specific Aims 
The current study has the following specific aims: 
1. Apply direct and indirect standardization procedures to risk-adjust 
AbC in hospitals. 
2. Develop and validate regression models for risk-adjusting AbC in 
hospitals using two different AbC rates. 
3. Compare the two standardization methods with one another and 
the two regression models with one another as well as with the 
standardization procedures with respect to their ranking of 
hospitals based on their risk-adjusted rates and their agreement in 
identifying outliers. 
4. Apply direct and indirect standardization to risk-adjust and 
benchmark the components of AbC at the hospital level including 
the proportion of discharges receiving antibacterials and proxy 
measures for the length of therapy and the average number of 
administered antibacterials.  
5. Compare interhospital AbC and its components within specific 
strata that represent patients with similar medical conditions.
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Chapter II 
Background 
 
 
 
2.1 Background on Benchmarking 
Benchmarking may be defined as the process by which an institution 
compares its services, products, or performance with those of its 
competitors or industry leaders; with the purpose of using this as a 
reference to identify best practices that can be transferred to its own 
organization [10,11]. 
Benchmarking was first introduced to the corporate world as a formal 
process by the Xerox Corporation in the 1980s as part of its revival plan 
after its market share began to plummet due to fierce competition from 
Japanese and US competitors [12]. The company closely studied the best 
practices within as well as outside its industry and was able to regain its 
competitive advantage by employing these practices to reduce the cost and 
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improve the quality of its products. By the mid-1990s, motivated by the 
Xerox success story, hundreds of companies around the globe adopted 
benchmarking and implemented it at their facilities.  It was not too long 
before health care institutions followed suit and started employing 
benchmarking tools to quality control measures such as comparing staff 
satisfaction [13], improving energy efficiency [14], and determining the 
appropriate staffing level [15,16].  
Benchmarking has also found applications in almost every medical 
specialty and for a variety of objectives. For instance, it has been used in 
cardiology to evaluate quality of care of patients following acute myocardial 
infarction [17] and to compare bypass surgery mortality rates [18]. In 
pulmonology, benchmarking has been used to determine best practices for 
managing asthma patients [19], to compare the efficiencies in the treatment 
of mechanically ventilated patients [20], and in psychiatry, to determine the 
effectiveness of psychotherapy in adult depression [21,22]. 
2.2 Benchmarking in Infectious Diseases 
In the field of infectious diseases (ID), benchmarking has been used to 
compare infection rates [23,24] as well as antimicrobial use in both 
hospitals [5,6,8,9,25-27] and long-term care facilities [28]. In the context of 
comparing antimicrobial use between hospitals, benchmarking may be 
defined as the process of interhospital comparison of antimicrobial use 
using a risk-adjustment method that accounts for differences between 
7 
 
hospitals in patient-mix, hospital characteristics and other non-modifiable 
factors so that this comparison is as fair and meaningful as possible. 
2.3 Measuring Antimicrobial Consumption 
A key element in the process of benchmarking antimicrobial use is finding a 
valid, stable, and preferably universal measure for quantifying antimicrobial 
drug use which is sensitive to differences in antimicrobial use across 
hospitals and countries [29]. The most commonly used metric for measuring 
antimicrobial drug use and the one that is promoted by the World Health 
Organization (WHO) is the defined daily dose (DDD). Antibacterials for 
systemic use fall under the J01 category of the Anatomical Therapeutic 
Chemical (ATC) classification system which, along with the DDD 
assignment, is updated annually by the WHO Collaborating Center for 
Drugs Statistics Methodology (currently in its 15th edition) [30]. 
The DDD assignment is based on the assumed average daily 
maintenance dose for the main indication of the drug in adults. The number 
of DDDs of an antimicrobial agent is normalized, to account for differences 
in hospitals census, by dividing it by a measure of hospital occupancy 
(usually the number of total patient-days (PDs) or admissions) to allow the 
comparison of antimicrobial use between different hospitals [29]. However, a 
major limitation of using the DDD metric for comparing antimicrobial use 
between hospitals is the fact that it may not reflect the dose that is actually 
administered to patients. Several studies have demonstrated that using 
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DDDs to measure and benchmark AMC suffers from serious shortcomings 
including that differences in DDDs reflect not only differences in AMC but 
also differences in the formulary composition between hospitals [31-34]. 
These studies proposed using alternative metrics to measure antimicrobial 
use such as the recommended daily dose (RDD), prescribed daily dose (PDD) 
and days of therapy (DOTs). The RDD and PDD may be appropriate for 
internal benchmarking but not for the comparison of antimicrobial use 
between hospitals and countries as they have the same limitations as the 
DDD metric [29]. On the other hand, the DOTs metric is not compromised 
by some of these limitations since it is stable and not affected by changes in 
DDD or PDD over time or across countries. Accordingly, and as concluded 
by Polk et al. [32], it can be argued that the DOTs metric is superior to DDD 
for measuring and comparing antimicrobial use between hospitals and 
countries.  
The DOT measure, however, has its own limitations. The DOT is 
insensitive to the dosage administered and it does not provide an accurate 
measurement of the duration of therapy [29]. One metric that does measure 
the duration of therapy and that has been used to measure antimicrobial 
use has been called “antibiotic days” [35] and “patient-days receiving 
antimicrobials” [36]. Recently, it has been also used to benchmark AbC in 
hospitals and has been called “length of therapy (LOT)” [9]. It represents the 
number of days a patient receives systemic antibacterial therapy irrespective 
of the number of different antibacterial agents, number of doses or dosage 
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administered. Obviously, LOT suffers from a number of limitations and 
probably should not be used as the sole measure of antimicrobial use. 
However, the information obtained from the LOT measure complements that 
obtained from DOT since they capture different aspects of antimicrobial use. 
Moreover, the DOT/LOT ratio may be regarded as a parameter that 
measures the average number of antibacterial agents administered, which 
provides yet another dimension that may be helpful in benchmarking 
antimicrobial use [29]. 
The debate surrounding the measurement of antimicrobial use is not 
confined to the numerator of the antimicrobial use rate. Several studies 
have also debated the denominator of the antimicrobial use rate 
[34,35,37,38]. The most commonly used measures in the denominator of 
antimicrobial use rates are the number of patient days and, to a lesser 
extent, the number of admissions. The total number of patient days is the 
product of the total number of admissions and the average LOS (also the 
sum of the individual LOS). Expressing antimicrobial use with the number 
of admissions in the denominator rather than number of patient days may 
provide a better correlation with antimicrobial resistance [37]. In addition, 
the two denominators were found to lead to different conclusions in two 
investigations of antibiotic use trends over time [34,38]. This discrepancy 
between the two denominators may extend to the interhospital comparison 
of antimicrobial use.  
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2.4 Severity of Illness and Case-mix Index  
 
Hospitals often justify their high antimicrobial use by contending that they 
attend to a patient population with a high SOI [7]. Critically ill patients 
usually require an aggressive antimicrobial therapy approach to manage 
their infections. Such patients often receive multiple antimicrobial agents at 
higher doses and for longer durations compared to patients whose illnesses 
are less severe [29].  Thus, adjusting for SOI is imperative if valid 
conclusions are to be drawn from comparing antimicrobial use across 
hospitals.  
Several scoring systems have been developed to classify patients 
according to their SOI, comorbidities and mortality risk [39-42]. However, 
these systems measure SOI at the patient level rather than the institutional 
level. One measure that is widely used as a surrogate marker of SOI at the 
institutional level is the case-mix index (CMI) [7]. The CMI is an economical 
surrogate marker that relates the average SOI of patients admitted to a 
particular hospital during a specific time frame to their resource utilization. 
It represents the average relative weight (RW) of diagnosis-related groups 
(DRGs) assigned to all inpatient cases in a hospital during a given time 
period [43]. The RW is a numerical figure assigned to each DRG reflecting 
the expected national average resource utilization of patients in that group 
relative to the national average resource utilization of all patients [44]. 
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The development of the DRG classification system started in the 
1960s by a research group at Yale University but its first widespread 
application was not until the late 1970s when the New Jersey State 
Department of Health used DRGs for hospital reimbursement [45]. In 1983, 
the Centers for Medicare and Medicaid Services (CMS; formerly the Health 
Care Financing Administration, HCFA) adopted an expanded and 
thoroughly revised version (CMS-DRGs) of the original DRGs as part of its 
inpatient prospective payment system (IPPS) which reimburses hospitals for 
providing inpatient care to Medicare beneficiaries [46]. However, it has been 
argued that the CMS-DRGs do not adequately adjust for SOI and this may 
lead to inequities in reimbursement especially for hospitals that treat sicker 
patients [47,48]. Moreover, this classification system was developed using 
data in which special patient populations such as neonates and    the SOI in 
such populations. CMS addressed some of these limitations by introducing 
a substantially revised DRG classification system in 2007 known as the 
Medicare Severity DRG (MS-DRG) which is currently in its 29th version [44]. 
Each patient is assigned to one of over 700 MS-DRGs based on the principal 
and secondary diagnoses, gender, procedures performed, the presence of co-
morbidity and/or complications and discharge status. While this revised 
version may outperform the CMS-DRG system by more accurately relating 
resource utilization of patients with their SOI, it still suffers from the same 
shortcoming of its predecessor in underrepresenting special patient 
populations.  
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Several proprietary DRG classification systems have been developed, 
of which the All Patient Refined DRG (APR-DRG) developed by 3M Health 
Information systems (Salt Lake City, Utah)  is the most widely used [49]. The 
APR-DRG system was developed in 1990 (current version is 29) and has SOI 
as well as risk of mortality components for all patient populations. It 
expands the basic DRG structure by adding four SOI and risk of mortality 
subclasses to each DRG that are measured on an ordinal scale (1–4) 
representing, respectively, minor, moderate, major or extreme SOI or risk of 
mortality. The APR-DRG methodology has been validated in large databases 
and has been found to have the best ability (highest R2) in predicting LOS 
for hip fracture [50] and pneumonia patients [51]. The history and evolution 
of DRGs are summarized in Figure 1.1.  
The CMI has been found to be significantly correlated with AbC across 
various units of a university hospital as well as across different acute care 
hospitals in Switzerland [7]. Additionally, a study of general and tertiary 
care hospitals in Greece and Cyprus demonstrated the importance of 
adjusting for the CMI when comparing infection rates across hospitals [23]. 
However, these studies used international versions of DRGs to calculate the 
CMI which are likely to vary from MS-DRG and the APR-DRG based CMIs. It 
is not known whether CMIs calculated based on different DRG classification 
systems vary substantially in their usefulness for benchmarking 
antimicrobial use.    
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CMS; Centers for Medicare and Medicaid Services; HCFA, Health Care Financing Administration; MS-DRGs, Medicare 
Severity-Diagnosis Related Groups 
 
Figure 2.1   History and evolution of Diagnosis Related Groups (DRGs) 
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2.5 Risk-adjustment and Patient Mix 
As previously mentioned, the comparison of crude antimicrobial use rates 
between hospitals may lead to erroneous conclusions. Differences in 
antimicrobial use between hospitals may stem from differences in hospital 
characteristics and in the characteristics and risk factors of patients 
attending them.  Risk adjustment is a statistical process used to remove or 
minimize the effect of confounding factors that differ among comparison 
groups.  
Hospital characteristics and patient mix are two important 
confounding factors that should be accounted for when comparing 
antimicrobial use between hospitals. Patient mix refers to the distribution of 
patients’ demographics, risk factors, and diagnoses. Certain patient 
subgroups (e.g., Surgical and febrile neutropenic patients) are more likely to 
receive prophylactic or empiric antimicrobial therapy than others (e.g., 
psychiatry patients) [52].  Such patients are also at a higher risk of 
acquiring healthcare-associated infections (HAIs) and, consequently, also 
more likely to receive definitive antimicrobial therapy.  
In addition to differences in patient-mix, differences in AMC between 
hospitals may be associated with differences in hospital characteristics. 
Hospital characteristics such as the size, location, teaching status, as well 
as the quality of care and reputation of hospitals have a direct influence on 
the patient mix of these hospitals. Hospitals offering comprehensive and 
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advanced services require expensive medical equipment and specialized 
personnel, and tend to attract patients with severe conditions and complex 
clinical profiles. However, in addition to their influence on patient mix, 
hospital characteristics may also influence other determinants of AMC such 
as antimicrobial resistance rates. Accordingly, it may be important to 
account for both differences in hospitals characteristics and differences in 
patient mix in order for the interhospital comparison of AMC to be more fair 
and accurate. It is important to mention that benchmarking involves 
accounting for factors that are beyond the control of hospitals (non-
modifiable factors) and should not include factors related to the quality of 
service provided by these hospitals (modifiable factors). Patient mix and 
hospital characteristics are such non-modifiable factors. 
Regression modeling is the most commonly used statistical method 
for risk-adjustment [53-55]. Multivariable regression models such as linear 
and logistic regression have found wide application in risk-adjustment in 
the medical literature and have been previously used to benchmark 
antimicrobial use [5,6,27]. The procedure of applying multivariable 
regression to benchmarking outcomes in hospitals requires -as a first step- 
determining the important risk-adjustment factors for the outcome of 
interest and using these factors to build the model. The next step involves 
using the estimated model to calculate –for each hospital- expected 
(predicted) values of the outcome that are risk-adjusted for the factors 
identified in the first step. The third step is to calculate the residuals 
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(differences between observed and expected values) and use them to 
determine the hospitals that have higher than expected AMC and the ones 
that have lower than expected AMC. The final step is to determine potential 
outliers and to rank the hospitals according to their performance.  
Another widely used statistical method for risk-adjustment is 
“standardization (of rates)”. It is based on the stratification of the 
confounding variable into sub-groups and then calculating a weighted 
average of the stratum-specific (sub-group) rates. Standardization of event 
rates has been used to compare hospital performance in various medical 
specialties [56-58]; and recently, to risk-adjust antimicrobial use in 
hospitals [8,9].  
The two main standardization procedures are direct and indirect 
standardization. Direct standardization applies the stratum specific rates 
(e.g., incidence rate, mortality rate, DOTs/1000 PDs, etc.) of each study 
population (e.g., study hospital) to the number of cases (or number of 
person-years, PDs, etc.) in the corresponding stratum in the reference 
(standard) population. An expected number of cases (or deaths, DOTs, etc.) 
is generated for each stratum. These stratum specific numbers are added to 
yield the total expected number which is used in the numerator of the 
directly standardized rate (DSR).  The denominator is the total number of 
individuals (or total number of person-years, total number of PDs) in the 
reference population. DSRs can then be compared for different populations 
using relative risks (RR) or attributable risk (AR) differences. In indirect 
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standardization, the roles of the study population and the reference 
population are reversed. That is, the stratum specific rates are now provided 
by the reference population while stratum sizes of the study population are 
used as weights. The rest of the procedure is similar to that of direct 
standardization except that the summary statistic that is usually reported 
in indirect standardization is the standardized mortality ratio (SMR) or the 
standardized incidence ratio (SIR).  
The main advantage of DSRs is that they can be directly compared 
across different populations or hospitals whereas indirectly standardized 
rates cannot (except in limited cases when certain conditions are met) [59]. 
Therefore, direct standardization may be the more appealing of the two 
procedures in benchmarking outcomes and quality of care across healthcare 
institutions.  
The application of direct (and indirect) standardization to 
benchmarking antimicrobial use in hospitals entails stratifying 
antimicrobial use by meaningful categories (sub-groups) of the risk-
adjustment factor (confounder). Accordingly, standardization of rates 
methods may be employed to risk-adjust antimicrobial use in hospitals for 
patient mix by stratifying antimicrobial use by some criteria that represent 
patient mix such as patient care areas or primary diagnosis (DRGs).                                                                                                                           
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2.6 The Role of Benchmarking In Identifying Inappropriate 
Antimicrobial Therapy  
 
The majority of investigations that studied the consequences of 
inappropriate antimicrobial therapy focused on the impact of inappropriate 
selection of initial therapy or the delay in the initiation of appropriate 
therapy on patient outcomes [60-64]. These studies concluded that, in 
addition to having detrimental impact on patient outcomes and mortality, 
inappropriate therapy may also increase the rate by which antimicrobial 
resistance emerges. In addition to improper selection of initial therapy and 
the delay in initiation of appropriate therapy, inappropriate antimicrobial 
therapy includes situations where antimicrobial therapy is administered 
without being indicated. Inappropriate antimicrobial therapy also 
encompasses, among others, situations where the dose, dosage form, 
duration of therapy, as well as route and frequency of administration are 
less than optimal.  
According to the Centers for Disease Control and Prevention (CDC), 
25%-45% of antibiotic use in hospitals is inappropriate [65]; while different 
studies in the United States and the United Kingdom indicated that this 
figure may be as high as 50% [66-70]. The concept behind risk-adjusting 
and benchmarking healthcare outcomes is to adjust for differences in 
patient mix and other non-modifiable factors so that the remaining 
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variability between institutions may be attributed to differences in the 
quality of care. This concept can be applied to benchmarking antimicrobial 
use such that differences between risk-adjusted antimicrobial use rates in 
hospitals may be attributed to differences in inappropriate antimicrobial 
therapy. From a benchmarking perspective, inappropriate therapy may be 
expressed in the components of antimicrobial use rates including LOT, 
proportion of patients receiving therapy and/or patients receiving 
combination therapy. The extent of inappropriate therapy may be 
considered as a marker for the quality and effectiveness of ASPs and, 
perhaps to a lesser extent, infection control programs.   
While it is fairly easy to measure LOT and the proportion of patients 
receiving combination therapy, measuring inappropriate antimicrobial 
therapy is a more complicated and laborious undertaking that requires 
access to patient-level data and drug utilization reviews (DURs). However, 
the goal of benchmarking antimicrobial use is not necessarily to accurately 
quantify inappropriate antimicrobial therapy, but rather to entertain the 
possibility that differences in adjusted antimicrobial use rates between 
hospitals may be attributed-at least partially-to differences in inappropriate 
antimicrobial therapy rates.  
A validated benchmarking model for antimicrobial use will serve as a 
tool for identifying hospitals with extremes in antimicrobial usage. It will 
allow hospitals with high or average antimicrobial use to compare their 
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consumption rates with those of hospitals whose consumption is relatively 
low, after adjusting for factors that predict use volume. This will hopefully 
motivate the former hospitals to scrutinize their antimicrobial therapy and 
perform DURs in order to facilitate the identification of areas of deficiency in 
their antimicrobial prescribing and management. These hospitals can then 
develop a homegrown strategic plan or adopt a “battle-tested” paradigm 
from one of their top performing peers to help optimize their antimicrobial 
therapy and curtail their inappropriate therapy.  
Finally, hospitals could conduct internal benchmarking to compare 
their antimicrobial use before and after the adoption of either the local or 
the imported remedial program. This will serve the purpose of determining 
whether the antimicrobial use target has been met, needs to be reset or 
whether the program needs to be modified. The amount of reduction in total 
and inappropriate antimicrobial use will ultimately depend on – assuming 
no change in patient mix and severity of illness- the effectiveness of the 
newly adopted or modified strategy, how well a hospital implements and 
adheres to the strategy and the hospital’s baseline consumption rate.  
2.7 Effectiveness of Strategies Used to Reduce Inappropriate 
Antimicrobial Therapy 
 
Most of the literature on the effectiveness of the different strategies to 
minimize inappropriate antimicrobial therapy comes from single-center 
studies. A French study reported that a single 1-hour educational session 
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delivered by an ID physician reduced the use of inappropriate empirical 
antibiotic therapy in patients with positive urine cultures by 17% compared 
to the control group [71]. Another study conducted in a single tertiary care 
teaching hospital in the United States reported a 20.6% decrease in 
inappropriate vancomycin prescriptions after implementing a persuasive 
strategy (e.g., education, reminders, etc.) to control vancomycin 
prescriptions [72]. Another study in a teaching hospital in the United States 
reported a 17% decrease (from 53% to 36%) in inappropriate dosing of 
cefazolin after employing a persuasive strategy to control cefazolin 
prescribing [73]. 
While persuasive strategies may only result in modest reductions in 
inappropriate antimicrobial therapy, restrictive strategies (e.g., formulary 
restriction, pre-authorization of prescriptions and automatic stop orders) 
may have a greater impact [74]. Having said that, even a reduction as small 
as 5% in inappropriate antimicrobial use may be substantial if coupled with 
a significant improvement in clinical or operational performance (e.g., 
mortality rates and length of stay), economical performance (e.g., direct and 
indirect cost savings resulting from reduced antimicrobial use), or 
resistance rates.  
The importance of keeping antimicrobial use in check cannot be 
overstated given the well-documented association between antimicrobial use 
and antimicrobial resistance [75-79]. Antimicrobial resistance is an 
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inevitable consequence of the selection pressure exerted by the use of 
antimicrobials. Thus, resistant microorganisms will evolve even with the 
most prudent use of antimicrobials. However, inappropriate antimicrobial 
use may increase the rate by which resistant organisms emerge and; 
consequently, the rate by which these antimicrobials become obsolete. This 
is especially alarming given the dearth of novel antimicrobials in the drug 
development pipeline [80,81]. Accordingly, it is crucial to use the current 
antimicrobials as wisely as possible in order to preserve their effectiveness 
for as long as possible.  
It is difficult to discern how much reduction in inappropriate 
antimicrobial use is needed to have a significant reduction (if any at all) in 
resistance rates since the literature on this issue is quite sparse. The vast 
majority of studies that investigated the effect of inappropriate antimicrobial 
therapy focused on its detrimental impact on mortality rates, LOS, and cost 
[61-64]. The few studies that explored the relationship between 
inappropriate antimicrobial therapy and antimicrobial resistance reported a 
significance decrease in ceftazidime-resistant Klebsiella and in infections 
caused by resistant Enterobacteriaceae when measures enforcing 
appropriate antimicrobial therapy were employed [82,83]. 
2.8 Literature on Benchmarking Antimicrobial Consumption 
Most of the data on antimicrobial use and its variability between different 
hospitals or countries comes from antimicrobial surveillance programs that 
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usually collect such data with that on infection rates in order to highlight 
the association between antimicrobial use and antimicrobial resistance 
[84,85]. Such surveillance programs usually report crude antimicrobial use 
rates that are not adjusted for patient mix, SOI, and other important 
predictors of antimicrobial use because benchmarking was not their 
purpose. One surveillance program that did benchmark AbC is the CDC’s 
Intensive Care Antimicrobial Resistance Epidemiology (ICARE) Project 
[86,87]. The project pooled AbC in all study hospitals over the entire study 
period and subsequently risk-adjusted this aggregate AbC by stratifying 
hospitals according to patient areas where patient mix is likely to be 
relatively homogenous such as medical, surgical, and cardiothoracic 
intensive care units (ICUs). Study hospitals were then provided with these 
area-specific benchmarks to compare with their local AbC in the 
corresponding patient areas. 
Project ICARE was one of the earliest efforts to benchmark AbC in 
hospitals and whereas it used stratification as the risk-adjustment method, 
subsequent benchmarking investigation used univariable [7] and 
multivariable [5,6,27] regression models to risk-adjust AbC in hospitals. 
More recently, standardization (of rates) was used to risk-adjust AbC in 
hospitals [8,9]. I will first review the studies that used regression as a 
strategy for benchmarking hospital AbC and will then review the 
investigations that used standardization for this purpose.   
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Investigations that Used Regression Modeling to Benchmark Antibacterial 
Consumption  
The first study I will review used univariable weighted linear 
regression to examine the association between AbC (measured in DDD/100 
bed-days and DDD/100 admissions) and the CMI in 18 departments at the 
University Hospital Zurich, a tertiary care teaching hospital, as well as in 13 
acute care hospitals including the aforementioned tertiary care hospital, 2 
secondary care and 10 primary care hospitals in the Canton of Zurich in 
Switzerland [7]. The number of bed-days of each department or hospital was 
used as a weighing factor. The investigators reported a significant 
correlation between the CMI and AbC when measured in DDD/100 bed-
days as well as when measured in DDD/100 admissions, respectively, in 
the different university hospital departments (R2 = 0.57, p-value = 0.0002 
and R2 = 0.48, p-value = 0.0008) and also across the different acute care 
hospitals (R2 = 0.46, p-value = 0.0065 and R2 = 0.85, p-value < 0.0001), 
respectively.  
The other 3 investigations that used regression to benchmark AbC 
used multivariable regression models and are summarized in Table 2.1. The 
study by Amadeo et al. developed regression models to explain the 
variability in AbC in 34 public non-teaching and 43 private hospital in 
southwestern France [5]. The “best” model for public hospitals explained 
84% of the variability in AbC measured in DDD/1000 PDs using the 
25 
 
existence of an ID consultant and the proportion of PDs in medical and 
surgical wards and ICUs as predictor variables. The model fit was so good; 
however, that none of the hospitals fell outside the 90% prediction interval. 
For private hospitals, DDD/100 admissions was the “preferred” measure 
and the fitted model was able to explain 68% of the variability in AbC using 
the existence of an ID consultant, LOS, the proportion of PDs in the medical 
wards and the proportion of PDs in surgery as predictor variables. The 
variable “existence of ID consultant” was not statistically significant in 
either model but was forced into the models because the investigators 
deemed it to be an important factor in controlling AbC.  
The study by MacDougall and Polk identified hospital size, the 
number of ICU days, surgical volume, and the number of cases of 
bacteremia, pneumonia and urinary tract infection (UTI) as predictors of 
total AbC measured in DOTs/1000 PDs in a sample of US hospitals that 
was primarily composed of non-teaching community hospitals [6]. The 
sample of 130 hospitals was randomly split into 2 equally sized datasets; a 
training set to fit the model and derive the prediction equation, and a 
validation set to derive the predicted values and prediction intervals. The 
fitted model was only able to explain 31% of the variability in AbC . 
Nevertheless, both low and high outlier hospitals were identifiable in this 
study.   
The last study that used regression as a strategy to benchmark AbC 
was based in Germany [27]. Data including AbC over a 2-year period (2001-
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2002) were retrieved from 2 different network databases (cohorts) composed 
of 92 ICUs representing 64 hospitals (58 non-teaching and 6 teaching).  
AbC, measured in both DDD/100 PDs and RDD/100 PDs, was 
dichotomized at the 75% percentile and entered as a binary outcome in a 
logistic regression model while potential predictor variables included ICU 
type (surgical, medical, interdisciplinary), affiliation to a university hospital 
(yes, no), hospital bed size (< 400 beds, 400-799 beds, > 800 beds) and 
cohort type. Separate models were fit for all ICUs and for non-teaching ICUs 
only. The findings of the different models are summarized in Table 2.1. The 
investigators concluded that “in order to compare the use of antibiotics 
between ICU cohorts and to assess trends over time, data adjustment is 
required for hospital affiliation and size”. 
 
Investigations that Used Standardization to Benchmark Antibiotic Use 
The two studies that employed standardization to benchmark AbC thus far 
used the indirect standardization procedure. Polk and colleagues stratified 
adult AbC (measured as DOTs/1000 PDs and LOT/1000 PDs) in 70 US 
academic medical centers during 2009 into 35 CSLs. The assignment of 
patients to CSLs was based on the similarity of their clinical conditions as 
determined by their MS-DRG assignment.  The investigators applied indirect 
standardization to derive expected AbC rates and the observed-to-expected 
(O/E) ratios. The reported O/E ratios ranged from 0.73 to 1.44 for the 
DOTs/1000 PDs measure. The study also determined the CSL-specific O/E 
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ratios and benchmarked the CSL-specific components of AbC including the 
proportion of discharges receiving antibiotic therapy, LOT/discharge and 
DOTs/LOT ratio. According to the investigators, “Perhaps the greatest 
advantage of this method is that the reasons for the high O/E ratios in each 
CSL can be identified and also benchmarked against all 70 hospitals” [29]. 
The second study used a combination of regression modeling and 
indirect standardization to risk-adjust AbC in 30 acute care hospitals in 
Finland during a 7-day prevalence study in 2005 [8]. AbC was measured 
during the study day and the 6 days preceding it and was expressed as 
antibiotic use-days/100 PDs. Predicted AbC was determined for each 
individual based upon a regression model that adjusted for several risk 
factors of antibiotic use and the predicted values were aggregated to 
determine the mean predicted AbC for each hospital. The indirectly 
standardized ratios were calculated by dividing observed use by predicted 
use in each hospital. Finally, risk-adjusted antibiotic use (indirectly 
standardized rates) was determined by multiplying the indirectly 
standardized ratio by the observed AbC in the entire study population. The 
investigators compared observed AbC ranks to risk-adjusted ranks and 
found that the two ranked hospitals differently in 25 hospitals (83%). They 
concluded that “Case-mix adjustment may be a useful tool for 
benchmarking hospital antibiotic use”. 
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This review of the literature pertaining to benchmarking antimicrobial 
use in hospitals reveals marked variability in the type and size of compared 
hospitals, antimicrobial agents included, SOI measure used, explanatory 
variables considered and the metric used to measure antimicrobial use. This 
severely limits the comparability of these investigations and the ability to draw 
conclusions about the generalizability of the various antimicrobial use 
benchmarking models. 
 Teaching hospitals may be systematically different from their non-
teaching counterparts and the type of patients attending these hospitals 
may differ as well. Such differences are not always measurable or known 
but may be important determinants of antimicrobial use. Moreover, the vast 
majority of studies that benchmarked or compared antimicrobial use in the 
hospital setting are based in European countries that differ from the US in 
their healthcare systems and in some of the elements that may drive 
antimicrobial use. Countries differ in their antimicrobial therapy and 
microbiology laboratory guidelines, government sponsored healthcare 
insurance plans, healthcare awareness campaigns, approved antimicrobial 
agents, physicians’ training, endemic diseases, and prescribing practices 
driven by patients’ culture and expectations as well as by advertising and 
aggressive marketing strategies. Therefore, it is unlikely that a 
benchmarking model for antimicrobial use developed in one country can be 
adopted by another without alteration. 
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Table 2.1  A Summary of Investigations that Employed Multivariable Regression Models to Benchmark or Compare Antimicrobial Use 
Across Hospitals or Hospital Units 
 
Study  
Authors, 
year and 
location 
No. and 
type(s) of 
hospitals  
Study 
period 
Antimicro- 
bials 
included Antimicrobial use rate  
Potential predictors of 
antimicrobial use 
identified in the 
multivariable model Adjusted R2 
MacDougall 
and Polk, 
2008 [6]  
United 
States                                                                         
130 hospitals                                 
115 
community, 
15 teaching 
Aug 2002-
Jul 2003 
All systemic 
antibacterial 
drugs 
(n=87) 
Mean (SD): 789.8 
DOTs/1000 PDs (123.5) 
No. of beds, no. of ICU 
days, surgical volume, and 
no. of cases of pneumonia, 
UTI, and bacteremia 
0.31 
Amadeo et 
al., 2009 [4]            
France 
77 hospitals                                      
34 public 
(non-
teaching),               
43 private                                                
2005 
calendar 
year 
Group J01 
of ATC 
classification 
system 
(2006 
version) 
Median (range):                                                                                                     
DDD/1000 PDs and 
DDD/100 ADMS                                                                              
Public, 395 (196-737) and 
341 (180-792)                                                         
Private, 422 (113-117) and 
212 (38-510) 
Public (DDD/1000 PDs):
proportion of PDs in 
surgery, ICU, and medical
wards                      
Private (DDD/100 
ADMS): LOS, proportion 
of PDs in surgery and 
medical wards            
Public, 0.84                
Private, 0.68 
De With et 
al., 2006 
[27]                    
Germany         
Two cohorts 
of ICUs 
(n=92) 
representing 
64 hospitals (6 
teaching and 
58 non-
teaching) 
Two 
calendar 
years   
2001-2002 
Major 
antibiotic 
drug classes 
Median (IQR:                                                                              
DDD/100 PDs and 
RDD/100 PDs                                                                     
Teaching, 136.0 (99.1-
180.7) and 84.0 (66.5-
108.4)                                           
Non-teaching, 110.3 
(88.6-128.6) and 61.6 
(47.5-76.7) 
All ICUs                                                        
DDD/100 PDs: hospital 
affiliation         
RDD/100 PDs: hospital 
size                                
Non-teaching hospital 
ICUs                                                                                            
DDD/100 PDs: none                                              
RDD/100 PDs: ICU type  
Not applicable,
antimicrobial 
use was 
dichotomized 
and a logistic 
regression was 
fitted
ADMS: admissions, ATC: Anatomical Therapeutic Chemical, DDD: defined daily dose, DOTs: days of therapy, ICU: intensive care unit, IQR: interquartile range, LOS: length of stay, 
PDs: patient-days, RDD: recommended daily dose, SD: standard deviation, UTI: urinary tract infection 
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Chapter III 
Development and Validation of the 
Multivariable Linear Regression 
Models 
 
 
3.1 Methods 
3.1.1 Study Design and Data Source 
This study is a retrospective, cross-sectional, hospital-wide analysis of total 
antibacterial drug consumption (AbC) in a sample of US academic medical 
centers. Data on systemic AbC in adult (> 18 years) hospitalized patients for 
the 2009 calendar year was obtained from the University HealthSystem 
Consortium (UHC); an alliance of 107 academic medical centers and 221 of 
their affiliated hospitals representing all major geographical regions in the 
United States and 90% of the nation's non-profit academic medical centers. 
A subset of the UHC member hospitals participate in the Clinical Resource 
Manager (CRM) database which collects from its participants data such as 
diagnosis, patient outcomes, drug use, and demographics in addition to 
data on operational and financial performance.
31 
 
Further details on how the CRM database extracts drug use and other data 
was described in a publication that investigated trends in adult AbC within 
UHC [88]. The CRM database offers its members access to risk-adjusted 
comparative data and benchmarking tools that enables them to compare 
their clinical and operational performance with that of other member 
hospitals. The UHC database has been previously used to benchmark 
surgeon satisfaction [13], mechanical ventilation services [20], and the 
quality of palliative care services [89]. However, antimicrobial benchmarking 
is not currently available within the UHC system, nor any other multi-
hospital system of which I am are aware. This makes this database 
particularly suitable for developing benchmarking models for AbC in 
hospitals which is the main objective of the current study. This study has 
Institutional Review Board of Virginia Commonwealth University approval. 
3.1.2 Outcome Variable 
The total systemic AbC rate in adults is the primary outcome variable in the 
multivariable linear regression (MLR) models and is expressed as the 
number of DOTs per one thousand patient-days (DOTs/1000 PDs) in the 
first model (Model I) and as the number of DOTs per one thousand 
discharges (DOTs/1000 discharges) in the second model (Model II). The 
DOTs for 52 commonly used systemic antibacterial preparations (Table A1 
in Appendix) were summed up to give the total number of DOTs for each 
hospital which was divided by either the number of PDs or the number of 
32 
 
discharges and multiplied by 1000 to yield the DOTs/1000 PDs and 
DOTs/1000 discharges rates, respectively. All data were aggregated at the 
hospital level and patient-level data were not identifiable in this study.    
3.1.3 Predictor Variables  
The drivers of antimicrobial drug use have not been fully explored and may 
vary by hospital type and country. Therefore, this study does not have a 
primary independent variable since it is of interest to identify all predictors 
of antimicrobial drug use in US teaching hospitals.  
The CRM database obtains the numbers of various infections using 
the International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM) codes reported by participating hospitals (Table A2 
in Appendix). The rate of total infections was calculated from the ICD-9-CM 
based numbers of urinary tract infections (UTI), bloodstream infections 
(BSI), and pneumonias. An APR-DRG based CMI was also extracted from 
the CRM database. Another SOI measure extracted from the database was 
the percent of discharges in the combined major and extreme subclasses of 
the APR-DRG SOI classification. Other potential predictor variables provided 
by the database include bed size, geographic location, and the number of 
different types of surgeries and transplants. Again, the latter were summed 
up and normalized to yield a measure for the total surgery rate and another 
for the total transplant rate. The infection, surgery, and transplant rates 
were expressed as the number of events per 1000 discharges. 
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3.1.4 Statistical Analysis  
The mean and the standard deviation (SD) were used to describe the 
outcome variable and continuous predictor variables if normality was 
warranted. If the normality assumption was markedly violated, then the 
median and inter-quartile range (IQR) were used to describe these variables. 
Categorical variables were summarized using counts and proportions. All 
statistical analysis was performed using JMP (version 8; SAS Institute, 
Cary, NC) and SAS (version 9.1.3; SAS Institute, Cary, NC) software. 
All potential predictor variables listed under subsection 3.1.3 were 
separately fitted against each of the two outcomes (DOTs/1000 PDs and 
DOTs/1000 discharges) to screen candidate variables that are likely to be 
useful in explaining the variability in AbC in the two MLR models.  An MLR 
approach was used to build the models using those variables that were 
significant at the α= 0.30 significance level in the bivariate analyses.  The all 
possible regressions procedure was used in conjunction with the sequential 
variable selection procedures (forward selection, backward elimination, and 
stepwise regression) to select the “best” model for each outcome measure 
from the subset of potential predictor variables screened in the bivariate 
analyses. The significance level for the entry and retention of variables in 
the model using the stepwise regression procedure was set to α= 0.20 and 
α= 0.10, respectively. The former significance level was also used for entry of 
variables in the forward selection procedure while the latter significance 
level was also used as the criteria for retaining variables in the backward 
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elimination procedure. The all possible regressions procedure uses all k 
potential variables to fit (2k -1) possible subset models. The models are then 
ranked based on various selection criteria. The selection criteria considered 
were the R2, adjusted R2 ( 
AD 
2
), mean square error (MSE), Mallows’ Cp, the 
Predicted Residual Error Sum of Squares (PRESS) statistic, and the 
corrected Akaike information criterion (AICc). These statistics and 
acronyms, as well as the others mentioned in this subsection, are defined 
and discussed in more details in section 3.2. 
The assumptions of linear regression including linearity, 
independence, homoscedasticity of residuals and normality were checked 
for the final models. Consideration to a Poisson regression model, with the 
log of the denominator of the response variable as the offset, was given 
depending on whether these assumptions were violated or not. The 
final model was checked for multicollinearity problems using the variance 
inflation factors (VIFs). If multicollinearity was identified, then the least 
significant of the multicollinear variables would be taken out of the model. If 
this compromised the model’s performance substantially, a procedure that 
combats multicollinearity such as Ridge regression was considered. 
  The R-student statistic was used to identify outliers at α = 0.05 and α 
= 0.10. A hospital was considered to be a high outlier if its R-student value 
exceeded the upper critical value of the t-distribution at the given 
significance level, a low outlier if its R-student value was less than the lower 
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critical value of the t-distribution, and a non-outlier if its R-student value 
fell between the foregoing upper and lower critical values. Influence 
diagnostics were checked to determine if any hospitals had an undue 
influence on the models’ performance. DFFITS were used to check if any 
hospitals had a high influence on the fit of the regression model while 
DFBETAS were used to check whether any hospitals had an impact on the 
parameter estimates. COVRATIO were used to determine which hospitals, if 
any, had a positive or a negative impact on the model.  
The final models were validated using both internal and external 
validation methods. Internal validation was carried out using the “leave-one-
out cross validation” (LOOCV) method. In this procedure, an observation 
(e.g., the first observation) is removed from the dataset and the remaining n-
1 observations are used to fit the model. The predicted value of the excluded 
observation is calculated from the prediction equation of the model from 
which it was excluded (i.e., the model fitted with n-1 observations). The 
difference between this “leave-one-out” predicted value and the observed 
value is known as the “P ESS residual”. The excluded observation is then 
reinserted into the model and the next observation (e.g., the second 
observation) is removed from the model and so on. This procedure is 
repeated in a sequential manner for all n observations and all n PRESS 
residuals are calculated. The sum of squares of all n PRESS residuals is 
nothing but the aforementioned PRESS statistic. In addition to being a 
model selection criterion, the PRESS statistic is also useful for model 
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validation purposes. For the latter purpose, the PRESS statistic is usually 
expressed as the predicted R2 ( 
P ED
2
) since it allows direct comparison with 
the adjusted R2. The two statistics should be in “reasonable agreement”. 
More specifically, the predicted R2 should be within 0.2 of the adjusted R2 
for the model to be valid (not overfit) [90]. 
For the external validation method, the validation set consisted of a 
subset of the hospitals used in the calibration (i.e., model fitting) set but the 
data used was from 2008 instead of 2009. The prediction equations of 
Model I and Model II were applied to the validation set to obtain the 
respective predicted values. These were plotted against the corresponding 
observed values from the validation set to calculate the “validation” adjusted 
R2 which were compared to the corresponding “calibration” adjusted R2 of 
Model I and Model II.  
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3.2 Results 
 
3.2.1 Descriptive Statistics  
Hospital-wide Demographics  
Seventy UHC member hospitals provided their AbC data in adults for 2009. 
All hospitals provided data for all four quarters of 2009 with the exception of 
Hospital #44 and Hospital #70, which only provided three quarters worth of 
data. All major geographic regions (New England, Mid-Atlantic, 
Southeastern, Midwestern, Mid-continent, and Western) were well 
represented with the number of hospitals in each region ranging from 7 
(10%) in New England to 16 (23%) in the Midwestern region. Out of the 67 
hospitals whose bed size was known, a total of 56 hospitals (84%) had a bed 
size between 200 and 800; while the average bed size was 561.   
A total of 1,781,020 discharges (mean= 25,443, SD= 10,500) 
contributed an estimated 9,786,743 PDs (mean= 139,811, SD= 59,886) 
yielding an average LOS of 5.5 days (SD= 0.57).   An estimated 55.7% 
(range= 47.2%-81.1%) of discharged patients were females with the average 
age being 52.5 years (SD= 4.7). A more comprehensive summary of the 
demographic and clinical characteristics of this sample of hospitals is 
presented in Table 3.1.  
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                 Table 3.1  Demographic and Clinical Characteristics of 70 US Academic Medical  
                  Centers in 2009 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                        
 
                               APR- DRG, All Patient Refined Diagnosis Related Groups; SOI, Severity of Illness                                               
Characteristic  n Percent 
Geographic region  
  New England 7 10.0 
Mid-Atlantic 13 18.6 
Southeastern  11 15.7 
Midwestern 16 22.9 
Mid-Continent  14 20.0 
Western 9 12.9 
Bed size category (N= 67) 
  <200 1 1.5 
200-399 18 26.9 
400-599 20 29.9 
600-799 18 26.9 
800-999 9 13.4 
≥1000 1 1.5 
Characteristic  Mean (SD) Range  
Bed size (N= 67) 560.5 (204.3) 185-1156 
Age, years 52.5 (4.7) 40-65 
Discharges  25443 (10500) 4104-54204 
Total patient-days 139811 (59886) 14373-299505 
Length of stay, days 5.5 (0.57) 3.5-6.9 
Duration of total antibacterial 
therapy, days 
4.7 (0.62) 2.7-6.3 
Case mix index  1.68 (0.20) 1.12-2.07 
Surgical procedures per 1000 
discharges 
388 (69) 149-566 
Diagnoses per 1000 discharges 
  Bloodstream infections  55 (14) 14-88 
Pneumonias  63 (14) 20-94 
Urinary tract infections 85 (16) 29-119 
 
Median (IQR) Range  
Bone marrow transplants  2.3 (0-4.1) 0-15.3 
Solid organ transplants 5.0 (2.3-8.6) 0-28.1 
APR-DRG SOI subclass, no. of 
patients per 1000 discharges 
  Minor  261 (238-299) 176-425 
Moderate  376 (362-391) 321-496 
Major  270 (250-286) 134-400 
Extreme 98 (85-116) 9-146 
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Hospital-wide Aggregated Antibacterial Drug Consumption 
On average, 63.5% (range= 49.5%-76.1%) of discharged patients received at 
least one dose of an antibacterial agent. About 44.3% of these patients 
received a single antibacterial agent, 26.7% received two antibacterial 
agents, and 29% received three or more antibacterial agents.  The mean 
total AbC rate was 821.2 DOTs/1000 PDs (SD= 108.1, range= 560.8-
1104.1) or 4487.6 DOTs/1000 discharges (SD= 859.2, range= 2521.7-
7579.5), while the average LOT for total antibacterial drug therapy was 4.7 
days (SD= 0.62). Figure 3.1 and Table 3.2 summarize AbC by antibacterial 
drug class. Glycopeptides -represented by vancomycin as the sole agent- 
were the most widely used class and accounted for 15.6% of total AbC. They 
were followed by fluoroquinolones (14.6%), β-lactam/β-lactamase inhibitor 
combinations (12.8%), 1st and 2nd generation cephalosporins (12.6%), and 
3rd and 4th generation cephalosporins (10.5%). Broad spectrum antibacterial 
drugs (aminoglycosides, fluoroquinolones, third and fourth-generation 
cephalosporins, carbapenems, and β-lactam/β-lactamase inhibitor 
combinations) contributed a mean of 374.2 DOTs/1000 PDs or 2050 
DOTs/1000 discharges (45.6%) to the total AbC rate. 
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Others, tetracyclines, antistaphylococcal penicillins, nitrofurantoin, and sulfadiazine 
 
Figure 3.1  Breakdown of total antibacterial drug consumption at 70 US academic medical centers in 
2009 by antibacterial drug class. Each slice represents the mean antibacterial drug consumption (in 
days of therapy per one thousand patient-days) of the corresponding antibacterial class as a 
percentage of the mean total antibacterial drug consumption.
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β-Lactamase sensitive penicillins  Others
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Table 3.2  Summary of Antibacterial Drug Consumption Classified by Antibacterial Drug Class at 70 US Academic Medical Centers in 2009             
      
  
DOTs/1000 PDs DOTs/1000 discharges 
Group   Mean (SD) Min-Max Mean (SD) Min-Max 
Vancomycin 128.4 (30.2) 42.6-194.2 705.7 (202.7) 191.3-1197.8 
Fluoroquinolones 119.6 (38.9) 38.3-233 649.3 (212.0) 195.2-1087.5 
β-lactam/β-lactamase inhibitor combinations 105.4 (37.9) 13.0-182.2 579.5 (231.4) 68.3-1159.4 
1st generation cephalosporins 93.1 (33.5) 34.1-270.8 500.4 (149.8) 213.8-976.1 
3rd and 4th generation cephalosporins 86.6 (34.9) 21.3-253.2 475.4 (206.5) 114.7-1440.9 
Metronidazole 57.4 (19.6) 25.1-118 312.9 (110.0) 88.0-621.5 
Carbapenems 39.1 (21.4) 8.5-100.5 218.0 (129.8) 31.9-606.7 
Trimethoprim/sulfamethoxazole 35.1 (18.5) 5.0-91.2 194.8 (112.0) 28.5-626.2 
Macrolides 31.7 (10.8) 11.6-59.4 171.6 (57.1) 58.0-314.3 
Clindamycin 25.1 (10.0) 4.2-49.5 135.5 (54.9) 26.3-289.4 
Other anti-Gram-positive agents 23.8 (12.5) 1.8-72.9 133.2 (79.2) 6.3-440.2 
Aminoglycosides 23.5 (9.7) 9.8-58.6 127.8 (54.0) 46.2-320.8 
β-lactamase sensitive penicillins  22.8 (9.8) 6.8-69.6 121.7 (43.2) 38.9-275.4 
Tetracyclines 11.2 (6.4) 4.0-39.0 61.9 (37.9) 19.3-222.0 
 2nd generation cephalosporins 10.0 (9.3) 0-59.0 55.0 (51.5) 0-330.3 
Antistaphylococcal penicillins 5.8 (3.9) 0.8-25.7 32.1 (22.6) 4.7-151.5 
Miscellaneous  2.4 (2.7) 0-10.1 12.8 (14.7) 0-56.4 
Total antibacterial consumption 821.2 (108.1) 560.8-1104.1 4487.6 (859.2) 2521.7-7579.5 
DOTs/1000 PDs, days of therapy per one thousand patient-days; DOTs/1000 discharges, days of therapy per one thousand discharges; SD, standard deviation        
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Figure 3.2 and Figure 3.3 depict the total AbC at each of the 70 
hospitals broken down by antibacterial drug class and expressed as 
DOTs/1000 PDs and DOTs/1000 discharges, respectively. When the former 
rate was used, Hospital #29 had the lowest AbC with 560.8 DOTs/1000 PDs 
while hospital #48 had the lowest consumption when the latter rate was 
used with 2521.7 DOTs/1000 discharges. Hospital #28 had the highest 
total AbC with a rate of 1104.1 DOTs/1000 PDs (7597.5 DOTs/1000 
discharges). The two figures indicate that a hospital’s rank and whether it is 
perceived as an outlier may depend on the rate used to measure AbC.  
However, it is important to note that these are crude rates and that risk-
adjusted AbC rates may provide a better reflection of hospital ranks and 
their outlier status.   
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Others: tetracyclines, antistaphylococcal penicillins, nitrofurantoin and sulfadiazine; Other anti-Gram-positive agents: linezolid, daptomycin and tigecycline         
                                                                                                                                                                                                  
 Figure 3.2  Crude antibacterial drug consumption rates (in days of therapy [DOTs] per one thousand patient-days [1000 PDs]) at                               
70 US academic medical centers in 2009. Each entire bar represents the total systemic antibacterial consumption at an individual   hospital 
divided into 14 antibacterial classes.                                        
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others: tetracyclines, antistaphylococcal penicillins, nitrofurantoin and sulfadiazine; Other anti-Gram-positive agents: linezolid, daptomycin and tigecycline       
                                                                                                                                                                                                               
Figure 3.3  Crude antibacterial drug consumption rates (in days of therapy [DOTs] per one thousand discharges) at 70 US academic medical centers in 
2009. Each entire bar represents the total systemic antibacterial consumption at an individual hospital divided into 14 antibacterial classes.
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3.2.2 Variable Screening  
Figure 3.4 represents the bivariate relationships between AbC –measured in 
both DOTs/1000 PDs and DOTs/1000 discharges- and 7 potential predictor 
variables.  The Pearson correlation coefficients (r) and the respective p-
values for the association between the two measures of the outcome variable 
–in the above order- and the potential predictor variables were as follows: 
bed size (r= -0.003, p-value= 0.98) and (r= 0.18, p-value= 0.14), CMI (r= 
0.32, p-value= 0.007) and (r= 0.54, p-value< 0.001), percent of discharges 
assigned to the major and extreme levels of APR-DRG SOI classification 
(r=0.27, p-value= 0.02) and (r= 0.48, p-value< 0.001), number of surgeries 
per 1000 discharges (r= 0.13, p-value= 0.28) and (r= 0.16, p-value= 0.19),  
number of infections per 1000 discharges (r= 0.36, p-value= 0.002) and (r= 
0.44, p-value< 0.001), number of transplants per 1000 discharges (r= 0.44, 
p-value< 0.001) and (r= 0.54, p-value< 0.001), and LOS (r= 0.24, p-value= 
0.04) and (r= 0.72, p-value< 0.001). The potential collinearity between 
predictor variables is discussed in subsection 3.2.4.  
The One-way ANOVA did not suggest that there were any significant 
differences in AbC between different geographic locations using either the 
DOTs/1000 PDs measure, F(5,64)= 1.0, p-value= 0.42 or the DOTs/1000 
discharges measure, F(5,64)= 0.78, p-value= 0.57. Predictor variables that 
were significantly associated with either measure at α= 0.30 were considered 
for the model selection procedure. It was determined, through trial and 
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error, that there was no significant advantage for using the APR-DRG based 
measure over the CMI; therefore, the latter SOI measure was selected for the 
model selection stage. The infection rate, transplant rate, surgery rate and 
LOS were the other variables considered for the selection of Model I while, in 
addition to the CMI, all other 5 continuous variables were considered for the 
selection of Model II.  
 
*  Number of events per one thousand discharges, CMI= case-mix index, APR-DRG SOI= percent of discharges in major and 
extreme severity of illness levels according to All Patient Refined Diagnosis Related Group classification, LOS= length of stay 
 
Figure 3.4  A scatterplot matrix showing bivariate relationships between two measures of total 
antibacterial consumption (days of therapy per one thousand patient-days [DOTs/1000 PDs] and days of 
therapy per one thousand discharges [DOTs/1000 discharges]) and 7 potential predictor variables. The 
red ellipses represent the 95% confidence limits. A narrow ellipsoid with a diagonal orientation 
reflects a strong correlation while a more circular vertically oriented ellipsoid reflects a weak 
correlation.
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3.2.3 Model Selection  
Before presenting the results of the model selection procedure, an overview 
of the selection criteria: R2, adjusted R2, MSE, P ESS statistic, Mallows’ Cp, 
and AICc is warranted. The coefficient of determination, R2, can be 
interpreted as the proportion of variation in the outcome variable explained 
by the regression model. It is the ratio of the regression sum of squares 
(SSR) to the total sum of squares (SST). 
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where 
i
y  is the measured outcome variable of the ith data point 
(observation), ˆ
i
y  is the fitted value of the ith data point, and Y is the mean 
i
y  (i= 1, 2,…, n). Since    
 SST =SSR +SSE  (3.2) 
where SSE is the error sum of squares, Equation 3.1 can alternatively be 
written as 
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SST is fixed for a given sample of 
i
y  and is independent of the fitted model. 
SSR goes up with each predictor added to the model while SSE goes down. 
Therefore, R2 is not a useful criterion for the comparison of models that 
have different number of predictor variables since it always increases with 
the addition of new variables to the model.  
 The adjusted R2      
   is a modification of the R2 that adjusts for the 
number of variables in the model. Unlike R2, the adjusted R2 may drop when 
a variable is added to the model and increases only if the increment in R2 
outweighs the added penalty of introducing the additional variable. The 
adjusted R2 is given by 
 
2 1 1
ADJ
R    
SSE / SSE /
 
SST / SST /
ERROR
TOTAL
df n - p
df n - 1
 (3.4) 
where dfERROR is the error degrees of freedom, dfTOTAL is the total degrees of 
freedom, and p is the number of parameters in the model including the 
intercept (p = k +1). 
MSE, denoted by
2ˆ , is an unbiased estimator of the population variance
2( ) , provided that the fitted model is correct. 
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Equation 3.5 is just the numerator of the fraction term in Equation 3.4. It is 
easy to see that the model with the largest adjusted R2 will also have the 
smallest MSE and that the ranks of candidate models by both criteria will 
be identical. 
The ith “raw” residual (ei) is the difference between the ith value of the 
outcome variable and the ith fitted value obtained from the estimated 
regression equation. 
 ˆ
i i i
e y y   (3.6) 
The ith PRESS residual, on the other hand, is the difference between the ith 
value of the outcome variable and the ith predicted value obtained from a 
model fitted after setting aside the ith data point. For notation, a “−i” 
subscript is used to indicate that the analysis is carried out after setting 
aside the ith data point. Using this notation, the ith PRESS residual, ,i ie  , is 
given by      
 
, ,
ˆ
i i i i i
e y y
 
   (3.7) 
where 
,
ˆ
i i
y

 is the ith adjusted (PRESS) predicted value; that is, the predicted 
value obtained from a model fitted without the ith data point. This procedure 
of setting aside one data point at a time, fitting the model with the 
remaining n −1 data points, using the fitted model to calculate the predicted 
value for the data point that was set aside, reintroducing that data point to 
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the model, setting aside the next data point, and so on; this procedure is 
carried out sequentially for all n data points until all n PRESS residuals are 
obtained. Then, the PRESS statistic is the sum of squares of the PRESS 
residuals defined as 
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The calculation of PRESS may seem like a tedious and repetitive task. 
However, one does not need to run repeated regressions to calculate PRESS 
as the PRESS residuals can be easily obtained by fitting the pertinent model 
once using all n data points as explained in subsection 3.2.5. Unlike raw 
residuals, PRESS residuals are true prediction errors since 
,
ˆ
i i
y

 are 
independent of
i
y . The smaller the PRESS statistic, the better the predictive 
capabilities of the model. 
 The Cp statistic, proposed by Mallows [91], is given by  
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where 
2ˆ  is the MSE of the model under consideration and 2ˆ FULL is the MSE 
of the full model containing all k predictor variables. The fraction in the 
above equation is a measure of bias so large deviations of Cp above or under 
p indicate an underfit or overfit model, respectively. The smallest Cp that is 
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approximately equal to p is favorable. Obviously, for the full model, 
2ˆ = 
2ˆ FULL and consequently Cp= p so this should not be taken as evidence of the 
superiority of the full model.   
AICc was introduced in 1989 by Hurvich and Tsai [92] as a correction 
for the small sample bias of the original Akaike Information Criteria (AIC) 
[93].    
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logn p
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 (3.11) 
AICc is a measure of model performance where a smaller value denotes a 
better fitting model. AICc and AIC converge as n increases but AICc is 
preferred for small samples, particularly when n/p <40 for the full model. 
AICc seeks the most parsimonious model; the one that explains most of the 
variability with the least complexity. It does so by addressing the trade-off 
between bias (underfitting) and variance (overfitting). AICc is not an 
absolute measure but it is useful for the purpose of comparing different 
models providing they are based on the same dataset. If the AICc values of 
two models differ by more than 2, the model with the lower AICc is 
considered to have the better fit.  
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The all possible regressions procedure fitted 31 (i.e., 25-1) candidate 
models for the selection of Model I and 63 (i.e., 26-1) candidate models for 
the selection of Model II (the intercept- only models were not considered). 
The 5 “best” candidate models for both Model I and Model II according to the 
six selection criteria are presented in Table 3.3. For Model I, the table 
reveals that the candidate model that includes the transplant rate and the 
infection rate as predictor variables (Model IA) is superior to all other 
competing models. Moreover, this model was selected by the forward 
selection, the backward elimination and the stepwise regression procedures. 
Accordingly, Model IA was selected to represent Model I since its parsimony 
does not greatly sacrifice its performance. 
Similarly, the selection of a candidate model to represent Model II was an 
obvious one since the selection criteria of the candidate model that includes 
the transplant rate, infection rate and LOS (Model IIA) were superior to 
those of the other four competing models. It was also the model selected by 
all three sequential selection procedures. Thus, Model IIA was selected to 
represent Model II. It should be noted that the candidate models of Model II 
that have bed size as one of the potential predictor variables are based on 
67 observations only. Therefore, their selection criteria are not generally 
comparable with those of the models that do not include bed size which are 
based on the entire sample of 70 observations.  
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The parameter estimates and the VIFs for Model I and Model II are 
listed in Table 3.4. The predicted AbC rate for Model I was found to be 
541.57 + 6.54 * number of transplants/1000 discharges + 0.79 * number of 
infections/1000 discharges. This model accounted for 31% of the variability 
in AbC measured in DOTs/1000 PDs (F(2,67)= 15.3, p-value< 0.001). The 
predicted AbC rate for Model II was found to be – 1116.61 + 40.71 * number 
of transplants/1000 discharges + 4.34 * number of infections/1000 
discharges + 739.88 * LOS. This model accounted for 64% of the variability 
in AbC measured in DOTs/1000 discharges (F(3,66)= 39.4, p-value< 0.001). 
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Table 3.3   Selection Criteria of Candidate Models that Predict Total Hospital Antibacterial Drug Consumption Measured in Days of Therapy Per One 
Thousand Patient-days (Model I) and Days of Therapy Per One Thousand Discharges (Model II)    
 
                        Potential Predictor Variables                  Selection Criteria         
Model ID P 
Bed 
size CMI LOS 
Surgery 
rate* 
Infection 
rate* 
Transplant 
rate* 
 
R2 (adjusted R2) MSE PRESS Cp AICc 
  
I A 3 
    
X X   0.31 (0.29) 8252 607953 1.9 835.48   
I B 4 
   
X X X  0.32 (0.29) 8290 616367 3.2 837.07  
I C 4 
  
X 
 
X X   0.32 (0.29) 8307 622733 3.3 837.21   
I D 4 
 
X 
  
X X  0.31 (0.28) 8372 621238 3.8 837.76  
I E 5 
 
X 
 
X X X   0.33 (0.29) 8280 620222 4.1 838.31   
II A 4 
  
X 
 
X X  0.64 (0.63) 276490 21237012 3.2 1035.54  
II B 5 
  
X X X X   0.65 (0.63) 276600 21347446 4.3 1036.90   
II C 5 X 
 
X 
 
X X  0.65 (0.63) 273484 20606183 4.5 1037.11  
II D 5 
 
X X 
 
X X   0.64 (0.62) 280739 21789440 5.2 1037.92   
II E 6 X 
 
X X X X   0.66 (0.63) 272829 20677235 5.3 1038.36   
 
* number of events per one thousand discharges, p= number of parameters in the model including intercept; CMI= case-mix index, LOS= length of stay, MSE= mean square error, 
PRESS= PRESS statistic, Cp= Mallows’ Cp statistic, AICc=  corrected Akaike information criterion    
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Table 3.4   Parameter Estimates and Variance Inflation Factors of Model I and Model II 
 
 
Model I [y= days of therapy per 1000 patient-days] 
Term Estimate SE t p-value 95% CI VIF 
Intercept 541.57 
   
406.09 677.05 
 No. of transplants* 6.54 1.53 4.27 <.001 3.48 9.60 1.00 
No. of infections* 0.79 0.23 3.38 .0012 0.32 1.26 1.00 
 
Model II [y= days of therapy per 1000 discharges] 
Intercept -1116.61 
   
-2409.88 176.67 
 No. of transplants* 40.71 9.79 4.16 <.001 21.17 60.25 1.22 
No. of infections* 4.34 1.49 2.92 .0048 1.37 7.30 1.20 
LOS 739.88 132.15 5.60 <.001 476.036 1003.72 1.43 
 
*Per one thousand discharges, SE= standard error, CI= confidence interval, VIF= variance inflation factor, LOS= length of stay
56 
 
3.2.4 Checking for Multicollinearity                                                 
Multicollinearity refers to the correlation between predictor variables and 
exists to a troublesome degree when two or more predictor variables have a 
very strong linear association. Multicollinearity results in unstable 
parameter estimates in terms of magnitude and sign. Another impact of 
multicollinearity is that it lowers the power of the partial t-tests of the 
parameter estimates involved in the multicollinearity as a consequence of 
inflating the standard errors of these parameter estimates.  
The pairwise correlations between the predictor variables are 
presented in Table 3.5. The highest correlation is the one between the CMI 
and surgery rate (r= 0.62). While this correlation is relatively high, a 
correlation with an absolute value ≥ 0.90 is usually required for 
multicollinearity to be a serious problem. However, a high pairwise 
correlation is a sufficient but not a necessary condition for multicollinearity. 
That is, a very high pairwise correlation indicates a serious multicollinearity 
problem but its absence does not rule out the possibility of a 
multicollinearity problem. A more accurate assessment of multicollinearity 
can be attained by examining the VIFs (Table 3.4). VIFs measure the 
inflation of the variances of the parameter estimates above and beyond the 
ideal situation where multicollinearity is completely non-existent (VIF= 1).   
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The VIF of the jth predictor variable is given by     
 
2
1
VIF  
1-
j
j
R

 (3.12)  
where   
  is the    obtained from regressing the jth predictor variable on all 
the other predictor variables. As a rule of thumb, a VIF ≥4 indicates a 
potential multicollinearity problem while a VIF ≥10 indicates the presence of 
a severe multicollinearity problem. Since all VIFs are well below 4, 
multicollinearity is unlikely to be present to a detrimental degree in either 
Model I or Model II.  
 
Table 3.5   Pairwise Correlations between Predictor Variables  
 
Variable  1 2 3 4 5 6 
1. Bed size 1 
     2. CMI 0.36 1 
    3. LOS 0.42 0.58 1 
   4. No. of surgeries* 0.18 0.62 0.09 1 
  5. No. of infections* -0.07 0.24 0.38 -0.27 1 
 6. No. of transplants* 0.18 0.59 0.4 0.35 0.03 1 
 
* Per one thousand discharges, CMI= case-mix index, LOS= length of stay   
 
 
                                                                                                                               
                                                                                                                              
 
 
58 
 
3.2.5 Analysis of Residuals  
The analysis of residuals is carried out to identify observations that exert 
undue influence on the regression. Residuals are also useful in checking the 
assumptions underlying linear regression. This subsection is devoted to 
identifying outliers and influential observations while their influence on 
Model I and Model II is discussed in the next section. 
 In order to discuss analysis of residuals and influence diagnostics, it 
is helpful to introduce the general linear regression model in matrix 
notation, 
 y = Xβ + ε  (3.13) 
1
2
n
y
y
y
 
 
 
 
 
 
y ,  
11 12 1
21 22 2
1 2
1
1
1
k
k
n n nk
x x x
x x x
x x x
 
 
 
 
 
 
X , 
0
1
k



 
 
 
 
 
 
β , 
1
2
n



 
 
 
 
 
 
ε   
Where y is an n×1 vector of values of the outcome variable, X is an n×p full 
column rank matrix of known predictor variables that may include a 
constant, β is a p×1 vector of unknown parameters to be estimated, and      
ε is an n×1 vector of random errors that are independent and identically 
distributed (i.i.d) with mean zero and a constant but unknown variance σ2. 
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The vector of fitted values, denoted by yˆ , is given by  
 ˆˆ y Xβ  (3.14) 
where βˆ is the vector of ordinary least squares (OLS) parameter estimates 
given by 
  ˆ  
-1
β XX Xy  (3.15) 
where X is the transpose of the matrix X  and 
-1
X X  is the inverse of 
 X X . Substituting Equation 3.15 into Equation 3.14  
  ˆ  
-1
y X X X X y  (3.16) 
Equation 3.16 can be rewritten as   
 yˆ = Hy  (3.17) 
where  
   
-1
H X X X X  (3.18) 
  
H is a symmetric (Hʹ=H) and an idempotent (H2=H) matrix known as the  
“Hat” matrix. The diagonal elements of H, called the Hat diagonals (hii.), play  
a central role in regression diagnostics. The hii. value is a measure of  
leverage where the leverage of the ith data point is the standardized  
distance from that point to the center of the data in the x’s. A data point  
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with a large hii   is a high leverage point or an extreme point in the x 
direction. It can be shown that for a model with an intercept term, 
1
1
ii
h
n
   
and [94]   
 
1
n
ii
i
h p

  (3.19) 
where p is the number of model parameters. Then, the average size of hii 
equals p/n and a data point with a hii ≥2p/n (twice the average size) may be 
considered as a high leverage point [95]. Applying this cut-off to Model I (p= 
3, n= 70), potential high leverage points were identified as those hospitals 
that had hii ≥ 0.0857 while for Model II (p= 4, n= 70), hospitals that had hii ≥ 
0.114 were considered as potential high leverage points. Figure 3.5 plots hii 
against the predicted total AbC for Model I (Figure A) and Model II (Figure 
B). Both models identified Hospitals #20, #28, #35, and #48 as potential 
high leverage points while Hospital #54 was identified by the former model 
only.  High leverage points do not necessarily exert undue influence on the 
regression model as will be explained shortly. Also, those high leverage 
points that do have a substantial influence on the model may be labeled as 
“good” if they improve the model fit and “bad” if they hurt it.  
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Figure 3.5  Plots of Hat diagonals versus predicted total antibacterial drug consumption showing 
potential high leverage points of Model I (Figure A) and Model II (Figure B). The green horizontal 
lines represent the cut-off points of the Hat diagonals (2p/n) above which data points are 
considered to be high leverage points (green data points). The two models identified the same 
hospitals as being potential high leverage points with the exception of Hospital #54 which was 
identified by Model I only.
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As mentioned in subsection 3.2.3, there is no need to run multiple 
regressions to calculate the PRESS residuals. It turns out that the PRESS 
residual is a function of the raw residual and the Hat diagonal. The ith 
PRESS residual can be calculated from fitting a single regression model with 
all n data points using the following equation  
 
,
1
i
i i
ii
e
e
h



 (3.20) 
Whereas a high leverage point is extreme in the x direction, an outlier is a 
data point that is extreme in the y direction given its x values. That is, an 
outlier is a data point with a large residual. By substituting Equation 3.17 
into the matrix form of Equation 3.6, it is easy to show that the vector of 
residuals, e, can be written as  
 e = (I - H)y
     
 (3.21) 
Where I is an n×n identity matrix. Accordingly, the variance of 
i
e  is given by 
 
2( ) (1 )
i ii
var e h   (3.22) 
The residuals (ei) are estimates of the errors (εi) and should ideally behave 
like them. However, the constant variance assumption that is made on εi  
does not generally hold for ei as can be seen from Equation 3.22. The 
variance of ei is smaller for a data point that is remote from the data     
center (large hii) than that of a data point near the data center (small hii). 
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Also, since ei sum to zero, they are necessarily not independent. Therefore, 
raw residuals are not optimal for serving as diagnostic tools or detecting 
outliers.  
 Standardization of the raw residuals by dividing them by their 
standard errors creates a scale-free statistic with zero mean and unit 
standard deviation. The standard error of ei  is the square root of Equation 
3.22. Hence, the ith standardized residual, also known as a studentized 
residual (ri), is  
 
ˆ
ˆ 1
i i
y - y



i
ii
r
h
 (3.23) 
where ˆ MSE  . Studentized residuals are leverage (location) 
independent, and accordingly can be validly compared among each other. It 
is worth mentioning that standardization of the PRESS residual given in 
Equation 3.7 yields the studentized raw residual in Equation 3.23 [96]. They 
are called studentized residuals because they follow a t-like distribution. 
They do not follow an exact t-distribution because of the dependence 
between the numerator and denominator of Equation 3.23. This dependence 
can be eliminated by replacing ˆ  with ˆ
 i
 which is just MSE  of the model 
fitted without the ith data point. This creates the externally studentized 
residual, often called R-student (ti), which is given by  
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ˆ
ˆ 1
i i
y - y



i
ii
t
h
-i
 (3.24) 
As with the PRESS residual, there is no need to fit multiple regression 
models to calculate . 
 
can be calculated by fitting a single regression 
model with all n data points as follows 
 
2 2ˆ( ) / (1 )
ˆ
1
i ii
n p e h
n p



  

 
i  (3.25)   
If the standard assumptions, including normality, on the εi  are 
satisfied, then R-student follows tn-p-1 which is an exact t-distribution with  
n-p-1 degrees of freedom (df). Therefore, it makes more sense to use the 
critical points from student’s t-distribution for ti than it does for ri. The ith 
data point is considered a potential outlier if 
/2, 1i n p
t t
  
 .  
For both Model I (df= 66) and Model II (df= 65), the critical value at α= 
.05 was ±1.997 while the corresponding value at α= .10 was ±1.669. 
Hospitals whose ti were as or more extreme than these critical values were 
identified as potential outliers at the respective significance level as shown 
in Figure 3.6. At α=.05, both models identified Hospitals #4 and #26 as 
potential high outliers while Hospital #28 was identified by Model II only. 
Hospital #22 was identified as a potential high outlier by Model I at the 
same significance level whereas it was identified by Model II at α=.10. Also 
i
ˆ
 i
ˆ

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at α=.10, both models identified Hospital #45 as a potential high outlier. 
Both models identified Hospital #29 at α=.05 and Hospital #59 at α=.10 as 
potential low outliers. In addition to their value in identifying outliers, 
residual by predicted plots such as Figure 3.6 are also useful in the 
detection of violations of some of the assumptions of linear regression as 
explained in the next subsection.  
It can be argued that a Bonferroni-type correction may be warranted 
when using R- student to detect outliers since this approach involves 
simultaneous testing of multiple data points. Therefore, one should 
arguably compare all n values of ti with the more conservative critical value 
of the t-distribution 
( /2 ), 1n n p
t
  
 rather than the uncorrected critical value 
/2, 1n p
t
  
. However, it is probably best to view R-student as a diagnostic rather 
than a hypothesis–testing tool. That is, only relatively crude-off points need 
to be considered and suspect data points should be closely examined 
regardless of statistical significance. 
 
Another commonly used method for detecting potential outliers 
involves the construction of prediction intervals around the predicted values 
at the desired confidence level. One then determines the observations whose 
observed values fall above the upper limit or below the lower limit of the 
corresponding prediction interval and identifies them as high or low outliers, 
respectively. Figure 3.7 depicts the observed AbC rates along with the 95% 
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and 90% prediction intervals of Model I and Model II. As illustrated in the 
figure, the identity of hospitals that were identified as outliers and the 
confidence level at which they were declared as outliers differed from the R-
student method in Figure 3.6. When a suspected outlier is included in the 
calculation of its corresponding prediction interval, one runs the risk of 
missing some outliers. This is because a point with a large residual would 
inflate the MSE and consequently results in wider prediction intervals. 
Therefore, as indicated earlier, one should leave out the observation in 
question when trying to determine if it is an outlier. Since R-student is the 
more sensitive method, it was the one adopted for the detection of outliers in 
this project.     
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Figure 3.6  Plots of externally studentized residuals (R-student) versus predicted total antibacterial drug 
consumption showing potential outlier hospitals identified by Model I (Figure A) and Model II (Figure 
B). The red reference lines and the blue reference lines represent the critical values of the t- 
distribution with n-p-1 degrees of freedom at the 95% and 90% confidence levels, respectively. 
The red data points represent potential outliers at α=.05 while the blue data points represent 
potential outliers at α=.10. The two models identified the same hospitals with the exception of 
Hospital #28 which was identified as a potential high outlier by Model II only and Hospital #22 
which was identified as a potential high outlier by Model I at α=.05 while it was identified by 
Model II at α=.10. These plots are also useful for detecting violations in some of the 
assumptions of linear regression as explained in the next section. These plots should ideally 
reveal a random scattering of the studentized residuals around 0 (black line).
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Figure 3.7  Observed antibacterial drug consumption along with the 95% and 90% prediction intervals of Model I (upper panel) and Model II 
(lower panel). At the 95% confidence level, Hospitals #4 and #26 were identified as potential high outliers while Hospital #29 was 
identified as a potential low outlier by both models. At the 90% confidence level, Hospital #22 was identified as a potential high 
outlier while Hospital #59 was identified as a potential low outlier by both models.
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A data point is considered to be influential if its exclusion from a 
model results in a noticeable change in the performance of that model or its 
various regression statistics. Figure 3.8 (B) demonstrates that an outlier is 
not necessarily influential (depends on leverage). A high leverage point may 
or may not be influential as illustrated in Figure 3.8 (A) and Figure 3.8 (B), 
respectively. In fact, the most influential data points are those that have 
both high leverage and large residuals as illustrated in Figure 3.8 (B). This 
implies that Hospital #28 is a high influence point in Model II and, perhaps 
to a lesser extent, in Mode I. Other data points that are considered high 
influence points include, but are not limited to, Hospitals #20 and #48 in 
both models as they have both large residuals and high leverage despite not 
being labeled as either outliers or high leverage points. The influential 
status of such data points can be verified by the inspection of the various 
influence diagnostics which are discussed next.   
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Figure 3.8  Different scenarios of outliers, high leverage points, and their influence on the fit of the 
model. Figure A, the black line was fitted using the black data points while the orange line was fitted 
using the same data points in addition to point D which is a high leverage point. Clearly, point D is a high 
influence point that has a positive impact on the fit of the model. Figure B, the black line was fitted using 
the black data points only. The red line was fitted using the same data points in addition to point A which 
is a high leverage point but not an outlier. The influence of point A on the regression is minimal since it 
falls along the general trend of the rest of the data. The blue line was fitted with the black data points in 
addition to point B which is an outlier but exhibits low leverage. The blue line is parallel and near the 
black one indicating that point B does not exert undue influence on the regression. The green line was 
fitted using the black data points in addition to point C which is both a high leverage point and an outlier. 
It is obvious that Point C is a high influence point that has a negative impact on the fit of the model.  
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3.2.6 Influence Diagnostics  
Having identified potential high leverage points, outliers and high influence 
points, this subsection is devoted to determining the influence of such 
suspect data points, if present, on the regression model. This is 
accomplished by examining various influence diagnostics. Influence 
diagnostics measure the impact of each data point on model performance. 
More specifically, these diagnostics measure the extent by which each data 
point contributes to the magnitude of parameter estimates and the 
prediction of fitted values. 
(i) Influence on the Fitted Value (DFFITS)    
DFFITS, which stands for “DiFference in FIT, Standardized”, was first 
proposed in 1980 by Belsley et al. [97]. It represents (roughly) the number of 
standard errors that the fitted value of the ith data point ( ˆ
i
y ) changes after 
refitting the model without the ith data point. Since the variance of ˆ
i
y  is 
given by   
 
2ˆ ˆVar( )
i ii
y h  (3.26)  
then the ith DFFITS is given by  
 
,
ˆ ˆ
(DFFITS)
ˆ
i i i
i
i ii
y y
h



  (3.27) 
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It turns out that DFFITS can be expressed as a function of R-student and hii  
 
1/2
(DFFITS) ( -student)
1
ii
i i
ii
h
R
h
 
  
 
 (3.28)  
A rule of thumb is to consider the ith data point as having a high influence 
on the fitted value if |(DFFITS)i|≥ 2√    .[97] According to this rule, the 
cut-off value for Model I is ±0.414 while the corresponding value for Model II 
is ±0.478. Figure 3.9 represents plots of (DFFITS)i versus predicted (fitted) 
values of the two models. As shown in the figure, Hospitals #20, #26, #28, 
#29 and #48 exceed the cut-offs of both models while Hospitals #4 and #27 
exceed the cut-off of Model II only. As evident in the figure, Hospital #48 in 
both models and Hospital #28 in Model II have (DFFITS)i  values that are 
considerably more extreme than those of the rest of the hospitals.   
 One may be interested in expressing the influence of the ith data point 
on its fitted value in terms of the units of the outcome variable. This can be 
accomplished by multiplying (DFFITS)i by the standard error of prediction of 
the ith data point which is the square root of Equation 3.26 with used in 
place of 
2ˆ . Obviously, this expression of the prediction error is also the 
denominator of (DFFITS)i  in Equation 3.27 and multiplying DFFITS by its 
denominator yields 
,
ˆ ˆ
i i i
y y

  which is the difference in the fitted value of the 
ith data point when the ith data point is included in the model and when it is 
removed from it.   
i
ˆ

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For Model I, (DFFITS)48 = 0.93 indicates that the removal of Hospital 
#48 from Model I decreases its predicted outcome by 0.93 standard errors. 
Transforming this difference into units of the outcome variable as explained 
above, one concludes that the presence of Hospital #48 in Model I decreases 
the predicted AbC of this hospital by 45 DOTs/1000 PDs. For Model II, 
(DFFITS)48 = 1.10 indicates that the removal of Hospital #48 from Model II 
decreases its predicted outcome by 1.10 standard errors which is equivalent 
to 328.4 DOTs/1000 discharges. 
74 
 
 
Figure 3.9  Plots of DFFITS versus predicted (fitted) total antibacterial drug consumption for Model I 
(Figure A) and Model II (Figure B). The orange lines represent the cut-off   √    (±0.414 for 
Model I and ±0.478 for Model II). The orange data points exceed these cut-off values and are 
therefore considered to have high influence on their fitted values.  
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(ii) Influence on the Parameter Estimates (DFBETAS) 
DFBETAS measures the number of standard errors that the jth parameter 
estimate 
j
ˆ )  changes after refitting the model without the i
th data point. 
Since the variance of 
j
ˆ is given by 
 
2 1
j
ˆVar( ) (X X)    (3.29) 
Then the influence of the ith data point on the jth parameter estimate is given 
by 
 
,
,
ˆ ˆ
(DFBETAS)
ˆ
j j i
j i
i jj
c


 
  (3.30) 
where 
,
ˆ
j i
  is the j
th parameter estimate of the model fitted without the ith 
data point and cjj  is the jth diagonal element of  
1(X X) . Like DFFITS, 
DFBETAS can be expressed as a function of R-student and hii allowing its 
computation from the original regression with all n data points without the 
need of fitting multiple models. However, the formula is more complex than 
that of DFFITS and the reader is referred to Myers for details [94]. A rule of 
thumb is to consider the ith data point as having a high influence on the jth 
parameter estimate if |(DFBETAS)j,i|≥ 2 √ . [97] According to this rule, the 
cut-off value is ±0.239 for both Model I and Model II. The DFBETAS for 
Model I are listed in Table 3.6 while those for Model II are listed in Table 3.7. 
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The values in boldface in the two tables indicate |(DFBETAS)j,i|≥ 0.239 and 
are therefore likely to exert a high influence on the parameter estimates. 
Unsurprisingly, the data points with the most extreme DFBETAS are the 
ones that were identified as having the most extreme DFFITS (Hospital #48 
in Model I and Hospitals #48 and #28 in Model II). In Model I, the removal of 
Hospital #48 increases the parameter estimate of infection rate by 0.87 
standard errors. In Model 2, the removal of Hospital #48 increases the 
parameter estimate of the same variable by 0.74 standard errors while 
removing Hospital #28 decreases the parameter estimate of transplant rate 
by 0.81 standard errors. (DFBETAS)j,i can be transformed (by making use of 
the standard error of the parameter estimates) to reflect the influence of the 
ith data point on the jth parameter estimates in terms of the unit of the 
outcome (DOTs/1000 PDs or DOTs/1000 discharges).  
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               Table 3.6   DFBETAS for Model I  
 
  DFBETAS 
  
DFBETAS 
Hospital  
ID 
Transplant 
Rate 
Infection 
Rate 
  Hospital  
ID 
Transplant 
Rate 
Infection 
Rate 
1 -0.031 -0.113 
 
36 0.017 0.090 
2 0.073 0.106 
 
37 -0.010 0.007 
3 -0.059 0.038 
 
38 -0.024 0.021 
4 0.008 0.094 
 
39 -0.003 -0.061 
5 0.004 0.040 
 
40 0.015 0.090 
6 0.181 0.137 
 
41 0.047 0.043 
7 0.050 -0.054 
 
42 0.015 -0.032 
8 -0.067 0.093 
 
43 -0.020 0.005 
9 -0.151 -0.070 
 
44 -0.051 -0.030 
10 0.005 -0.015 
 
45 -0.042 -0.112 
11 -0.013 -0.080 
 
46 0.093 -0.041 
12 -0.013 0 
 
47 0.101 -0.020 
13 0.098 -0.255 
 
48 -0.221 -0.872 
14 -0.040 0.044 
 
49 0.150 0.081 
15 -0.096 -0.025 
 
50 0.003 -0.002 
16 0.003 0.059 
 
51 -0.078 0.062 
17 -0.078 0.064 
 
52 -0.016 0.002 
18 -0.003 0.036 
 
53 0 0.017 
19 0.069 0.002 
 
54 -0.201 0.071 
20 -0.500 0.091 
 
55 -0.056 -0.087 
21 -0.088 -0.014 
 
56 -0.002 0.016 
22 0.025 0.172 
 
57 -0.030 0.009 
23 -0.024 0.031 
 
58 -0.004 -0.001 
24 0.132 -0.014 
 
59 0.200 0.136 
25 -0.004 -0.054 
 
60 -0.012 0.011 
26 -0.370 -0.240 
 
61 -0.051 -0.021 
27 0.034 0.214 
 
62 0.056 -0.037 
28 0.649 0.010 
 
63 0.008 0.005 
29 0.359 -0.214 
 
64 0.071 -0.044 
30 -0.004 0.014 
 
65 0.016 0.005 
31 0.026 0.099 
 
66 -0.010 0.039 
32 0.019 0.033 
 
67 -0.129 0.107 
33 0.017 -0.057 
 
68 -0.077 0.046 
34 -0.022 0.000 
 
69 0.023 -0.109 
35 0.035 0.162 
 
70 -0.018 0.045 
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Table 3.7   DFBETAS for Model II  
 
  DFBETAS 
   
DFBETAS   
Hospital 
ID 
Transplant 
Rate 
Infection 
Rate LOS 
  Hospital 
ID 
Transplant 
Rate 
Infection 
Rate LOS 
1 -0.068 -0.151 0.086   36 0.030 0.093 -0.036 
2 0.082 0.110 -0.048   37 -0.021 0.008 0.011 
3 -0.074 0.033 0.022   38 -0.048 -0.007 0.063 
4 -0.178 -0.083 0.439   39 -0.042 -0.099 0.093 
5 -0.042 0.010 0.112   40 0.031 0.077 -0.050 
6 0.099 0.070 0.061   41 0.052 0.049 -0.043 
7 0.036 -0.055 0.019   42 0.039 -0.003 -0.061 
8 -0.059 0.084 0.000   43 -0.012 0.006 -0.006 
9 -0.112 -0.041 -0.057   44 -0.043 -0.026 -0.002 
10 0.007 -0.008 -0.008   45 -0.098 -0.159 0.145 
11 -0.014 -0.068 0.009   46 0.098 0.000 -0.073 
12 -0.057 -0.007 0.018   47 0.104 0.003 -0.048 
13 0.070 -0.200 0.011   48 -0.063 -0.736 -0.378 
14 -0.029 0.051 -0.022   49 0.086 0.039 0.046 
15 -0.110 -0.041 0.041   50 -0.003 -0.021 0.034 
16 -0.013 0.054 0.040   51 -0.046 0.087 -0.067 
17 -0.072 0.056 0.004   52 -0.059 -0.029 0.077 
18 0.028 0.061 -0.070   53 -0.032 0.010 0.074 
19 0.099 0.040 -0.095   54 -0.185 0.081 -0.027 
20 -0.596 0.019 0.189   55 -0.134 -0.162 0.193 
21 -0.074 -0.007 -0.017   56 -0.021 0.001 0.045 
22 0.101 0.213 -0.192   57 0.002 0.025 -0.049 
23 -0.005 0.029 -0.023   58 0.000 0.000 -0.001 
24 0.109 0.034 -0.100   59 0.310 0.248 -0.306 
25 -0.031 -0.089 0.063   60 -0.009 0.012 -0.006 
26 -0.353 -0.245 0.111   61 -0.027 -0.004 -0.033 
27 -0.107 0.174 0.376   62 0.041 -0.026 -0.002 
28 0.808 -0.123 0.340   63 0.003 0.000 0.014 
29 0.650 0.063 -0.688   64 0.072 -0.018 -0.039 
30 -0.025 -0.004 0.049   65 -0.010 -0.006 0.009 
31 0.070 0.134 -0.110   66 -0.035 0.013 0.061 
32 0.009 0.015 -0.002   67 -0.030 0.131 -0.139 
33 -0.003 -0.077 0.047   68 -0.009 0.067 -0.093 
34 -0.037 -0.012 0.030   69 0.036 -0.058 -0.047 
35 0.007 0.072 0.025   70 0.007 0.064 -0.055 
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(iii) Influence on the Performance (COVRATIO) 
The DFFITS and DFBETAS diagnostics highlight those data points whose 
presence in the analysis bears a noticeable influence on the regression 
results. However, they do not indicate whether this influence is favorable or 
detrimental. One can gain insight into model performance by examining the 
variance-covariance matrix of the parameter estimates given by Equation 
3.29. The determinant of this matrix is known as the generalized variance 
(GV) 
 
2 1GV = det [ (X X) ]   (3.31) 
The ratio of GV of the model that is fitted after removing the ith data point to 
GV of the model fitted with the ith data point included is called COVRATIO. 
The estimators and 
2ˆ  are used instead of 
2  in the numerator and 
denominator, respectively. Then, the ith COVRATIO is given by   
 
2 1
2 1
ˆdet [ (X X ) ]
(COVRATIO)
ˆdet [ (X X) ]
i i i
i



  




 (3.32) 
where X
i
 denotes the (n -1)×p data matrix with the ith data point (row) 
removed. Since smaller GV values indicate higher precision in the 
estimation of the parameters, then a (COVRATIO)-i > 1 implies that the 
presence of the ith data point in the model is favorable as it reduces GV. 
i
ˆ

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Conversely, a (COVRATIO)-i < 1 implies that the presence of the ith data 
point in the model is detrimental as it increases GV.   
A computational form of COVRATIO is given by    
 
2
2
ˆ 1
(COVRATIO)
ˆ 1
p
i
i
ii
h



  
       
 (3.33) 
The term 1/1-hii  in the above Equation 3.33 is the ratio of det
1[(X X) ] to          
det
1[(X X ) ]
i i

 
 . If the ith data point is a high leverage point (hii  1) then it will 
yield a large (COVRATIO)i which indicates that the ith data point has a 
favorable effect on the precision of the parameter estimates, assuming that 
the point is not an outlier in the y direction. If the ith data point is, in fact, 
an outlier then 
2ˆ
i


 
2ˆ    will be less than one by a considerable margin. 
Thus, similar to DFFITS and DFBETAS, the combination of leverage 
(distance of the data point from the center of the x space) and outlier status 
(error in y direction) work hand in hand to create the diagnostic criterion.   
A yardstick is to consider the ith data point as having a positive impact on 
the regression if (COVRATIO)i  
3
1
p
n
  while (COVRATIO)i  
3
1
p
n
   indicates 
that the ith data point has a negative impact on the regression [97]. Applying 
this yardstick to Model I, the ith data point was deemed to be favorable if 
(COVRATIO)i  > 1.129 while it was deemed to be detrimental if (COVRATIO)i < 
0.871. For Model II, the corresponding cut-off points were 1.171 and 0.829, 
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respectively. The (COVRATIO)i  values of the two models are plotted against 
the predicted values in Figure 3.10. As illustrated in the figure, (COVRATIO)i  
of Hospitals #4, #26, and #29 falls below the low cut-off point in both 
models and these hospitals are therefore considered to have a potentially 
detrimental impact on the two models. However, in order to put things in 
perspective, it is important to note that COVRATIO should be taken in 
context with DFFITS, DFBETAS, outlier status and leverage. With the 
exception of Hospital #4 in Model II, these hospitals were identified by both 
DFFITS and DFBETAS in the two models. Moreover, all three hospitals that 
were labeled as “bad” by COVRATIO in the two models were also identified 
as outliers in both models. This is not surprising since by definition, an 
outlier is a data point with a large residual and the presence of such a data 
point  in the model will increase variance (
2ˆ ) causing the  2ˆ
i


 
2ˆ    ratio in 
Equation 3.33, and ultimately (COVRATIO)i  , to fall considerably below 1. In 
general, outlier data points that have low leverage (small hii.) produce a 
(COVRATIO)i  well below one which indicates that they decrease the 
precision of the parameter estimates.  
Figure 3.10 also reveals that (COVRATIO)i  for Hospitals #35 and #48 
falls above the upper cut-off point in both models, (COVRATIO)i  for 
Hospitals #12, #20, #28 and #54 surpasses this point in Model I only, and 
(COVRATIO)i  for Hospital #68 exceeds this cut-off in Model II only. Recall 
that, with the exception of Hospitals #12 and #68, these hospitals were 
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previously determined to be high leverage points. Hospitals #20 and #28 in 
Model I, in addition to Hospital #48 in both models, were highlighted by 
DFFITS and DFBETAS. These diagnostics did not highlight any of the other 
hospitals that were labeled as being “good” by COVRATIO in either model. 
However, this does not necessarily imply that these non-highlighted 
hospitals are “inert”. These data points may impact hypothesis testing and 
the conclusions drawn from the analysis by virtue of their favorable impact 
on the precision of the parameter estimates as indicated by their large 
(COVRATIO)i . In general, data points that have high leverage (large hii.) but 
are not outliers produce a (COVRATIO)i  well above one which indicates that 
they increase the precision of the parameter estimates. Such high leverage 
points will cause the term (1/1
ii
h ) in Equation 3.33, and ultimately 
(COVRATIO)i, to be considerably higher than one.  
As previously mentioned, Hospital #28 was identified as a high 
influence point in Model I. The reason why its (COVRATIO)i  is larger than 
one is because its “outlier-ness”, which pulls (COVRATIO)i  down, is 
outweighed by its high leverage, which pushes (COVRATIO)i  up. Thus, the 
magnitude of COVRATIO and its direction, above or below unity, is 
determined by the extent by which one of the two opposing forces, leverage 
and outlierness, outweighs the other. In Model II, (COVRATIO)i  for Hospitals 
#20 and #28, among others, does not exceed the upper cut-off point as 
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shown in Figure 3.10. However, such hospitals should be examined closely 
since were highlighted by both DFFITS and DFBETAS. 
   The analysis of residuals and influence diagnostics play an 
important role in determining whether the model is being dictated by a few 
suspect data points. One can predict the impact of suspect data points on 
the model by determining their status as outliers, high leverage points or 
high influence points. On the other hand, influence diagnostics determine 
the exact impact of such suspect data points. An unexpected magnitude or 
sign of a parameter estimate may be due to the effect of a few suspect data 
points. Inspection of DFBETAS pinpoints the data points implicated in such 
scenarios. COVRATIO is a measure of the precision of the parameter 
estimates and the presence of extreme (COVRATIO)i  values in either 
direction may change the significance of parameter estimates and may 
consequently affect our model selection.  Finally, the presence of a set of 
outliers or high influence points may indicate the need to apply a 
transformation on the outcome variable or even consider a different model 
altogether.   
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Figure 3.10  Plots of COVRATIO versus predicted total antibacterial drug consumption for Model I 
(Figure A) and Model II (Figure B). The horizontal violet lines represent the   
  
 
 cut-off point 
above which data points are considered to have a favorable impact on the model (violet data 
points). The horizontal gray lines represent the  −
  
 
 cut-off point below which data points are 
considered to have detrimental effect on the model (gray data points). As explained in the text, 
COVRATIO should be taken in the context of other the other influence diagnostics to be 
meaningful. 
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3.2.7 Checking Model Assumptions  
The popularity of OLS is largely attributed to the attractive properties of the 
OLS estimators. According to the Gauss-Markov Theorem, OLS estimators 
are Best Linear Unbiased Estimators (BLUE). Here “best” means that OLS 
estimators are efficient in the sense of having the least variance among all 
linear unbiased estimators. However, this desirable property holds only 
when the assumptions underlying OLS are satisfied. Therefore, checking the 
following assumptions should ideally be carried out whenever a linear 
regression model is fitted. 
(i) Linearity 
As the name linear regression implies, the outcome variable is assumed to 
be a linear function of the predictor variable(s). If one fits a linear regression 
model when the functional form of the relationship is in fact non-linear, 
then the OLS estimates will no longer be unbiased. The linearity assumption 
can be checked graphically by inspecting the bivariate scatterplots in Figure 
3.4 and/or the residual (studentized residual) by predicted plots such as the 
ones depicted in Figure 3.6. One would typically look for any nonlinear 
trends such as curvilinear patterns when inspecting such plots. Neither 
graph shows any non-linear patterns so the linearity assumption seems to 
hold here for both Model I or Model II.  
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(ii) Homoscedasticity (constant variance)  
As previously mentioned, the errors are assumed to have the same variance 
regardless of the value of the x’s. This assumption is also known as 
homoscedasticity which is Greek for “same variance”. If this assumption is 
violated, then the OLS estimators will still be unbiased but they are no 
longer efficient (do not have the minimum variance among all linear 
unbiased estimators).  
The homoscedasticity assumption is usually checked graphically by 
examining the residual (studentized residual) by predicted plots such as the 
ones displayed in Figure 3.6. The plots should ideally reveal a random 
scattering around 0 (the horizontal black line in the figure) with no 
particular pattern. The random scattering is evident in the figure but 
probably to a greater degree in Figure 3.6 A (Model I) than Figure 3.6 B 
(Model II). However, one should relatively be comfortable that the 
homoscedasticity assumption holds for both models.   
(iii) Independence 
The independence assumption refers to the lack of dependence between the 
error terms and, consequently, the y values. In other words, there should be 
no autocorrelation between the errors for this assumption to be satisfied. In 
the presence of autocorrelation, the OLS estimates will remain unbiased but 
they are no longer efficient. Autocorrelation usually leads to 
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underestimating the standard errors of the parameter estimates and, 
consequently, inflating the Type I error.   
  The independence assumption can be verified either graphically or by 
formal statistical tests.  However, this is not usually done unless one has 
reason to suspect that autocorrelation may have been introduced by the 
methods used in sampling or collecting the data. Also, autocorrelation is 
usually present to an appreciable extent in certain types of data such as 
time series and clustered data.  Since there is no reason to believe that the 
consumption of antibacterial drugs in one hospital may be dependent on 
that of another, the independence assumption is assumed to be satisfied for 
the two models.  
(iv) Normality 
The three assumptions above are necessary for the OLS estimators to be 
BLUE. On the other hand, normality of the errors need not be assumed to 
achieve this desirable property. Nonetheless, the normality assumption is 
required for performing inferential statistics since both the t-test and F-test 
assume normality. Moreover, if the normality assumption is satisfied (in 
addition to the assumptions of linearity, homoscedasticity, and 
independence), the OLS estimators will have enhanced properties since they 
become Uniformly Minimum-Variance Unbiased Estimators (UMVUE). That is, 
OLS estimators will have minimum variance among all unbiased estimators, 
not just the linear ones. 
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 If the normality assumption is satisfied, a histogram of the raw 
residuals or, preferably, the studentized residuals would reasonably assume 
the “bell-shaped” curve that is typical of the normal distribution.  Q-Q plots 
(also known as normal quantile plots) are another graphical method for 
checking the normality assumption. A Q-Q plot can be constructed by 
plotting the studentized residuals on one axis and the corresponding 
expected z-scores (normal quantiles) from the standard normal distribution 
on the other. If the data were perfectly normally distributed, then the data 
points of the Q-Q plot would perfectly fall along a 45-degree diagonal line.  
Conversely, if the point pattern of a Q-Q plot exhibits considerable 
curvature that strays away from the perfect linear fit, this would indicate a 
marked departure from normality. The histograms of the studentized 
residuals with overlaid normal density curves are displayed along with the 
Q-Q plots for Model I and Model II in Figure 3.11. For both models, the 
histograms appear to be reasonably symmetric and follow the normal 
density curves fairly closely while the data points in the Q-Q plots do not 
appear to deviate extensively from the 45-degree diagonal line representing 
perfectly normally distributed data. Therefore, it is probably safe to assume 
normality in both models. Since the assumptions of linear regression were 
met, no consideration was given to Poisson regression.      
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Figure 3.11  Normal quantile plots (upper panel) and histograms with overlain normal density curves 
(lower panel) of the studentized residuals obtained from Model I (Figure A) and Model II (Figure B). 
The two histograms appear reasonably symmetric and follow the overlaid normal density curves 
fairly closely. The red solid diagonal lines in the Q-Q plots represent the ideal path data would 
follow if it were perfectly normal.  Since data do not deviate markedly from this ideal line and do 
not cross the dashed red lines, then one can conclude that there are no serious departures from 
normality in either model.   
 
 
 
 
 
 
90 
 
3.2.8 Model Validation 
 
(i) Internal Validation  
Model validation is an important guard against overfitting the model to the 
study sample. One of the objectives of model validation is to evaluate the 
usefulness of a given model in predicting the outcome of future 
observations. R2 is a goodness-of-fit statistic and a high R2 does not 
necessarily imply that the model will be useful for prediction purposes. 
While the R2 quantifies the proportion of the variability in the outcome 
variable explained by the model using the existing dataset, the predicted R2 , 
on the other hand, measures the proportion of the variability in the outcome 
variable the model is expected to explain when it is fitted to a new dataset 
(i.e., new observations). Thus, unlike the “ordinary” R2, the predicted R2 is 
useful for model validation purposes as it provides a useful insight into the 
predictive capabilities of a model.  
The predicted R2 is obtained by the LOOCV method which is identical 
to the previously described method of obtaining the PRESS statistic. The 
predicted R2 is given by 
 
2 1
PRED
R  
PRESS
SST
 (3.34) 
Since SST is constant for any given dataset, then Equation 3.34 implies that 
the model with the smallest PRESS will also have the largest predicted R2. 
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The candidate models selected to represent Model I and Model II (Model IA 
and Model IIA in Table 3.3) had the highest predicted R2 among all 
competing models. The predicted R2 for the two models, in the above order, 
is 0.25 and 0.58 which is in reasonable agreement with the adjusted R2  of 
0.29 and 0.63, respectively. This indicates that neither model was overfit.      
LOOCV is a resource intensive procedure but it is often superior to 
the simpler and more commonly used “hold-out cross validation” which 
splits the sample into a training set and a testing set. This is especially true 
when the sample size is small like the one in this study since the latter 
method wastes valuable data and may result in imprecise and biased 
parameter estimates [98]. However, while LOOCV produces approximately 
unbiased prediction errors, it may also have very high variance and may 
consequently select the “wrong” model [99].  
(ii) External Validation  
External validation should ideally be carried out using a validation set that 
is independent of the calibration set. However, most studies, including this 
one, do not have the luxury of having a completely independent dataset for 
validation. The validation set consisted of n= 55 hospitals that are a subset 
of the n= 70 hospitals composing the calibration set but whereas the data 
used in the latter was from 2009, the one used in the former was from the 
2008 calendar year. The validation adjusted R2 for model I was 0.25 while 
that for Model II was 0.57. These were in agreement with both the 
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corresponding adjusted R2 for the two models and the corresponding 
predicted R2 obtained from the internal validation method. In line with the 
previous conclusion from internal validation, the external validation results 
indicate that neither model was overfit. The internal and external validation 
scatterplots are displayed in Figure 3.12. 
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Figure 3.12  Observed by predicted plots representing internal (upper panel ) and external (lower panel) 
validation methods. Internal validation used the original calibration set to perform the leave-one-out 
cross validation (LOOCV) method and consequently obtain the adjusted predicted values and the 
predicted R2 (     
 = 0.25 for Model I and 0.58 for Model II). In external validation, the 
prediction equations of the two models were applied to the validation set (see text for details on 
validation set) to derive the corresponding predicted values, which were in turn plotted against 
the corresponding observed values of the validation set and the validation adjusted R2 were 
obtained (    
 = 0.25 for Model I and 0.57 for Model II). The results of both internal and 
external validation methods do not suggest that either model was overfit. 
External Validation 
Internal Validation 
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Chapter IV 
The Application of Standardization 
Methods to the Risk-adjustment of 
Antibacterial Drug Use 
 
 
4.1 Methods 
4.1.1 Data Source and Assignment of Patients to Clinical Service Lines 
A second dataset was provided by UHC where adult discharges in each of 
the 70 hospitals that subscribed to the CRM database during 2009 (section 
3.1) were stratified into 35 distinct categories. The UHC assigned adult 
patients in each hospital to 1 of these categories, which hereinafter will be 
referred to as clinical service lines (CSLs) and are listed in Table 4.1. This 
classification of patients into CSLs is based on their assignment to 1 of 745 
MS-DRGs by the CMS MS-DRG Grouper software upon discharge 
(http://www.ntis.gov/products/grouper.aspx; accessed on 16 January 
2012). The software classifies patients into groups (MS-DRGs) expected to 
have similar hospital resource utilization based upon primary and 
secondary diagnoses, procedures, the presence of complications and 
comorbidities, demographics and discharge status [44]. The grouping of 
patients into CSLs was based upon the similarity and relatedness of their 
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clinical conditions as determined by their MS-DRG assignment. The 
complete MS-DRG composition of the 35 CSLs can be found in Table A3 in 
the appendix. The CSLs assumed the role of the strata in the 
standardization procedures and the CSL-specific AbC rates and weights 
were used to derive the standardized hospital-wide rates as will be explained 
shortly.  
4.1.2 Data Components and Descriptive Statistics  
The following variables were available in the dataset within each CSL for 
each hospital: the number of discharges, the number of discharges receiving 
(at least one dose of) antibacterial drug therapy, the number of patient days, 
the number of DOTs and the number of LOT. These variables were pooled 
across the entire sample of 70 hospitals to create the reference population. 
However, since the CSL composition varied from one hospital to another 
(i.e., not all hospitals had all 35 CSLs), it was not possible to standardize all 
hospitals to a common reference population and a different reference 
population was created for each set of hospitals that had the same CSL 
composition (see page 117 for further details).   
In both individual hospitals as well as the reference population, the 
above mentioned variables were used to calculate the CSL-specific AbC rate 
in DOTs/1000 discharges and DOTs/1000 patient days; in addition to the 
different components of these measures, including LOT/discharge for 
patients receiving antibacterial therapy, proportion of discharges receiving 
antibacterial therapy, DOTs/LOT ratio and mean LOS. For the sake of 
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brevity and clarity, I will henceforth refer to the discharges receiving 
antibacterial drug therapy as “cases” while the term “discharges” will be 
used to refer to all discharged patients irrespective of whether or not they 
received antibacterial therapy. The data were summarized using the mean 
and median as measures of central tendency while the range was used as 
the measure of dispersion.  
4.1.3 The Application of Direct and Indirect Standardization  
         Procedures 
The Direct Standardization Procedure 
For each hospital, the CSL-specific AbC rate (DOTs/discharge) within each 
CSL was multiplied by the number of discharges in the corresponding CSL 
of the reference population to yield the expected number of DOTs in that 
CSL. These expected CSL-specific number of DOTs were summed across all 
the CSLs that compose the given hospital to give the expected hospital-wide 
total number of DOTs in the reference population. The DSR, or the expected 
(i.e., adjusted) hospital-wide AbC rate measured in DOTs/1000 discharges 
was obtained by dividing the expected hospital-wide total number of DOTs 
by the total number of discharges in the corresponding reference population 
and multiplying the result by 1000. The hospital-wide E/O ratio for a given 
hospital was calculated by dividing its DSR by the crude (i.e., observed) rate 
of its corresponding reference population.   
The direct standardization procedure was also applied to derive the 
standardized values of the four components of AbC rates mentioned in 
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section 4.1.2. Specifically, the expected hospital-wide DOTs/LOT ratio was 
obtained by dividing the expected hospital-wide total number of DOTs by 
the expected hospital-wide total number of LOT. The latter was derived 
through direct standardization in a similar manner to the former. Similarly, 
the direct standardization procedure was also used to calculate the expected 
hospital-wide total number of cases using the CSL-specific proportion of 
cases in the study hospitals and the number of discharges in the 
corresponding CSLs of the reference population. The expected hospital-wide 
total number of cases was divided by the total number of discharges in the 
corresponding reference population to yield the expected hospital-wide 
proportion of cases. Moreover, the expected hospital-wide LOT/case was 
obtained by dividing the expected hospital-wide total number of LOT by the 
expected hospital-wide total number of cases.  
Finally, the expected hospital-wide mean LOS was calculated by 
dividing the expected hospital-wide total number of patient days by the total 
number of discharges in the corresponding reference population. The 
numerator was obtained through direct standardization using the CSL-
specific mean LOS in the study populations and the number of discharges 
in the corresponding CSLs of the reference population.     
The Indirect Standardization Procedure 
The indirect standardization procedure is a mirror image of its direct 
counterpart. That is, for each hospital, the CSL-specific DOTs/discharge 
rate within each CSL of the corresponding reference population was 
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multiplied by the number of discharges in the corresponding CSL of the 
given hospital to yield the expected number of DOTs in that CSL. These 
expected CSL-specific number of DOTs were summed across all the CSLs 
that compose the given hospital to give the expected hospital-wide total 
number of DOTs for that hospital. The expected hospital wide DOTs/1000 
discharges rate was obtained by dividing the expected hospital-wide total 
number of DOTs for the hospital by its total number of discharges and 
multiplying the result by 1000.  
The hospital-wide O/E ratio for a given hospital was calculated by 
dividing its observed rate by its expected one. An O/E ratio was also 
calculated for each of the four components of AbC rates. The expected 
hospital-wide values of these components were calculated as described in 
the direct standardization procedure but by applying indirect 
standardization instead of direct standardization. Finally, the ISR was 
calculated by multiplying the O/E ratio for the DOTs/1000 discharges rate 
by the crude rate in the corresponding reference population.  
Identifying Outliers for Both Standardization Procedures  
In order to identify outliers, I first calculated z-scores by subtracting 
the E/O (O/E) ratio of each hospital from the mean E/O (O/E) ratio of the 
entire study population and subsequently dividing by the corresponding 
standard deviation. I then classified hospitals as high or low outliers at the 
95% confidence level if their z-score was higher than +1.96 or lower than   
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 -1.96, respectively. On the other hand, hospitals were classified as high or 
low outliers at the 90% confidence level if their z-score was higher than  
+1.64 and lower than -1.64, respectively. 
4.1.4 Comparison of Antibacterial Drug Consumption Measures and 
Risk-adjustment Methods 
          
In the direct and indirect standardization procedures, hospitals were ranked 
according to their E/O and O/E ratios, respectively, while in the MLR 
models, hospitals were ranked based on their R-student statistic. The 
weighted kappa coefficient (weighted ) was used to compare the extent of 
agreement of direct standardization with indirect standardization, Model I 
with Model II and Model II with either standardization procedure with 
respect to ranking hospitals. The weighted coefficients were obtained using 
the PROC FREQ procedure in SAS. The guidelines proposed by Altman were 
used to interpret the  scores [100]. The agreement between the different 
methods with respect to the hospitals they identified as outliers was also 
described. 
4.1.5 Comparison of Interhospital Antibacterial consumption at the   
CSL   CSL Level 
 
A direct comparison of the observed CSL-specific AbC rates and their 
components between hospitals was carried out. Weighted was also used to 
measure the extent of agreement between the CSL-specific DOTs/1000 
discharges and DOTs/1000 PDs rates in ranking hospitals. 
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4.2 Results 
4.2.1 Descriptive Statistics   
Demographics by Clinical Service Line 
Table 4.1 provides the summary statistics for the number of discharges, the 
number of patient-days and LOS stratified by CSL. The general medicine 
CSL had both the largest number of discharged patients (median, 5099; 
range, 232-12,800) and the largest number of patient-days (median, 21,693; 
range, 933-69,761) accounting for 21.1% of the 1,791,172 total discharges 
and 16.9% of the 9,820,959 total patient-days. Other CSLs with appreciable 
size included obstetrics which accounted for 11.5% of the total number of 
discharges (median, 2710; range, 6-8668) and 6.6% of the total number of 
patient-days (median, 8493; range, 16-30,227), cardiology which accounted 
for 10% of the total number of discharges (median, 2267; range, 46-6333) 
and 7.6% of the total number of patient-days (median, 8688; range, 152-
29,214) and general surgery which accounted for 8.2% of the total number 
of discharges (median, 1895; range, 94-6703) and 10.7% of the total 
number of patient-days (median, 14,021; range, 576-44,396).   
At the opposite end, the transplant CSLs in general had some of the 
smallest sizes. For example, the heart transplant/implant of heart assist 
system CSL accounted for only 0.10% of the total number of discharges 
(median, 30; range, 1-113) and only 0.70% of the total number of patient-
days (median, 1009; range, 2-7887), whereas the BMT CSL accounted for 
only 0.28% of the total number of discharges (median, 88; range, 1-453) and 
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only 1.14% of the total number of patient-days (median, 1972; range, 1-
8405). However, unlike the aforementioned large size CSLs, the transplant 
CSLs were among the CSLs not represented at every hospital (Table 4.1).  
The two transplant CSLs, in the above order, had a mean LOS of 32.5 days 
and 23.5 days. The other CSL with a notably long LOS was the ventilator 
support (mean, 30.7 days) while the gynecology (mean, 2.7 days) and the 
obstetrics (mean, 3.2 days) CSLs had the shortest LOS.  
 
Aggregated Antibacterial Drug Consumption by Clinical Service Line 
Table 4.2 summarizes different measures of total aggregate AbC stratified by 
CSL. When AbC was measured in DOTs/1000 PDs, the lung transplant CSL 
had the highest consumption (mean, 2039; range, 933-2967) followed by the 
Human Immunodeficiency Virus (HIV) CSL (mean, 1704; range, 705-2533) 
whereas the psychiatry CSL had the lowest consumption (mean, 97; range, 
29-488). When AbC was measured in DOTs/1000 discharges, the ventilator 
support CSL had the highest consumption (mean, 38,874; range, 18,333-
71,979) followed by the heart transplant/implant of heart assist system CSL 
(mean, 35,928; range, 2000-71,156) and the lung transplant CSL (mean, 
34,753; range, 13,067-75,545) whereas the psychiatry CSL had the lowest 
consumption (mean, 824; range, 190-3108). 
The other variables in Table 4.2 measure different meaningful 
components of AbC. LOT/case is a proxy measure of the average duration of 
therapy per treated patient while the DOT/LOT ratio is a proxy measure of 
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the average number of administered antibacterial drugs. The product of 
these two variables is DOTs/case. LOT/1000 PDs may be considered a 
proxy measure of the average percentage patient days that are treatment 
days (i.e., a patient day where at least one dose of an antibacterial drug is 
administered).   
 The components of AbC are somewhat obscured by the DOTs/1000 
PDs and DOTs/1000 discharges measures. However, the two measures can 
be decomposed and expressed as a function of these components. More 
specifically, the DOTs/1000 discharges measure is the product of the 
DOTs/LOT ratio and LOT/1000 discharges.  
 
. . .
. . .
 
no of DOTs no of DOTs no of LOT
no of discharges no of LOT no of discharges
 (4.1) 
Since LOT/1000 discharges is the product of LOT/1000 cases and the  
percentage of cases (discharges receiving antibacterial therapy),  
Equation 4.1 can be rewritten as 
 
. . . .
. . . .
  
no of DOTs no of DOTs no of LOT no of cases
no of discharges no of LOT no of cases no of discharges
 (4.2) 
 
DOTs
discharge
               
DOTs
ratio
LOT
   
LOT
case
     
percent discharges
receiving antibiotics
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DOTs/1000 PDs, on the other hand, is the product of the DOTs/LOT ratio 
and LOT/1000 PDs.  
 
. . .
. . .
 
no of DOTs no of DOTs no of LOT
no of patient days no of LOT no of patient days
 (4.3) 
Dividing both numerator and denominator of the last term by the number of 
discharges  
. . . .
. . . .
 
no of DOTs no of DOTs no of LOT no of discharges
no of patient days no of LOT no of patient days no of discharges  
Thus, in analogy to Equation 4.2, the above equation can be rewritten as  
 
. .
. .. .
. . . .
 
no of LOT no of casesno of cases no of dischargesno of DOTs no of DOTs
no of patient days no of LOT no of patient days no of discharges
 (4.4) 
 
DOTs
patient day
             
DOTs
ratio
LOT
  
LOT
case
               LOS      
percent discharges
receiving antibiotics
                    
A comparison of Equation 4.4 with Equation 4.2 reveals that the percent 
discharges receiving antibiotics, LOT/case and DOTs/LOT ratio are 
components that are common to both the DOTs/1000 discharges and 
DOTs/1000 PDs measures. This comparison also reveals the well-known 
fact that the latter measure equals the former divided by the average LOS. 
Figure 4.1 shows AbC displayed in ascending order and measured in 
both DOTs/1000 discharges (upper panel) and DOTs/1000 PDs (lower 
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panel), along with the above-mentioned components, in 5 CSLs with 
different consumption patterns. As expected, the upper panel shows that as 
the DOTs/1000 discharges measure increases, the three components that 
compose it also exhibit a general increasing trend. However, as shown in the 
lower panel, this linear pattern between these components and AbC was 
clearly absent when the latter was measured in DOTs/1000 PDs. This is 
especially true for the LOT/case component and, to a lesser extent, the 
percent number of cases component.   
 The figure, as well as Table 4.2, also reveals that the two AbC rates 
were concordant within the lung transplant, gastroenterology and 
psychiatry CSLs as they had very high, average and very low use, 
respectively, in both rates. Conversely, the two measures were discordant 
within the heart transplant/implant of heart assist system and, to a lesser 
extent, the ophthalmology CSLs. As reported in Table 4.2 and illustrated in 
Figure 4.1, the former had a very high use in DOTs/1000 discharges (mean, 
35,928) but only a moderate use in DOTs/1000 PDs (mean, 912) while the 
latter had a relatively low use in DOTs/100 discharges (mean, 3,664) but a 
relatively high use in DOTs/1000 PDs (mean, 1,112). The two CSLs, in the 
above order, had a mean percent discharges receiving antibiotics of 99% 
and 69.8%, a mean LOT/case of 21.6 days and 3.3 days, a mean DOTs/LOT 
ratio of 1.68 and 1.57 and a mean LOS of 39.4 days and 3.3 days.  
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The discrepancy between the two measures within the two CSLs is 
attributed to LOS since it is a component of the DOTs/1000 PDs but not the 
DOTs/1000 discharges measure while the other 3 components are common 
to both measures as previously indicated. It is clear that this paradoxical 
situation was caused by the extremely long LOS in the first CSL and the 
extremely short one in the second resulting in a disproportionate deflation 
and inflation, respectively, of the DOTs/1000 PDs measure relative to the 
DOTs/1000 discharges measure. This disproportionate effect of LOS was 
also reflected in the LOT/1000 PDs measure which was moderate for the 
first CSL (mean, 544) and relatively high for the second (mean, 708).  
 
 
 
 
 
 
 
 106 
 
 
 Table 4.1   Characteristics of Adult Discharges at 70 U.S. Academic Medical Centers in 2009 Stratified by Clinical Service Line  
 
CSL ID CSL Description N Sum % of Total Mean Median Min Max Sum % of Total Mean Median Min Max Mean SD Min Max
1 Bone Marrow Transplant 50 5014 0.28% 100 88 1 453 112030 1.14% 2241 1972 1 8405 22.3 6.80 1.0 44.2
2 Burns 66 4945 0.28% 75 10 1 445 43445 0.44% 658 99 1 4395 8.8 3.49 1.0 16.3
3 Cardiology 70 178678 9.98% 2553 2267 46 6333 748276 7.62% 10690 8688 152 29214 4.2 0.64 2.9 5.9
4 Cardiothoracic Surgery 70 59619 3.33% 852 688 5 3412 521190 5.31% 7446 5492 32 24264 8.7 1.70 6.1 16.8
5 Dental/Oral Surgery 69 3307 0.18% 48 42 9 221 11079 0.11% 161 140 28 480 3.4 1.08 1.4 8.3
6 Dermatology 69 3473 0.19% 50 42 11 194 15351 0.16% 222 181 39 888 4.4 0.93 2.8 6.8
7 Gastroenterology 70 126928 7.09% 1813 1738 71 4828 588163 5.99% 8402 7788 308 21203 4.6 0.48 3.6 5.8
8 Gynecology 70 30453 1.70% 435 399 19 1246 79471 0.81% 1135 1043 46 3303 2.6 0.47 1.3 3.9
9 Heart Transplant/ Implant of Heart 
Assist System
51 1756 0.10% 34 30 1 113 69171 0.70% 1356 1009 2 7887 39.4 16.63 2.0 74.2
10 HIV 69 8421 0.47% 122 72 5 1194 73535 0.75% 1066 685 27 10521 8.7 3.25 3.9 24.2
11 Kidney/Pancreas Transplant 59 6285 0.35% 107 87 13 284 46100 0.47% 781 633 110 3365 7.3 2.09 3.8 14.3
12 Liver Transplant 46 2396 0.13% 52 48 6 163 40782 0.42% 887 724 73 4679 17 4.85 7.9 28.7
13 Lung Transplant 30 687 0.04% 23 15 2 70 11710 0.12% 390 309 30 1216 17 4.63 9.5 28.9
14 Medical Oncology 70 62416 3.48% 892 804 6 2417 415843 4.23% 5941 5103 27 17278 6.7 1.19 4.2 9.6
15 Medicine General 70 378417 21.13% 5406 5099 232 12800 1663899 16.94% 23770 21693 933 69761 4.4 0.54 3.1 5.8
16 Neurology 70 98160 5.48% 1402 1303 31 3232 433657 4.42% 6195 5625 150 14033 4.4 0.61 3.0 6.4
17 Neurosurgery 70 37203 2.08% 531 454 1 1451 269137 2.74% 3845 3373 5 11483 7.2 2.14 4.5 17.3
18 Obstetrics 70 206121 11.51% 2945 2710 6 8668 646232 6.58% 9232 8493 16 30227 3.1 0.45 2.1 4.6
19 Ophthalmology 69 4199 0.23% 61 42 7 570 13838 0.14% 201 152 24 1159 3.3 0.92 2.0 6.5
20 Orthopedics 70 111418 6.22% 1592 1337 363 5705 483740 4.93% 6911 6189 2087 23177 4.3 0.76 3.1 6.3
21 Otolaryngology 70 17110 0.96% 244 207 7 862 79645 0.81% 1138 1033 18 2745 4.7 0.98 2.6 8.0
22 Plastic Surgery 70 10778 0.60% 154 138 6 520 105930 1.08% 1513 1337 63 5382 9.8 2.87 5.8 21.8
23 Psychiatry 69 57829 3.23% 838 718 21 4444 492023 5.01% 7131 5696 73 33762 8.5 2.64 2.5 13.4
24 Rehabilitation 32 15713 0.88% 491 447 16 1167 207860 2.12% 6496 6280 242 14830 13.2 2.94 8.4 19.3
25 Rheumatology 70 12337 0.69% 176 157 6 460 57861 0.59% 827 765 10 2009 4.7 0.99 1.7 8.0
26 Substance Abuse 70 13819 0.77% 197 135 4 1511 62695 0.64% 896 638 19 5440 4.5 1.01 2.9 7.0
27 Surgical Oncology 70 9691 0.54% 138 107 6 538 63676 0.65% 910 773 16 3156 6.6 2.01 2.7 13.1
28 Surgery General 70 146339 8.17% 2091 1895 94 6703 1053701 10.73% 15053 14021 576 44396 7.2 0.98 4.4 9.6
29 Trauma 70 15831 0.88% 226 186 2 841 133920 1.36% 1913 1731 14 9435 8.5 2.08 3.5 13.0
30 Urology 70 47203 2.64% 674 565 86 2658 189328 1.93% 2705 2409 231 8079 4 0.80 2.2 6.2
31 Vascular Surgery 69 19758 1.10% 286 249 36 943 101723 1.04% 1474 1281 363 4779 5.1 1.44 3.2 12.5
32 Ventilator Support 70 20985 1.17% 300 277 3 728 647794 6.60% 9254 8626 31 22758 30.9 6.70 10.3 50.0
33 Spinal Surgery 70 48299 2.70% 690 591 3 2362 203382 2.07% 2905 2523 57 9437 4.2 2.20 1.8 19.0
34 Injuries/complications of prior care 70 15093 0.84% 216 202 32 566 86480 0.88% 1235 1171 144 2782 5.7 1.02 3.4 8.4
35 Gynecology/Oncology 70 10491 0.59% 150 136 2 524 48292 0.49% 690 621 22 2071 4.6 1.42 1.6 11.0
No. of discharges No. of patient days Length of stay
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DOTs
/case
LOT
/case 
Percent 
discharges 
receiving 
antibiotics 
CSL 
ID Sum
% of 
Total MeanMedian Min Max Mean* Median Min Max Mean* Median Min Max Mean* Sum
% of 
Total Mean Median Min Max Mean*Median Min Max Mean* Median Min Max Mean* Mean* Mean* Min Max
1 142118 1.75% 2842 2348 2 10720 1269 1238 827 2333 28344 26394 2000 82746 29.5 85177 1.62% 1704 1474 2 7195 760 813 495 2000 16988 17171 2000 33113 17.7 96.1% 1.67 1.00 2.53
2 26771 0.33% 406 70 1 3492 616 655 189 5000 5414 4822 500 17000 9.7 18757 0.36% 284 53 1 2099 432 474 159 2000 3793 3498 500 9000 6.8 56.0% 1.43 1.00 2.57
3 405518 4.98% 5793 4798 83 17028 542 557 324 919 2270 2220 1293 5193 6.0 282243 5.38% 4032 3337 70 11616 377 384 249 572 1580 1529 975 3358 4.2 37.9% 1.44 1.19 1.66
4 389334 4.78% 5562 4365 74 16888 747 753 449 2313 6530 6782 3539 17468 7.0 260458 4.97% 3721 2954 35 13313 500 506 362 1094 4369 4460 2725 10623 4.7 92.6% 1.49 1.24 2.11
5 14109 0.17% 204 168 23 723 1274 1282 775 1841 4266 4179 2000 12409 5.4 9773 0.19% 142 115 18 425 882 882 632 1137 2955 2857 1565 7250 3.7 78.9% 1.44 1.13 1.75
6 12430 0.15% 180 149 24 538 810 801 423 1595 3579 3423 1743 8219 6.1 8543 0.16% 124 103 23 331 557 567 314 889 2460 2411 1371 5125 4.2 59.0% 1.45 1.04 1.97
7 501481 6.16% 7164 6829 284 19417 853 858 598 1150 3951 3826 2437 5745 7.5 319960 6.10% 4571 4434 184 11772 544 548 426 684 2521 2480 1706 3528 4.8 52.6% 1.57 1.31 1.89
8 64167 0.79% 917 824 55 2089 807 836 475 1196 2107 2255 1210 3234 2.6 45278 0.86% 647 568 37 1623 570 593 312 868 1487 1602 761 2153 1.9 80.1% 1.42 1.19 1.81
9 63089 0.78% 1237 705 2 7226 912 916 357 2565 35928 29000 2000 71156 36.3 37606 0.72% 737 437 2 4636 544 536 273 1000 21416 16160 1500 41027 21.6 99.0% 1.68 1.00 3.11
10 125290 1.54% 1816 1106 31 19251 1704 1581 705 2533 14878 13333 6000 32348 16.2 62583 1.19% 907 558 19 9302 851 849 432 1217 7432 7155 3667 15333 8.1 91.8% 2.00 1.40 2.41
11 51514 0.63% 873 607 143 4055 1117 1106 491 1664 8196 7727 2569 17255 8.2 38321 0.73% 650 432 105 2922 831 836 424 1072 6097 5989 2115 12434 6.1 99.6% 1.34 1.09 1.85
12 49809 0.61% 1083 927 63 5737 1221 1230 744 1776 20788 21029 8034 35750 20.9 30154 0.57% 656 558 57 3381 739 761 483 1034 12585 12714 5371 20742 12.6 99.5% 1.65 1.11 1.98
13 23875 0.29% 796 701 89 3037 2039 2138 933 2967 34753 36396 13067 75545 34.9 10721 0.20% 357 286 31 1193 916 927 614 1153 15606 15797 8576 26818 15.7 99.7% 2.23 1.47 3.31
14 363448 4.47% 5192 4463 23 21310 874 791 471 1510 5823 5263 2258 12112 11.7 219748 4.19% 3139 2765 19 9894 528 503 328 704 3521 3356 1467 6692 7.1 49.8% 1.65 1.21 2.16
15 1884609 23.16% 26923 26457 1228 70476 1133 1149 688 1611 4980 5041 2604 7020 8.2 1136175 21.66% 16231 15533 837 47019 683 699 477 897 3002 3074 1733 3784 4.9 60.8% 1.66 1.37 2.04
16 158315 1.95% 2262 2097 55 5265 365 383 217 578 1613 1631 922 2573 6.0 115582 2.20% 1651 1540 41 3724 267 270 176 393 1178 1190 725 1862 4.4 27.0% 1.37 1.21 1.59
17 207850 2.55% 2969 2596 2 7511 772 758 400 1181 5587 5612 2000 12455 6.3 145539 2.77% 2079 1915 2 5313 541 529 342 746 3912 3916 2000 7455 4.4 88.4% 1.43 1.00 1.67
18 276965 3.40% 3957 3605 17 12349 429 441 281 1333 1344 1400 853 3294 2.6 198876 3.79% 2841 2602 12 8547 308 316 190 1000 965 1007 576 2471 1.9 52.0% 1.39 1.16 1.71
19 15387 0.19% 223 156 20 1482 1112 1102 405 1810 3664 3658 1613 7537 5.2 9790 0.19% 142 106 13 914 708 733 305 1019 2332 2406 1082 4173 3.3 69.8% 1.57 1.16 2.03
20 398961 4.90% 5699 5179 1199 20263 825 814 553 1180 3581 3659 2051 6261 3.8 303249 5.78% 4332 3728 942 14752 627 621 451 823 2722 2779 1741 3999 2.9 93.4% 1.32 1.16 1.57
21 92193 1.13% 1317 1136 13 4302 1158 1103 702 1845 5388 5083 1857 8040 6.2 66531 1.27% 950 826 9 2913 835 808 500 1184 3888 3764 1286 6120 4.4 87.5% 1.39 1.09 1.74
22 133909 1.65% 1913 1680 117 8010 1264 1288 841 1857 12424 11778 6627 32149 12.9 86989 1.66% 1243 1118 64 4805 821 842 584 1021 8071 7800 4627 18574 8.4 96.5% 1.54 1.23 1.83
23 47657 0.59% 691 589 4 3159 97 111 29 488 824 820 190 3108 5.8 43186 0.82% 626 523 4 2832 88 101 26 383 747 737 190 2392 5.2 14.3% 1.10 1.00 1.43
24 70943 0.87% 2217 2119 68 4313 341 338 183 535 4515 4433 2878 9504 9.4 58793 1.12% 1837 1752 66 3508 283 282 142 448 3742 3717 2361 7965 7.8 48.0% 1.21 1.03 1.29
25 40240 0.49% 575 509 8 1464 696 672 377 1084 3262 3104 1333 8675 7.0 27051 0.52% 386 358 6 973 468 460 279 673 2193 2122 1000 5310 4.7 46.8% 1.49 1.21 1.74
26 16231 0.20% 232 171 6 838 259 257 101 801 1175 1201 390 4310 6.0 11814 0.23% 169 130 4 592 188 190 91 472 855 893 259 3288 4.4 19.5% 1.37 1.09 1.74
27 58699 0.72% 839 736 13 3211 922 869 290 1365 6057 5726 2167 15860 6.9 39498 0.75% 564 468 12 2245 620 599 230 858 4076 3910 1917 9062 4.6 88.0% 1.49 1.08 1.92
28 1043968 12.83% 14914 14063 655 43720 991 1002 742 1337 7134 7213 4061 11658 7.9 664401 12.67% 9491 8851 417 28019 631 641 458 801 4540 4585 2651 7243 5.0 90.5% 1.57 1.30 1.86
29 87484 1.08% 1250 1195 10 6557 653 679 288 1216 5526 5053 1000 12679 8.7 61698 1.18% 881 856 9 4603 461 481 237 646 3897 3676 824 7864 6.1 63.8% 1.42 1.11 2.02
30 187540 2.30% 2679 2316 368 7754 991 991 544 1593 3973 4295 1615 6298 4.4 134207 2.56% 1917 1693 278 5889 709 716 380 1203 2843 3056 1127 4396 3.2 89.8% 1.40 1.23 1.61
31 76022 0.93% 1102 845 185 3812 747 719 406 1072 3848 3847 1581 7278 5.2 53732 1.02% 779 649 150 2454 528 516 329 668 2720 2754 1282 5722 3.7 74.0% 1.41 1.18 1.66
32 815768 10.02% 11654 10440 55 26554 1259 1281 871 1854 38874 37841 18333 71979 39.4 445265 8.49% 6361 5580 22 16078 687 704 526 887 21218 20880 7333 34615 21.5 98.7% 1.83 1.50 2.50
33 165110 2.03% 2359 2003 36 6704 812 780 459 1578 3419 3284 1750 12000 3.5 129875 2.48% 1855 1599 34 5472 639 632 371 1015 2689 2620 1490 11333 2.8 97.3% 1.27 1.06 1.74
34 98699 1.21% 1410 1316 191 3676 1141 1141 739 1592 6539 6143 4117 11363 8.1 62937 1.20% 899 829 135 2080 728 733 501 972 4170 4086 2587 6801 5.2 80.5% 1.57 1.31 1.99
35 28511 0.35% 407 339 11 1428 590 581 199 933 2718 2594 774 6632 3.3 20890 0.40% 298 257 8 1038 433 439 157 763 1991 1943 608 4000 2.4 82.1% 1.36 1.05 1.76
* Pooled mean; CSL: Clinical Service Line
LOT/1000 PDs LOT/1000 discharges
DOTs/LOT 
ratioNo. of days of therapy (DOTs)
DOTs/1000 patient 
days (PDs) DOTs/1000 discharges No. of length of therapy (LOT)
Table 4.2  Adult Antibacterial Drug Consumption at 70 U.S. Academic Medical Centers in 2009 Stratified by Clinical Service Line 
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DOTs, days of therapy; LOS, length of stay, LOT, length of therapy; PDs, patient days                   
                
Figure 4.1  Antibacterial consumption measured in DOTs/1000 discharges (upper panel) and 
DOTs/1000 PDs (lower panel), along with the components of each measure, in 5 clinical service lines 
(CSLs) with different use patterns. The lung transplant, gastroenterology and psychiatry CSLs had 
very high, average and very low use, respectively, in both measures. The two measures, however, 
were discrepant in the heart transplant/implant of heart assist system and, to a lesser extent, the 
ophthalmology CSLs. The extremely long LOS in the former and extremely short one in the 
latter is responsible for this discrepancy. Measuring LOS and the other components enables 
identifying their relative contribution to the magnitude of these two measures.  
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4.2.2 Hospital-wide Aggregated Antibacterial Drug Consumption  
 
The Application of Direct Standardization to the Risk-adjustment of Anti-
bacterial Drug Use 
Table 4.3 demonstrates the calculations pertaining to the application of 
direct and indirect standardization to risk-adjust AbC and its components 
in Hospital #28. The direct standardization procedure entails calculating the 
expected number of DOTs in the reference population. This is the expected 
number of DOTs in the reference population had it had the same CSL-
specific rates as the study population (e.g., study hospital). For notation, 
upper case letters will be used throughout this chapter to refer to variables 
pertaining to the reference population while small case letters will be used 
for variables pertaining to the study hospitals. Using this notation, the 
expected number of DOTs in the reference population is given by 
 
1
( )
k
ij
i j
j
ij
d
E D N
n
  (4.5) 
Where E(Di)is the expected number of DOTs of the reference population 
using the CSL-specific rates of the ith study population (i= 1, 2,…, m where 
m is the number of study populations), k is the number of CSLs (i.e., strata), 
dij is the number of DOTs in the jth CSL of the ith study population (j= 1, 
2,…, k), nij  is the number of discharges in the jth CSL of the ith study 
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population and Nj  is the number of discharges in the jth CSL of the reference 
population. 
    Applying Equation 4.5 to Hospital #28  
28
5081 31 246
5014 4945 ... 10491 11240519
123 4 95
(E D   
     
     
     
 DOTs)=   
   The expected number of DOTs (Equation 4.5) can be transformed to DSR 
by dividing it by the total number of discharges in the reference population.
1
/
k
ij
j
j
ij
i D D
Expected total number of DOTs in reference population
Total number of discharges in reference population
d
N
n
N


(DSR = =)  (4.6)  
Where (DSRi)D/D is the directly standardized rate for the DOTs/1000 
discharges measure, N is the total number of discharges of the reference 
population (N= ΣNj) and the other notation is as defined before. Applying 
Equation 4.6 to Hospital #28 and multiplying by 1000 to express the rate in 
DOTs/1000 discharges 
/28
11240519
6.2755 DOTs/discharge 6276 DOTs/1000discharges
1791172
( )
D D
DSR      
(DSR28)D/D represents the expected AbC rate of the reference population (in 
DOTs/1000 discharges) had it had the same CSL-specific rates as Hospital 
#28 or, alternatively, the expected AbC rate of Hospital #28 had it had the 
same CSL distribution as the reference population. It is worth mentioning 
that Equation 4.6 can be simplified by expressing DSR as a weighted 
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average of the CSL-specific rates of the study population where the 
corresponding weights are supplied by the reference population (Table 4.3). 
 
/ /
1
( ) ( )
k
i D D ij d d j
j
DSR r W

  (4.7) 
Where (rij)d/d is the DOTs/1000 discharges rate in the jth CSL of the ith study 
population ((rij)d/d = dij/nij) and Wj is the weight of the jth CSL of the reference 
population (Wj = Nj/N). Equation 4.7 shows that if two populations have the 
same CSL-specific rates then their DSRs will necessarily be identical as long 
as they are standardized to the same reference population.  
  The expected number of DOTs can also be used to obtain a relative risk 
type measure; the expected-to-observed ratio, which is calculated as follows   
1
( )
k
ij
j
j
ij
Di
Expected total number of DOTs in reference population
Observed total number of DOTs in reference population
d
N
n
E O
D

 

 (4.8)  
Where (E/Oi)D is the ith expected-to-observed ratio for DOTs, D is the 
(observed) total number of DOTs of the reference population (D= ΣDj where Dj 
is the number of DOTs in the jth CSL of the reference population) and the 
other notation is as defined before. It should be obvious that, by dividing 
both the numerator and denominator in Equation 4.8 by the total number 
of discharges of the reference population (N), the E/O ratio can be 
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equivalently expressed as the ratio of DSR to the crude rate in the reference 
population (RD/D).   
 
/
/
/
( )
( ) i D D
D Di
D D
DSR
R
E O   (4.9) 
Applying Equation 4.8 and Equation 4.9 to Hospital #28 
/28 28
11240519 6276
1.38
45438138014
( ) ( )
D D D
E O E O     
Accordingly, one can interpret (E/O28)D/D as an expected 38% increase in 
the AbC rate of the reference population had it had the same CSL-specific 
rates as Hospital #28. In other words, the (adjusted) AbC rate of Hospital 
#28 was 38% higher than the crude rate of the reference population.  
While the E/O ratio provides a useful comparison between DSR and 
the crude rate in the reference population, its greatest asset lies in its ability 
to facilitate the comparison of DSRs across different study populations. It 
should be evident that for any two populations, the ratio of their E/O ratios 
equals the ratio of their DSRs.  
 
( / )
( / )

population A population A
population B population B
E O DSR
E O DSR
 (4.10) 
Applying Equation 4.10 to compare DSR28 with DSR59 which was the lowest 
among the 70 hospitals (the referent hospital) 
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28 /
59 /
( ) 6276
1.85
( ) 3396
D D
D D
DSR
DSR
   
Therefore, the adjusted (i.e., standardized) AbC rate of Hospital #28 was 
about 85% higher than that of Hospital #59. However, it should be noted 
that all study populations should be standardized to the same reference 
population for Equation 4.10 to hold and the DSRs to be directly 
comparable. This was not possible in this study since the CSL composition 
varied from one hospital to another. However, the CSLs that were not 
common to all hospitals had such small weights (Table 4.1) that the 
differences between the different reference populations were generally 
marginal. The ratio of the observed rates of the two hospitals was 2.21. 
The Application of Indirect Standardization to the Risk-adjustment of Anti-
bacterial Drug consumption                                                                                              
An example of the application of indirect standardization to the risk-
adjustment of AbC is presented in Table 4.4 using Hospital #28 as a 
representative of the study population. The indirect standardization 
procedure is a mirror image of its direct counterpart. That is, the reference 
population is the source of the CSL-specific AbC rates while the study 
population provides the corresponding number of discharges. Then, the 
expected number of DOTs in the study population is calculated as follows 
 
1
( )
k
j
i ij
j
j
D
e d n
N
  (4.11) 
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Where e(di) is the expected number of DOTs in the ith study population and 
the other notation is as defined before. Equation 4.11 represents the 
expected number of DOTs in the study population had it had the same CSL-
specific rates as the reference population. 
Applying Equation 4.11 to Hospital #28 
28
142118 26771 28511
... 104712 DOTs
5014 4945 10491
123 4 95e d   
     
     
     
 ( )=  
The statistic that is usually reported in indirect standardization is the 
observed-to-expected ratio which is given by 
 
1
( / ) i
i d k
j
ij
j
j
Observed total number of DOTs in study population
Expected total number of DOTs in study population
d
D
n
N
o e

 

 (4.12) 
Where (o/ei)d is the observed-to-expected ratio (for DOTs) of the ith study 
population, di is the (observed) total number of DOTs in the ith study 
population (di= Σdij) and the other notation is as defined before.  
Applying Equation 4.8 to Hospital #28 
28
145654
1.39
104712
)( /
d
o e    
Thus, the o/e ratio obtained through indirect standardization was virtually 
identical to the E/O ratio obtained through the direct standardization 
procedure for Hospital #28, as well as for almost all the other hospitals with 
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the notable exception of Hospital #61 (Figure 4.2). For both ratios, a value 
above 1 indicates higher than expected use while a value below 1 indicates 
lower than expected use. 
In analogy to Equation 4.9 which can be rearranged to express DSR as the 
product of the E/O ratio and the crude rate in the reference population, ISR 
can similarly be expressed as the product of the o/e ratio and the latter 
  / //( ) /i d d i D Dd dISR o e R   (4.13) 
Where (ISRi)d/d is the indirectly standardized rate of the ith study population 
and the rest of the notation is as defined before.     
Applying Equation 4.8 to Hospital #28 
 
28 /
DOTs/1000discharges( ) 1.391 4543 6319
d d
ISR     
Obviously, comparing the E/O ratio to the o/e ratio is equivalent to 
comparing DSR to ISR.  However, it should be noted that two populations 
that have identical CSL-specific rates may have quite different ISRs in spite 
of having identical DSRs.
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Table 4.3 An Example of the Application of Direct Standardization to the Risk-adjustment of Antibacterial Consumption in Hospital #28   
 
  
1 5014 4818 112030 142118 85177 17.7 96.1% 1.67 22.3 0.0028 28.344 16.988
2 4945 2770 43445 26771 18757 6.8 56.0% 1.43 8.8 0.0028 5.414 3.793
3 178678 67757 748276 405518 282243 4.2 37.9% 1.44 4.2 0.0998 2.270 1.580
4 59619 55233 521190 389334 260458 4.7 92.6% 1.49 8.7 0.0333 6.530 4.369
5 3307 2610 11079 14109 9773 3.7 78.9% 1.44 3.4 0.0018 4.266 2.955
6 3473 2048 15351 12430 8543 4.2 59.0% 1.45 4.4 0.0019 3.579 2.460
7 126928 66721 588163 501481 319960 4.8 52.6% 1.57 4.6 0.0709 3.951 2.521
8 30453 24388 79471 64167 45278 1.9 80.1% 1.42 2.6 0.0170 2.107 1.487
9 1756 1739 69171 63089 37606 21.6 99.0% 1.68 39.4 0.0010 35.928 21.416
10 8421 7728 73535 125290 62583 8.1 91.8% 2.00 8.7 0.0047 14.878 7.432
11 6285 6263 46100 51514 38321 6.1 99.6% 1.34 7.3 0.0035 8.196 6.097
12 2396 2385 40782 49809 30154 12.6 99.5% 1.65 17.0 0.0013 20.788 12.585
13 687 685 11710 23875 10721 15.7 99.7% 2.23 17.0 0.0004 34.753 15.606
14 62416 31088 415843 363448 219748 7.1 49.8% 1.65 6.7 0.0348 5.823 3.521
15 378417 229996 1663899 1884609 1136175 4.9 60.8% 1.66 4.4 0.2113 4.980 3.002
16 98160 26455 433657 158315 115582 4.4 27.0% 1.37 4.4 0.0548 1.613 1.177
17 37203 32900 269137 207850 145539 4.4 88.4% 1.43 7.2 0.0208 5.587 3.912
18 206121 107161 646232 276965 198876 1.9 52.0% 1.39 3.1 0.1151 1.344 0.965
19 4199 2932 13838 15387 9790 3.3 69.8% 1.57 3.3 0.0023 3.664 2.332
20 111418 104023 483740 398961 303249 2.9 93.4% 1.32 4.3 0.0622 3.581 2.722
21 17110 14979 79645 92193 66531 4.4 87.5% 1.39 4.7 0.0096 5.388 3.888
22 10778 10406 105930 133909 86989 8.4 96.5% 1.54 9.8 0.0060 12.424 8.071
23 57829 8280 492023 47657 43186 5.2 14.3% 1.10 8.5 0.0323 0.824 0.747
24 15713 7550 207860 70943 58793 7.8 48.0% 1.21 13.2 0.0088 4.515 3.742
25 12337 5768 57861 40240 27051 4.7 46.8% 1.49 4.7 0.0069 3.262 2.193
26 13819 2697 62695 16231 11814 4.4 19.5% 1.37 4.5 0.0077 1.175 0.855
27 9691 8528 63676 58699 39498 4.6 88.0% 1.49 6.6 0.0054 6.057 4.076
28 146339 132451 1053701 1043968 664401 5.0 90.5% 1.57 7.2 0.0817 7.134 4.540
29 15831 10097 133920 87484 61698 6.1 63.8% 1.42 8.5 0.0088 5.526 3.897
30 47203 42367 189328 187540 134207 3.2 89.8% 1.40 4.0 0.0264 3.973 2.843
31 19758 14626 101723 76022 53732 3.7 74.0% 1.41 5.1 0.0110 3.848 2.720
32 20985 20712 647794 815768 445265 21.5 98.7% 1.83 30.9 0.0117 38.874 21.218
33 48299 46996 203382 165110 129875 2.8 97.3% 1.27 4.2 0.0270 3.418 2.689
34 15093 12151 86480 98699 62937 5.2 80.5% 1.57 5.7 0.0084 6.539 4.170
35 10491 8608 48292 28511 20890 2.4 82.1% 1.36 4.6 0.0059 2.718 1.991
 
 
Reference Population, Observed
No. of cases
(  
 ) 
No. of 
discharges
(  )
  
      
 
= 1125916
No. of 
patient days 
(      ) 
         
= 9820959
Observed no. 
of DOTs 
(  ) 
       = 
8138014
Observed no. 
of LOT (  ) 
       = 
5245400
LOT/case 
          
  /  
 )
         
  /  
 =  4.7
Percent no. of cases
(     
    ) 
      
    
= 62.9 %
DOTs/LOT ratio 
(         ) 
         
= 1.55
Mean LOS 
(         
  ) 
     
      = 5.5
Weights   
(        ) 
       = 
1.00
DOT/
discharge 
           
   /  )
        
      = 4.543
LOT/
discharge 
           
   /  )
         
  /   = 2.928
(
        
= 1791172
Standardized Rate
   
CSL 
ID 
(  )
Total
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1 4973 132035 207123 118787 23.9 99.2% 1.74 26.3 41.309 0.11564
2 4945 59340 38324 30906 6.3 100.0% 1.24 12.0 7.750 0.02140
3 91968 966402 735258 470482 5.1 51.5% 1.56 5.4 4.115 0.41049
4 57542 538159 556301 323690 5.6 96.5% 1.72 9.0 9.331 0.31058
5 2606 10222 15232 9721 3.7 78.8% 1.57 3.1 4.606 0.00850
6 1858 12519 7996 7188 3.9 53.5% 1.11 3.6 2.302 0.00446
7 78722 738260 712426 446775 5.7 62.0% 1.59 5.8 5.613 0.39774
8 27494 82194 88184 60329 2.2 90.3% 1.46 2.7 2.896 0.04923
9 1756 89821 99234 54252 30.9 100.0% 1.83 51.2 56.512 0.05540
10 7966 91038 143385 68278 8.6 94.6% 2.10 10.8 17.027 0.08005
11 6285 45397 56089 42317 6.7 100.0% 1.33 7.2 8.924 0.03131
12 2396 68778 84330 49699 20.7 100.0% 1.70 28.7 35.196 0.04708
13 687 11133 25997 10820 15.8 100.0% 2.40 16.2 37.841 0.01451
14 42711 599213 713853 417692 9.8 68.4% 1.71 9.6 11.437 0.39854
15 258526 1737018 2386133 1344847 5.2 68.3% 1.77 4.6 6.306 1.33216
16 30593 442658 200731 145457 4.8 31.2% 1.38 4.5 2.045 0.11207
17 32872 295163 285469 185966 5.7 88.4% 1.54 7.9 7.673 0.15938
18 123510 606265 296135 211990 1.7 59.9% 1.40 2.9 1.437 0.16533
19 3643 13406 19730 11788 3.2 86.7% 1.67 3.2 4.699 0.01102
20 100441 510071 474396 352732 3.5 90.1% 1.34 4.6 4.258 0.26485
21 16726 77572 128581 80103 4.8 97.8% 1.61 4.5 7.515 0.07179
22 10778 64824 95830 62559 5.8 100.0% 1.53 6.0 8.891 0.05350
23 8897 144016 28358 22242 2.5 15.4% 1.28 2.5 0.490 0.01583
24 10153 256968 105076 85495 8.4 64.6% 1.23 16.4 6.687 0.05866
25 7368 66483 69139 40781 5.5 59.7% 1.70 5.4 5.604 0.03860
26 3418 81725 14711 10699 3.1 24.7% 1.38 5.9 1.065 0.00821
27 9601 53704 59447 42847 4.5 99.1% 1.39 5.5 6.134 0.03319
28 142588 1048041 1104300 724388 5.1 97.4% 1.52 7.2 7.546 0.61652
29 11534 192686 200714 124500 10.8 72.9% 1.61 12.2 12.679 0.11206
30 46409 204074 243958 172132 3.7 98.3% 1.42 4.3 5.168 0.13620
31 14700 100371 86856 59274 4.0 74.4% 1.47 5.1 4.396 0.04849
32 20921 905756 1510471 726389 34.7 99.7% 2.08 43.2 71.979 0.84329
33 46634 264257 271474 187922 4.0 96.6% 1.44 5.5 5.621 0.15156
34 12879 114640 148113 88814 6.9 85.3% 1.67 7.6 9.813 0.08269
35 9939 52565 27166 22418 2.3 94.7% 1.21 5.0 2.589 0.01517
 
Reference Population, Expected (Direct Standardization)
2.928
Expected no. 
of cases
(     
   
       )
    
   
       
   = 
1254037
Expected no. of
patient days 
(        
         )
       
          = 
10676776
      
         = 
11240519
Expected no. of
DOTs 
(       
            )
Expected no. of
LOT (       
            )
      
         = 
6814277
Expected LOT/case 
             
       
      
    
           
             
   = 5.4
Expected perecent 
of cases          
     
       
         
     
          =
70.0%
           
                  
= 1.65
            
               
= 6.0
Expected 
DOTs/LOT ratio 
          
             )
Expected mean 
LOS 
           
            
Expected DOTs/
discharge 
            
            
 
           
          
= 6.276
             
           
[               
= 6.276  
E/O
CSL 
ID 
(  )
Total
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1 1.35 1.03 1.05 1.18 1.46
2 0.92 1.79 0.87 1.37 1.43
3 1.23 1.36 1.09 1.29 1.81
4 1.19 1.04 1.15 1.03 1.43
5 1.00 1.00 1.09 0.92 1.08
6 0.93 0.91 0.76 0.82 0.64
7 1.18 1.18 1.02 1.26 1.42
8 1.18 1.13 1.03 1.03 1.37
9 1.43 1.01 1.09 1.30 1.57
10 1.06 1.03 1.05 1.24 1.14
11 1.10 1.00 0.99 0.98 1.09
12 1.64 1.00 1.03 1.69 1.69
13 1.01 1.00 1.08 0.95 1.09
14 1.38 1.37 1.03 1.44 1.96
15 1.05 1.12 1.07 1.04 1.27
16 1.09 1.16 1.01 1.02 1.27
17 1.28 1.00 1.07 1.10 1.37
18 0.92 1.15 1.00 0.94 1.07
19 0.97 1.24 1.06 0.97 1.28
20 1.20 0.97 1.02 1.05 1.19
21 1.08 1.12 1.16 0.97 1.39
22 0.69 1.04 1.00 0.61 0.72
23 0.48 1.07 1.16 0.29 0.60
24 1.08 1.34 1.02 1.24 1.48
25 1.18 1.28 1.14 1.15 1.72
26 0.71 1.27 1.00 1.30 0.91
27 0.96 1.13 0.93 0.84 1.01
28 1.01 1.08 0.97 0.99 1.06
29 1.77 1.14 1.14 1.44 2.29
30 1.17 1.10 1.01 1.08 1.30
31 1.10 1.01 1.04 0.99 1.14
32 1.62 1.01 1.13 1.40 1.85
33 1.46 0.99 1.14 1.30 1.64
34 1.33 1.06 1.06 1.33 1.50
35 0.93 1.15 0.89 1.09 0.95
 
Reference Population, E/O ratios
E/O ratio for percent 
no. of cases
     
  
   
              
 
E/O ratio for 
DOTs/LOT ratio 
     
  
    
                 
 
          
                        
E/O ratio for LOT/case
     
  
     
                     
 
        
                
         
                  
          
                    
E/O ratio for mean 
LOS
     
  
     
                  
 
E/O ratio for 
DOTs/discharge
     
  
     
                    
 
          
                         
CSL 
ID 
(  )
Total
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Table 4.4 An Example of the Application of Indirect Standardization to the Risk-adjustment of Antibacterial Consumption in Hospital #28   
 
1 123 122 3239 5081 2914 23.9 99.2% 1.74 26.3 41.309 23.691
2 4 4 48 31 25 6.3 100.0% 1.24 12.0 7.750 6.250
3 1461 752 7902 6012 3847 5.1 51.5% 1.56 5.4 4.115 2.633
4 976 942 8810 9107 5299 5.6 96.5% 1.72 9.0 9.331 5.429
5 33 26 102 152 97 3.7 78.8% 1.57 3.1 4.606 2.939
6 43 23 155 99 89 3.9 53.5% 1.11 3.6 2.302 2.070
7 1356 841 7887 7611 4773 5.7 62.0% 1.59 5.8 5.613 3.520
8 422 381 1139 1222 836 2.2 90.3% 1.46 2.7 2.896 1.981
9 86 86 4399 4860 2657 30.9 100.0% 1.83 51.2 56.512 30.895
10 37 35 400 630 300 8.6 94.6% 2.10 10.8 17.027 8.108
11 251 251 1813 2240 1690 6.7 100.0% 1.33 7.2 8.924 6.733
12 163 163 4679 5737 3381 20.7 100.0% 1.70 28.7 35.196 20.742
13 44 44 713 1665 693 15.8 100.0% 2.40 16.2 37.841 15.750
14 643 440 6173 7354 4303 9.8 68.4% 1.71 9.6 11.437 6.692
15 3109 2124 14271 19604 11049 5.2 68.3% 1.77 4.6 6.306 3.554
16 1046 326 4717 2139 1550 4.8 31.2% 1.38 4.5 2.045 1.482
17 756 668 5998 5801 3779 5.7 88.4% 1.54 7.9 7.673 4.999
18 2283 1368 6715 3280 2348 1.7 59.9% 1.40 2.9 1.437 1.028
19 83 72 265 390 233 3.2 86.7% 1.67 3.2 4.699 2.807
20 609 549 2788 2593 1928 3.5 90.1% 1.34 4.6 4.258 3.166
21 534 522 2421 4013 2500 4.8 97.8% 1.61 4.5 7.515 4.682
22 138 138 830 1227 801 5.8 100.0% 1.53 6.0 8.891 5.804
23 104 16 259 51 40 2.5 15.4% 1.28 2.5 0.490 0.385
24 195 126 3189 1304 1061 8.4 64.6% 1.23 16.4 6.687 5.441
25 144 86 776 807 476 5.5 59.7% 1.70 5.4 5.604 3.306
26 93 23 550 99 72 3.1 24.7% 1.38 5.9 1.065 0.774
27 216 214 1197 1325 955 4.5 99.1% 1.39 5.5 6.134 4.421
28 2263 2205 16207 17077 11202 5.1 97.4% 1.52 7.2 7.546 4.950
29 140 102 1704 1775 1101 10.8 72.9% 1.61 12.2 12.679 7.864
30 832 818 3597 4300 3034 3.7 98.3% 1.42 4.3 5.168 3.647
31 250 186 1270 1099 750 4.0 74.4% 1.47 5.1 4.396 3.000
32 327 326 14114 23537 11319 34.7 99.7% 2.08 43.2 71.979 34.615
33 174 168 952 978 677 4.0 96.6% 1.44 5.5 5.621 3.891
34 225 192 1709 2208 1324 6.9 85.3% 1.67 7.6 9.813 5.884
35 95 90 476 246 203 2.3 94.7% 1.21 5.0 2.589 2.137
 
Hospital 28 (Study Population), Observed
No. of
cases (   
 ) 
No. of 
discharges
(   )
No. of 
patient days 
(    ) 
No. of 
DOTs (   ) 
No. of 
LOT (   ) 
Percent no. 
of cases
(       
     ) 
Mean LOS 
           
   ) 
  
       
 
= 14229
       
= 19258
          
= 131464
        
= 145654
        
= 87306
      
    
= 74.9 %
LOT/case 
          
=    /   
 )
          
  /  
 =  6.1
DOTs/LOT ratio 
(            ) 
DOT/
discharge 
          
    /   )
         
  /  =  7.563
          
= 1.67
           
= 6.8
LOT/
discharge 
           
    /   )
          
  /  =  4.533
CSL 
ID 
(  )
 
Total
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1 118 2748 3486 2090 17.7 96.1% 1.67 22.3 28.344
2 2 35 22 15 6.8 56.0% 1.43 8.8 5.414
3 554 6118 3316 2308 4.2 37.9% 1.44 4.2 2.270
4 904 8532 6374 4264 4.7 92.6% 1.49 8.7 6.530
5 26 111 141 98 3.7 78.9% 1.44 3.4 4.266
6 25 190 154 106 4.2 59.0% 1.45 4.4 3.579
7 713 6283 5357 3418 4.8 52.6% 1.57 4.6 3.951
8 338 1101 889 627 1.9 80.1% 1.42 2.6 2.107
9 85 3388 3090 1842 21.6 99.0% 1.68 39.4 35.928
10 34 323 550 275 8.1 91.8% 2.00 8.7 14.878
11 250 1841 2057 1530 6.1 99.6% 1.34 7.3 8.196
12 162 2774 3389 2051 12.6 99.5% 1.65 17.0 20.788
13 44 750 1529 687 15.7 99.7% 2.23 17.0 34.753
14 320 4284 3744 2264 7.1 49.8% 1.65 6.7 5.823
15 1890 13670 15484 9335 4.9 60.8% 1.66 4.4 4.980
16 282 4621 1687 1232 4.4 27.0% 1.37 4.4 1.613
17 669 5469 4224 2957 4.4 88.4% 1.43 7.2 5.587
18 1187 7158 3068 2203 1.9 52.0% 1.39 3.1 1.344
19 58 274 304 194 3.3 69.8% 1.57 3.3 3.664
20 569 2644 2181 1658 2.9 93.4% 1.32 4.3 3.581
21 467 2486 2877 2076 4.4 87.5% 1.39 4.7 5.388
22 133 1356 1715 1114 8.4 96.5% 1.54 9.8 12.424
23 15 885 86 78 5.2 14.3% 1.10 8.5 0.824
24 94 2580 880 730 7.8 48.0% 1.21 13.2 4.515
25 67 675 470 316 4.7 46.8% 1.49 4.7 3.262
26 18 422 109 80 4.4 19.5% 1.37 4.5 1.175
27 190 1419 1308 880 4.6 88.0% 1.49 6.6 6.057
28 2048 16295 16144 10274 5.0 90.5% 1.57 7.2 7.134
29 89 1184 774 546 6.1 63.8% 1.42 8.5 5.526
30 747 3337 3306 2366 3.2 89.8% 1.40 4.0 3.973
31 185 1287 962 680 3.7 74.0% 1.41 5.1 3.848
32 323 10094 12712 6938 21.5 98.7% 1.83 30.9 38.874
33 169 733 595 468 2.8 97.3% 1.27 4.2 3.418
34 181 1289 1471 938 5.2 80.5% 1.57 5.7 6.539
35 78 437 258 189 2.4 82.1% 1.36 4.6 2.718
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1 1.35 1.03 1.05 1.18 1.46 41.309
2 0.92 1.79 0.87 1.37 1.43 7.750
3 1.23 1.36 1.09 1.29 1.81 4.115
4 1.19 1.04 1.15 1.03 1.43 9.331
5 1.00 1.00 1.09 0.92 1.08 4.606
6 0.93 0.91 0.76 0.82 0.64 2.302
7 1.18 1.18 1.02 1.26 1.42 5.613
8 1.18 1.13 1.03 1.03 1.37 2.896
9 1.43 1.01 1.09 1.30 1.57 56.512
10 1.06 1.03 1.05 1.24 1.14 17.027
11 1.10 1.00 0.99 0.98 1.09 8.924
12 1.64 1.00 1.03 1.69 1.69 35.196
13 1.01 1.00 1.08 0.95 1.09 37.841
14 1.38 1.37 1.03 1.44 1.96 11.437
15 1.05 1.12 1.07 1.04 1.27 6.306
16 1.09 1.16 1.01 1.02 1.27 2.045
17 1.28 1.00 1.07 1.10 1.37 7.673
18 0.92 1.15 1.00 0.94 1.07 1.437
19 0.97 1.24 1.06 0.97 1.28 4.699
20 1.20 0.97 1.02 1.05 1.19 4.258
21 1.08 1.12 1.16 0.97 1.39 7.515
22 0.69 1.04 1.00 0.61 0.72 8.891
23 0.48 1.07 1.16 0.29 0.60 0.490
24 1.08 1.34 1.02 1.24 1.48 6.687
25 1.18 1.28 1.14 1.15 1.72 5.604
26 0.71 1.27 1.00 1.30 0.91 1.065
27 0.96 1.13 0.93 0.84 1.01 6.134
28 1.01 1.08 0.97 0.99 1.06 7.546
29 1.77 1.14 1.14 1.44 2.29 12.679
30 1.17 1.10 1.01 1.08 1.30 5.168
31 1.10 1.01 1.04 0.99 1.14 4.396
32 1.62 1.01 1.13 1.40 1.85 71.979
33 1.46 0.99 1.14 1.30 1.64 5.621
34 1.33 1.06 1.06 1.33 1.50 9.813
35 0.93 1.15 0.89 1.09 0.95 2.589
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  Figure 4.2  Observed-to-expected (o/e) and Expected-to-observed (E/O) ratios derived from the application of indirect 
and direct standardization, respectively, to the risk-adjustment of antibacterial drug consumption rates (measured in days of 
therapy per one thousand discharges) at 70 US academic medical centers in 2009. The two ratios are interpreted similarly 
with a value >1 indicating higher than expected use and a value < 1 indicating lower than expected use. The O/E ratio 
ranged from 0.76 (Hospital #59) to 1.44 (Hospital #4) while the o/e ratio ranged from 0.73 (Hospital #6) to 1.45 (Hospital 
#4). The two ratios were in agreement with a few exceptions of which Hospital #61 was the most notable.  
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Risk-adjusted Components of Antibacterial Drug Consumption 
As shown in Table 4.3, direct standardization can also be used to derive 
hospital-wide expected values of the components of AbC. Using direct 
standardization, the expected LOT/case is given by 
 
1
/
1
k
ij
j
j
ij
ki L C
ij j
j
Expected total number of LOT in reference population
Expected total number of  cases in reference population
E R
l
N
n
p N




( ) = =  (4.14) 
where E(Ri)L/C  is the expected LOT/case rate in the reference population, lij 
is the number of LOT in the jth CSL of the ith study population, pij is the 
proportion of cases in the jth CSL of the ith study population and the other 
notation is as defined before.  
The expected proportion of cases in the reference population (E(Pi)) is given 
by 
 
1
k
ij j
j
i
Expected total number of cases in reference population
 Total number of  discharges in reference population
E P
p N
N


( ) = =  (4.15) 
While the expected DOTs/LOT ratio (E(DLi))  in the reference population is 
given by 
 124 
 
 
1
1
k
ij
j
j
ij
i k
ij
j
j
ij
Expected total number of DOTs in reference population
 Expected total number of  LOT in reference population
E
d
N
n
l
N
n




(DL ) = =   (4.16) 
These expected values can be compared to their observed counterparts and 
the respective E/O ratios can be obtained as shown in Table 4.3.   
Multiplying the above three equations together 
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 (4.17) 
Therefore, the product of the three expected (i.e., adjusted) components is 
the DSR measured in DOTs/1000 discharges. Figure 4.3 depicts the DSRs 
along with expected values of the three components for the 70 hospitals. 
Hospital #4 had the highest DSR followed by Hospital #28 and Hospital #27 
while Hospital #59 had the lowest DSR followed by Hospital #6. In addition 
to facilitating the interhospital comparison of risk-adjusted AbC rates, this 
figure allows hospitals to compare the magnitude of the individual 
components that compose these rates with their peers. Moreover, it enables 
hospitals to determine the relative contribution of each of the three 
components to their adjusted AbC rates. For example, the figure 
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 shows that, despite having a low DSR, adjusted DOTs/LOT ratio and 
adjusted proportion of cases, Hospital #31 has a notably high adjusted 
LOT/case. On the other hand, Hospital #13 which has an above average 
DSR and adjusted proportion of cases and a high adjusted DOTs/LOT ratio, 
has a notably low adjusted LOT/case. 
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Figure 4.3  Directly Standardized rates (DSRs) of antibacterial drug consumption measured in DOTs/1000 discharges along with the directly 
standardized (i.e., adjusted) values of the components that compose them at 70 US academic medical centers in 2009. In addition to providing 
hospitals with a tool to compare their risk-adjusted hospital-wide antibacterial drug consumption rates with those of their peers, this graph also 
allows the interhospital comparison of the risk-adjusted hospital-wide antibacterial consumption components. This will enable antimicrobial 
stewardship programs to identify the component(s) where interventions are likely to be the most beneficial.   
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Comparison of Antibacterial Drug Consumption Measures and Risk-
adjustment Methods 
 
The mean E/O ratio was 1.02 (SD, 0.13) while the mean O/E ratio was 1.00 
(SD, 0.14). The upper and lower critical E/O ratios corresponding to a z-
score of ±1.96 were (0.76, 1.28) while those corresponding to a z-score of 
±1.64 were (0.80, 1.24). The corresponding critical values for the O/E ratios 
were (0.72, 1.27) and (0.77, 1.23), respectively. Hospitals whose E/O (O/E) 
ratios fell above the upper or below the lower corresponding critical values 
were identified as outliers at the respective confidence level.  
  Table 4.5 lists hospital-wide AbC rankings and outlier statuses for the 
different measures and risk-adjustments methods. Outliers at the 95% 
confidence level are displayed in red text while outliers at the 90% 
confidence level are in displayed in blue text. The table shows that there is a 
general agreement in identifying outliers between the two standardization 
methods as well as between the two regression models while the agreement 
between either standardization method and Model II is to a lesser extent.  
 The weighted κ measures the degree of interrater agreement on a 
variable that is measured on an ordinal scale by assigning more weight to 
the agreement when the categories or rankings are close to each other [101]. 
The most commonly used weights are the linear and the quadratic ones. The 
former were used to calculate the weighted κ in this study. Further details 
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on how the SAS PROC FREQ procedure computes weighted κ coefficients 
and the associated confidence interval (CI) are found in the SAS user’s guide 
(http://support.sas.com/documentation/cdl/en/statug/63033 
HTML/default/viewer.htm#statug_freq_a0000000647.htm ; accessed on 20 
February 2012).  
  The weighted κ matrix is presented in Table 4.6 while an 
interpretation of the κ values as proposed by Altman is shown in Table 4.7 
[100]. According to these guidelines, there was a very good agreement in the 
ranking of hospitals between direct and indirect standardization (weighted κ 
= 0.85) as well as between the two regression models (weighted κ = 0.91). 
The agreement between Model II and either direct or indirect 
standardization was moderate (weighted κ = 0.46 and 0.44, respectively) 
while there was a moderately good agreement between the observed 
DOTs/1000 discharges and DOTs/1000 PDs rates (weighted κ = 0.61).  
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Table 4.5 Hospital Rankings and Outlier Statuses Based on Different Antibacterial Consumption Measures and Risk-adjustment Methods 
 
Model II Model I Direct Indirect Model II Model I Direct Indirect
Hospital 
ID
Observed 
DOTs/1000 
Discharges
Observed 
DOTs/1000 
PDs
R-student 
(DOTs/1000 
Discharges)
R-student 
(DOTs/1000 
PDs) E/O ratio O/E ratio
Hospital 
ID
Observed 
DOTs/1000 
Discharges
Observed 
DOTs/1000 
PDs
R-student 
(DOTs/1000 
Discharges)
R-student 
(DOTs/1000 
PDs) E/O ratio O/E ratio
1 4638 (44) 863 (47) -0.589 (20) -0.533 (22) 0.970 (26) 0.955 (30) 36 3819 (14) 709 (10) -0.636 (16) -0.673 (16) 0.959 (25) 0.938 (26)
2 5434 (64) 970 (65) 0.789 (60) 0.845 (58) 1.174 (66) 1.165 (65) 37 4541 (39) 801 (30) 0.121 (40) 0.065 (37) 1.036 (42) 0.959 (31)
3 4371 (33) 812 (34) -0.496 (23) -0.409 (26) 1.092 (52) 1.066 (51) 38 3745 (12) 714 (11) -1.174 (7) -1.221 (8) 0.907 (15) 0.882 (14)
4 6569 (68) 1088 (69) 3.289 (70) 3.008 (69) 1.435 (70) 1.455 (70) 39 4858 (48) 824 (37) 0.530 (54) 0.493 (53) 1.124 (58) 1.111 (60)
5 5638 (67) 894 (56) 0.642 (57) 0.435 (49) 1.129 (60) 1.101 (57) 40 4913 (51) 936 (61) 0.316 (46) 0.465 (52) 1.071 (48) 1.064 (50)
6 2936 (3) 620 (3) -0.949 (9) -1.254 (7) 0.811 (2) 0.725 (1) 41 4997 (52) 929 (60) 0.506 (53) 0.633 (55) 1.115 (56) 1.106 (59)
7 4070 (22) 769 (21) -0.509 (22) -0.529 (23) 0.937 (18) 0.933 (22) 42 4123 (25) 724 (15) -1.085 (8) -1.126 (9) 0.984 (31) 0.940 (27)
8 4886 (49) 888 (54) 0.681 (58) 0.694 (56) 0.980 (30) 1.019 (41) 43 3949 (18) 788 (25) 0.110 (39) 0.132 (39) 1.069 (47) 1.039 (46)
9 4236 (29) 725 (16) -1.635 (3) -1.641 (3) 0.943 (20) 0.935 (24) 44 5055 (55) 863 (48) -0.366 (27) -0.384 (27) 1.038 (43) 1.036 (45)
10 4622 (42) 812 (35) -0.195 (32) -0.230 (32) 0.999 (34) 0.997 (35) 45 5301 (61) 943 (63) 1.670 (66) 1.714 (67) 1.148 (63) 1.143 (64)
11 4115 (24) 796 (27) 0.398 (50) 0.456 (51) 0.889 (13) 0.887 (15) 46 4895 (50) 940 (62) 0.851 (61) 1.077 (62) 1.030 (40) 1.023 (42)
12 5160 (59) 922 (59) -0.195 (33) -0.045 (35) 1.014 (38) 1.000 (36) 47 3855 (15) 701 (8) -0.869 (11) -0.951 (11) 0.841 (6) 0.756 (3)
13 4685 (47) 890 (55) 0.989 (62) 1.181 (63) 1.058 (45) 1.036 (44) 48 2522 (1) 720 (14) 1.585 (64) 1.461 (66) 0.974 (27) 1.025 (43)
14 4298 (32) 771 (22) -0.624 (17) -0.597 (18) 1.056 (44) 1.047 (48) 49 3125 (4) 648 (4) -0.818 (12) -1.054 (10) 0.820 (5) 0.809 (5)
15 4514 (37) 814 (36) -0.797 (14) -0.754 (14) 0.917 (16) 0.895 (16) 50 3648 (9) 802 (32) -0.156 (34) -0.042 (36) 0.859 (8) 0.837 (7)
16 5449 (65) 906 (57) 0.539 (55) 0.411 (48) 1.125 (59) 1.125 (62) 51 4656 (45) 786 (24) -0.620 (19) -0.594 (19) 0.932 (17) 0.931 (21)
17 3902 (16) 715 (12) -1.268 (5) -1.283 (5) 0.880 (10) 0.870 (12) 52 5042 (54) 801 (31) 0.291 (45) 0.166 (42) 1.091 (51) 1.104 (58)
18 3917 (17) 698 (7) -1.260 (6) -1.281 (6) 0.937 (19) 0.946 (29) 53 5624 (66) 871 (50) 0.354 (49) 0.139 (40) 1.169 (65) 1.197 (66)
19 4205 (27) 719 (13) -0.624 (18) -0.675 (15) 1.094 (54) 1.077 (54) 54 5033 (53) 845 (43) -0.714 (15) -0.665 (17) 1.029 (39) 1.006 (39)
20 4627 (43) 834 (39) -1.462 (4) -1.294 (4) 0.978 (29) 0.928 (20) 55 5266 (60) 910 (58) 1.442 (63) 1.396 (65) 1.160 (64) 1.137 (63)
21 4605 (41) 799 (29) -0.811 (13) -0.793 (13) 0.906 (14) 0.874 (13) 56 3725 (10) 780 (23) -0.311 (29) -0.245 (31) 0.815 (4) 0.820 (6)
22 5376 (62) 1034 (68) 1.767 (67) 2.068 (68) 1.129 (61) 1.114 (61) 57 3953 (19) 840 (42) 0.288 (44) 0.439 (50) 0.864 (9) 0.850 (9)
23 4245 (30) 847 (44) 0.191 (41) 0.271 (45) 0.976 (28) 0.980 (34) 58 5063 (57) 840 (41) -0.010 (37) -0.073 (34) 1.094 (53) 1.071 (52)
24 4665 (46) 953 (64) 0.471 (52) 0.863 (59) 1.013 (37) 1.003 (37) 59 3408 (5) 592 (2) -1.840 (2) -1.877 (2) 0.760 (1) 0.741 (2)
25 4408 (35) 852 (45) -0.395 (26) -0.314 (29) 0.952 (23) 0.937 (25) 60 4161 (26) 811 (33) 0.080 (38) 0.077 (38) 1.003 (35) 0.978 (33)
26 5387 (63) 1026 (67) 2.969 (69) 3.261 (70) 1.282 (67) 1.239 (67) 61 3759 (13) 791 (26) 0.354 (48) 0.402 (47) 1.137 (62) 0.860 (10)
27 6716 (69) 989 (66) 1.587 (65) 0.978 (61) 1.391 (69) 1.369 (68) 62 4079 (23) 760 (19) -0.293 (30) -0.370 (28) 1.031 (41) 1.004 (38)
28 7580 (70) 1104 (70) 2.111 (68) 1.322 (64) 1.381 (68) 1.391 (69) 63 5056 (56) 864 (49) 0.207 (42) 0.173 (43) 1.115 (57) 1.083 (56)
29 3479 (6) 561 (1) -2.951 (1) -2.745 (1) 0.850 (7) 0.842 (8) 64 4228 (28) 746 (17) -0.475 (24) -0.554 (20) 1.059 (46) 1.061 (49)
30 5120 (58) 861 (46) 0.429 (51) 0.349 (46) 1.094 (55) 1.044 (47) 65 4538 (38) 886 (53) -0.063 (36) 0.159 (41) 1.007 (36) 1.008 (40)
31 3953 (20) 695 (6) -0.872 (10) -0.892 (12) 0.950 (22) 0.933 (23) 66 3733 (11) 756 (18) -0.569 (21) -0.550 (21) 0.813 (3) 0.787 (4)
32 3510 (7) 703 (9) -0.082 (35) -0.171 (33) 0.884 (11) 0.866 (11) 67 3991 (21) 876 (52) 0.628 (56) 0.840 (57) 0.999 (33) 0.965 (32)
33 4276 (31) 829 (38) -0.348 (28) -0.314 (30) 0.958 (24) 0.912 (17) 68 3594 (8) 836 (40) 0.336 (47) 0.507 (54) 0.885 (12) 0.915 (18)
34 4554 (40) 797 (28) 0.249 (43) 0.202 (44) 1.089 (50) 1.079 (55) 69 4379 (34) 873 (51) 0.698 (59) 0.896 (60) 0.946 (21) 0.924 (19)
35 2896 (2) 654 (5) -0.277 (31) -0.505 (24) 0.995 (32) 0.942 (28) 70 4459 (36) 765 (20) -0.443 (25) -0.440 (25) 1.086 (49) 1.073 (53)
Regression Regression StandardizationStandardization
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Table 4.6  Weighted Kappa Coefficients and Associated 95% Confidence Intervals Measuring the 
Agreement Between Different Risk-adjustment Methods in Ranking Antibacterial Drug 
Consumption 
 
 
 
Table 4.7  Guidelines for the Interpretation of Kappa Scores [100]  
 
Kappa   Interpretation  
< 0.20 Poor agreement 
0.21-0.40 Fair agreement 
0.41-0.60 Moderate agreement 
0.61-0.80 Good agreement 
0.81-1.00 Very good agreement 
 
 
 
 
 
 
 
DOTs/1000 
Discharges (1)
DOTs/1000 
PDs (2) Model II (3) Model I (4) Direct (5) Indirect (6)
(1) 0.61 (0.52, 0.70)  0.39 (0.25, 0.52) - 0.59 (0.48, 0.70) 0.61 (0.50, 0.71)
(2) - 0.59 (0.49, 0.70) - -
(3) 0.91 (0.88, 0.93) 0.46 (0.33, 0.59) 0.44 (0.31, 0.57)
(4) - -
(5) 0.85 (0.78, 0.92)
(6)
Observed Regression Standardization
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4.2.3 Comparison of Interhospital Antibacterial Drug Consumption at 
the CSL Level 
 
The relative internal homogeneity of strata is a necessary assumption of 
standardization and other stratified analysis methods. For this assumption 
to hold, the variability within the same stratum should be less than that 
between different strata [102]. If this assumption is valid, then the direct 
comparison of observed CSL-specific rates would seem reasonable. It is 
worth mentioning that the CSL-specific O/E ratios obtained from indirect 
standardization are identical to the CSL-specific E/O ratios obtained from 
direct standardization as both represent the ratio of the observed CSL-
specific rates in the study populations to the corresponding rates in the 
reference population. Therefore, within the same CSL, the interhospital 
comparison of CSL-specific E/O or O/E ratios is the same as the 
comparison of the observed CSL-specific rates measured in DOTs/1000 
discharges.          
 Figures 4.4, 4.5, 4.6 and 4.7 represent interhospital comparisons of 
AbC rates - measured in both DOTs/1000 discharges and DOTs/1000 PDs 
and ordered from lowest to highest consumption- and their associated 
components within 4 representative CSLs. The ventilator support CSL is 
representative of CSLs that have patient populations with complex clinical 
profiles and high SOI (e.g., transplant CSLs). Such CSLs typically have high 
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AbC but exhibit very little interhospital variability in the proportion of cases 
since nearly all patients receive antimicrobial therapy (Figure 4.4). However, 
the variability in the other components is quite high and the high variability 
in LOS may explain why the agreement between the two AbC rates in 
ranking hospitals within the ventilator support CSL is only fair (weighted κ = 
0.32,  95% CI (0.17-0.47)).  
Figures 4.5 represents a comparison of interhospital AbC within the 
general medicine CSL. This CSL represents CSLs that may have a relatively 
heterogeneous patient mix and moderate AbC. These CSLs typically exhibit 
little interhospital variability in the components of AbC as shown in the 
figure (Note that this figure is drawn to the same scale as Figure 4.6 and 
Figure 4.7 which is different from that of Figure 4.4). The agreement 
between the two AbC rates within the general medicine CSL was moderate 
(weighted κ = 0.52, 95% CI (0.40-0.64)). Other CSLs that have a similar 
pattern of use include, among others, the gastroenterology and orthopedics 
CSLs.  
The gynecology CSL (Figure 4.6), on the other hand, is a fairly 
homogenous CSL with a relatively low AbC. However, it has an exceptionally 
high interhospital variability in the proportion of cases as shown in the 
figure. The agreement between the two AbC rates within this CSL was fair 
(weighted κ = 0.40, 95% CI (0.26-0.55)). Finally, Figure 4.7 represents the 
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interhospital comparison of AbC within the psychiatry CSL. This CSL is 
characterized by very low AbC but a high interhospital variability in 
LOT/case and LOS relative to the average values of these components. The 
agreement between the two AbC rates within this CSL was fair to moderate 
(weighted κ = 0.41, 95% CI (0.27-0.56)). 
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Figure 4.4  A comparison of interhospital antibacterial drug consumption, measured in DOTs/1000 discharges (Figure A) and DOTs/1000 patient 
days (figure B), along with the associated components of consumption within the ventilator support clinical service line (CSL) in 70 U.S. academic 
medical centers during 2009. The yellow bar represents the reference population (RP) and the black-bordered components represent the components of 
RP. The very high proportion of cases with very low interhospital variability is typical of high consumption CSLs which include, in addition to 
ventilator support, the transplant CSLs. However, these CSLs exhibit high variability in the other components and the high variability in the length of 
stay (LOS) may explain why the agreement between the two antibacterial consumption rates is only fair. 
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Figure 4.5  A comparison of interhospital antibacterial drug consumption, measured in DOTs/1000 discharges (upper figure) and DOTs/1000 patient 
days (lower figure), along with the associated components of consumption within the general medicine clinical service line (CSL) in 70 U.S. academic 
medical centers during 2009. This CSL exhibits moderate consumption with relatively low interhospital variability in the components of consumption 
despite its relatively heterogeneous patient-mix. Other examples of CSLs with similar use pattern include orthopedics and gastroenterology.  
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Figure 4.6  A comparison of interhospital antibacterial drug consumption, measured in DOTs/1000 discharges (Figure A) and DOTs/1000 patient 
days (figure B), along with the associated components of consumption within the gynecology clinical service line (CSL) in 70 U.S. academic medical 
centers during 2009. This CSL is characterized by a moderately low antibacterial consumption with a notably high variability in the proportion of cases. 
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Figure 4.7  A comparison of interhospital antibacterial drug consumption, measured in DOTs/1000 discharges (Figure A) and DOTs/1000 patient 
days (figure B), along with the associated components of consumption within the psychiatry clinical service line (CSL) in 70 U.S. academic medical 
centers during 2009. This CSL is characterized by very low antibacterial consumption but the variability in the components of consumption; namely 
LOT/case and LOS, is high relative to the average value of these components.  
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Figure 4.8 and Figure 4.9 represent the CSL-specific O/E ratios for the 
DOTs/1000 discharges rate and its 3 associated components in Hospital 
#13 and Hospital #31 in Figure 4.3, respectively. As previously shown in 
Figure 4.3, the risk-adjusted hospital-wide values of Hospital #13 were 
above average for the DOTs/1000 discharges rate and the proportion of 
cases, high for DOTs/LOT ratio and low for LOT/case. The CSL-specific O/E 
ratios in Figure 4.8 are in general agreement with this hospital-wide pattern 
as explained in the figure legend. Figure 4.3 also showed that the risk-
adjusted hospital-wide values of Hospital #31 were low for the DOTs/1000 
discharges rate, the proportion of cases and the DOTs/LOT ratio but 
notably high for LOT/case. Figure 4.9 shows a very clear agreement with 
this hospital-wide pattern.  
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Figure 4.8  Observed to expected (O/E) ratios for antibacterial drug consumption (DOTs/1000 discharges) and its associated components in 33 
clinical service lines (CSLs) that compose hospital #13. This hospital had no patients in the liver transplant (CSL #12) or rehabilitation (CSL #24) 
CSLs. The O/E ratios for DOTs/1000 discharges are represented by the yellow spheres for clarity while the red dotted line represents an O/E ratio 
value of 1.00. The above figure shows that the CSL-specific O/E ratios for LOT/case were higher than 1.00 in 8 of the 33 CSLs only (compared to 23 
CSLs for DOTs/LOT ratio and 22 CSLs for the proportion of cases) and that the LOT/case had the lowest O/E ratio among the 3 components in 22 
of the 33 CSLs that compose this hospital. This CSL-specific pattern is in general agreement with the hospital-wide one illustrated in Figure 4.3.   
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Figure 4.9  Observed to expected (O/E) ratios for antibacterial drug consumption (DOTs/1000 discharges) and its associated components in 32 
clinical service lines (CSLs ) that compose hospital #31. This hospital had no patients in the liver transplant (CSL #12), lung transplant (CSL #13) or 
rehabilitation (CSL #24) CSLs. As shown in Figure 4.3, this hospital had a notably high risk-adjusted hospital-wide LOT/case despite having low risk-
adjusted hospital-wide DOTs/1000 discharges rate, DOTs/LOT ratio and proportion of cases. This is in agreement with the above figure which clearly 
shows that, with the notable exception the psychiatry CSL (CSL #23), antibacterial consumption in high consumption CSLs can be attributed to high 
LOT/case values. 
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Chapter V 
Discussion, Conclusion and  
Future Directions 
 
 
5.1 Summary of Findings and Study Strengths 
 
The need for the development of risk-adjusted AbC benchmarks in 
hospitals has been advocated by prominent ID societies [2]. The ID 
community responded and important advances have been made in 
benchmarking AbC in Europe [5,7,8] and the US [6,9]. However, 
benchmarking AbC is still in its infancy and much work remains to be done 
[29].  
Regression modeling has been the standard methodology for 
benchmarking AbC [5-7]. Recently however, indirect standardization 
emerged as a viable and appealing alternative for this purpose [8,9]. Direct 
standardization is a closely related risk-adjustment method that may be 
advantageous to indirect standardization for benchmarking purposes as it 
allows the direct comparison of risk-adjusted rates. However, direct 
standardization has not been previously applied to benchmark AbC.
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The current investigation applied both direct and indirect standardization to 
the benchmarking of adult AbC in 70 US academic medical centers. In 
addition, this investigation used regression modeling as a means of 
explaining the interhospital variability in AbC, measured in DOTs/1000 PDs 
and DOTs/1000 discharges, using LOS, the CMI, bed size and the infection, 
surgery and transplant rates as potential predictor variables. Finally, a 
comparison was made between the two standardization methods, the two 
regression models and between direct standardization and either regression 
model with respect to their agreement in ranking hospitals according to 
their risk-adjusted AbC as well as in identifying outlier hospitals.  
 When AbC was measured in DOTs/1000 discharges, the “best” model 
included LOS, infection rate and transplant rate as predictor variables and 
was able to explain 64% of the variability in interhospital AbC. This is in 
agreement with the results of an investigation in a sample of private 
hospitals in France which reported that a linear regression model that 
included LOS, the existence of an ID consultant, the proportion of PDs in 
the medical ward and the proportion of PDs in surgery as predictor 
variables, explained 68% of AbC measured in DDD/100 admissions [5]. 
When AbC was measured using DOTs/1000 PDs, the model selection 
criteria selected the model with infection rate and transplant rate as 
predictor variables. The model only explained 31% of the variability in AbC 
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between hospitals. This result is in agreement with MacDougal and Polk 
who reported the same percentage of explained variability using a model 
that included hospital size, the number of ICU days, surgical volume, and 
the number of cases of bacteremia, pneumonia, and UTI as predictors of 
total AbC measured in DOTs/1000 PDs in a sample of US hospitals [6]. 
However, the above French investigation was able to explain a much higher 
percentage (84%) of the variability in AbC measured in DDD/1000 PDs in a 
sample of public non-teaching hospitals using the existence of an ID 
consultant and the proportion of PDs in medical and surgical wards and 
ICUs as predictor variables. The agreement between the two regression 
models in ranking hospitals and identifying high and low outliers was very 
good in the current investigation. 
 The direct standardization method produced E/O ratios that ranged 
from 0.76 to 1.44 while the O/E ratios obtained from indirect 
standardization ranged from 0.73 to 1.45. The agreement between the 2 
methods in ranking hospitals and identifying outliers was very good. On the 
other hand, the agreement between either method and the regression model 
that used DOTs/1000 discharges as the outcome was moderate. The 
agreement between observed and risk-adjusted AbC ranged from fair to good 
depending on the risk-adjustment methodology. A recent investigation that 
used a combination of regression modeling and indirect standardization to 
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risk adjust hospital AbC in Finland found that hospital rankings according 
to their observed AbC rates did not match their risk-adjusted rankings in 25 
out of 30 hospitals [8]. However, while the study used percent agreement, I 
used weighted kappa to measure the agreement between observed and risk-
adjusted rankings.  
 In addition to deriving risk-adjusted AbC rates (DSRs), this 
investigation used direct standardization to risk-adjust the hospital-wide 
components of AbC including the proportion of discharges receiving 
antibiotics, LOT/discharge for patients receiving antibacterial therapy and 
DOTs/LOT ratio. These components have been recently used to benchmark 
AbC in hospitals at the CSL level [9].  However, this investigation provides 
hospitals with a strategy to benchmark both their AbC rates as well as the 
components of AbC with their peers at the hospital level. This is especially 
useful since the DOTs/1000 discharges measure is the product of the three 
above-mentioned components. Hospitals can also use this strategy to 
identify which component or combination of components is contributing the 
most to their hospital-wide AbC. This strategy does not focus on hospitals 
that are outliers in their AbC rates only. Non-outlier hospitals with respect 
to their AbC rates could also benefit from this strategy as they may have a 
high or an outlier value for one or more of these components. Hospitals can 
devise hospital-wide intervention strategies to address the most problematic 
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component(s). Obviously, benchmarks at the CSL or unit level are still 
needed as some CSLs/units will inevitably deviate from the general hospital-
wide use pattern.  
 Another important strength of this study is that it demonstrated that 
the DOTs/1000 discharges measure is better correlated than DOTs/1000 
PDs with non-modifiable factors such as LOS, infection and transplant rates 
as well as with factors that are amenable to intervention such as the 
proportion of discharges receiving antibacterial therapy, LOT/discharge for 
patients receiving antibacterial therapy and the DOTs/LOT ratio. In fact, 
these three components explained 99% of the variability in AbC in the 70 
hospitals when consumption was measured in DOTs/1000 discharges but 
only 82% of the variability in AbC measured in DOTs/1000 PDs (data not 
presented). LOT/discharge for patients receiving antibacterial therapy was 
the component with the strongest univariable correlation with the 
DOTs/1000 discharges measure (R2 = 0.68) followed by the DOTs/LOT ratio 
(R2 = 0.43) and the proportion of discharges receiving therapy (R2 = 0.20). 
Since these components (especially LOT/discharge for patients receiving 
antibacterial therapy and the proportion receiving antibiotic therapy) are 
thought to be strongly associated with antimicrobial resistance, this 
suggests that DOTs/1000 discharges may correlate better with 
antimicrobial resistance than DOTs/1000 PDs [37]. Accordingly, 
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benchmarking efforts should express antibiotic use rates using both 
denominators whenever possible. 
 Finally, this investigation showed that the variability in AbC rates and 
their associated components are generally higher in the high consumption 
CSLs such as the ventilator support and the transplant CSLs than in CSLs 
where AbC is average or below average such as the general medicine, 
orthopedics and gastroenterology CSLs. The high variability in the former 
CSLs may be due to the small number of discharged patients but it may 
also be due to interhospital differences in SOI or the proportion of 
inappropriate therapy.  
5.2 Limitations  
 
This attempt of benchmarking AbC in a subset of US teaching hospitals is 
limited by the use of an administrative database that has not been validated 
for the task at hand. Administrative databases are often used without 
validation and the accuracy of the information they provide may be 
considerably inferior to that of prospectively maintained databases [103]. 
However, variables pertaining to ischemic stroke patients in the UHC 
database have been previously validated and were found to highly agree 
with data retrieved from medical records [104,105]. Moreover, a study 
investigating trends in AbC among UHC hospitals conducted a limited 
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validation of the number of DOTs for drugs used in the management of 
Clostridium difficile disease in one of the UHC hospitals and found an 
excellent correlation (R2=0.99) between UHC data and that extracted locally 
from medical records [88]. Additionally, some participating hospitals were 
contacted and asked to provide their internally-generated AbC data (if 
available). These were compared against the UHC data and significant 
discrepancies were investigated.   
 It can be argued that the direct standardization approach adjusts for 
patient mix in a more accurate manner than the regression modeling 
approach. However, one limitation of standardization is that it cannot adjust 
for continuous variables (unless categorized). The CSLs may differ in their 
SOI, infection rates, and other important predictors of AbC. Also, while 
some CSLs are composed of a small number of DRGs and are relatively 
homogenous (e.g., BMT), others are composed of a large number of CSLs 
and may exhibit some heterogeneity that may contribute to residual 
confounding (e.g., general medicine). In addition, not all hospitals had the 
same CSL composition so using a common reference population was not 
possible. However, the CSLs that were not common to all hospitals had very 
small weights that the differences between the different reference 
populations were marginal. Therefore, differences in the CSL composition 
between hospitals are unlikely to have jeopardized the validity of the results.  
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Another limitation of this study lies in the assumption that some 
variables such as infection rates and LOS are exclusively non-modifiable. 
The total infection rate in a hospital is for the most part a mixture of HAIs 
which are generally considered to be preventable (i.e., modifiable), and 
community-acquired infections which are considered non-modifiable from 
the perspective of hospitals. Length of stay (LOS) may be considered a non-
modifiable variable in the sense of being regarded as a surrogate of SOI or 
as a modifiable factor indicative of the quality of health care. While HAIs 
cannot be entirely eliminated, they can be significantly reduced by 
implementing proven infection control measures and strategies [106]. The 
use of antimicrobials to treat avoidable HAIs may not constitute 
inappropriate use from a clinical perspective since these antimicrobials are 
used to treat definitive infections. However, an argument can be made that 
the use of antimicrobials to treat avoidable HAIs can be avoided as well, and 
thus, may be considered as inappropriate use.  Excluding HAIs from the 
total infection rate will increase the likelihood of identifying hospitals with 
high HAIs as being high outliers in terms of their antimicrobial use. 
Identifying avoidable HAI’s is probably best achieved with prospective 
patient-level data or through dedicated surveillance programs.  
 It should be emphasized that a relatively low antimicrobial use does 
not necessarily indicate the presence of an effective ASP. Low antimicrobial 
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use may be an indication of undertreating infections. It can also be a biased 
underestimation due to an inherent flaw in the metric used to measure 
antimicrobial use as previously mentioned. Benchmarking antimicrobial use 
is just one aspect of measuring the quality of care provided by a hospital’s 
ID team. Benchmarking infection rates, antimicrobial resistance, ASP, and 
infection control measures are just as important. Linking antimicrobial use 
benchmarks with these other performance benchmarks is crucial in order to 
assess the appropriateness of antimicrobial use in hospitals. 
5.3 Conclusion 
 
Identifying and effectively reducing inappropriate antimicrobial therapy 
without compromising patients’ well-being is central to the mission of ASPs.  
However, continuous monitoring of AbC at the patient level is prohibitive for 
many hospitals. Aggregate-level AbC data measured at the hospital and 
patient care area levels provide hospitals with a viable alternative for 
monitoring their AbC and benchmarking it against other hospitals. Indirect 
standardization has only been recently applied to benchmarking AbC in 
hospitals. The greatest advantage of this procedure over the more commonly 
used regression modeling method is its feasibility for risk-adjustment of AbC 
at both the hospital-wide and the unit or patient care area levels. However, 
one important limitation is that AbC rates are standardized using the 
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hospitals’ own patient mix distribution and therefore, the direct comparison 
of indirectly standardized rates is not always valid.  
Direct standardization is an alternative and closely related procedure 
that standardizes AbC rates to a common population mix enabling the direct 
comparison of interhospital AbC rates. Moreover, this procedure can be 
applied to standardize other meaningful components of AbC including the 
proportion of patients receiving antimicrobial therapy and proxy measures 
for the LOT and the average number of administered agents. Benchmarking 
these components along with AbC rates will enable hospitals to identify the 
specific component(s) that contributes the most to their AbC whether at the 
hospital level, or the unit or patient care area level. Hospitals can then 
devise strategies that effectively target the identified component(s). Although 
this investigation found the results of both standardization methods to be 
similar, this will not always be the case. Direct standardization should be 
regarded as the preferred method for the interhospital comparison of AbC 
unless there is some justification for preferring the indirect method such as 
the small size of strata.  
5.4 Future Directions  
 
The benchmarking literature is not extensive nor is it consistent and much work 
remains to be done and many research opportunities are available. A recent review 
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of benchmarking antibiotics in hospitals highlighted some of the gaps that need to 
be filled in the benchmarking literature [29]. Testing the “benchmarking 
hypothesis” is one area that deserves special consideration. The authors state,  
… Will hospitals respond to risk-adjusted comparative AbC data by 
implementing strategies and interventions to improve their antibiotic management 
and prescribing practices? If interventions are made in a number of hospitals, what 
interventions are most effective and how does AbC change? Will AbC just be shifted 
to other antimicrobials or will use be substantially reduced? And finally, if AbC is 
improved, will this be accompanied by important changes in clinical outcomes, 
including lower rates of antibiotic resistance and infections caused by resistant 
organisms, including rates of Clostridium difficile infection (CDI). Will reduced use 
be accompanied improved patient outcomes because of lower rates of HAIs caused 
by resistant organisms? Will the evidence be compelling enough for most hospitals 
to undertake similar interventions? [29] 
The only investigation to test the benchmarking hypothesis is the CDC Project 
ICARE [87]. This study reported that changes in prescriber practice, motivated by 
providing hospitals with national AbC benchmarks, were associated with a 
significant reduction in vancomycin use and a subsequent reduction in the 
prevalence of vancomycin-resistant enterococci (VRE).  
Other areas identified by the above review paper for prospective 
investigations include benchmarking antimicrobial use in developing 
countries and pediatric populations in addition to benchmarking antifungal 
and antiviral drug use. The usefulness of other statistical methods such as 
Bayesian regression, hierarchical regression and data envelopment analysis 
for benchmarking AbC is worth exploring. Also, adjusting for SOI within 
CSLs or hospital units is worth considering as it may provide a more 
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accurate adjustment and comparison of interhospital AbC. Finally, further 
work on developing and validating antimicrobial use measures seems 
warranted. 
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Appendix 
 
 
 
Table A1  A List of the 52 Antibacterial Agents that Were Used to Calculate Antibacterial Consumption 
 
Antibacterial Drug Class Antibacterial Agents 
β -lactamase-sensitive penicillins  amoxicillin, ampicillin, penicillin g potasium, 
penicillin g sodium, penicillin v potasium, 
piperacillin    
β-lactam/β-lactamase  inhibitor 
combinations  
amoxicillin/clavulanate potassium, 
ampicillin/sulbactam, piperacillin/tazobactam, 
ticarcillin/calvulanate  
Antistaphylococcal penicillins dicloxacillin, nafcillin sodium, oxacillin sodium  
First generation cephalosporins cefazolin, cephalexin 
Second generation cephalosporins cefaclor, cefotetan, cefoxitin, cefuroxime 
Third and fourth generation 
cephalosporins/Monobactam 
cefepime, cefotaxime sodium, cefpodoxime,  
ceftazidime, ceftriaxone sodium, aztreonam 
Carbapenems doripenem, ertapenem sodium, 
imipenem/cilastatin, meropenem 
Fluoroquinolones ciprofloxacin, levofloxacin, moxifloxacin 
hydrochloride, norfloxacin  
Aminoglycosides  amikacin, gentamicin sulfate, tobramycin 
Macrolides azithromycin, clarithromycin, erythromycin 
Tetracyclines demeclocycline, doxycycline, minocycline, 
tetracycline 
Glycopeptides vancomycin 
Other anti-gram-positive agents daptomycin, linezolid, tigecycline 
Imidazoles  metronidazole 
Sulfonamides  trimethoprim/sulfamethoxazole 
Lincosamides clindamycin  
Miscellaneous   nitrofurantoin,  sulfadiazine 
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Table A2  A List of the International Classification of Diseases, Ninth Revision (ICD-9-CM) Diagnosis 
and Procedure Codes that Compose the Different Diagnoses and Procedures  
  
Diagnosis/Procedure  Diagnosis or Procedure Codes  
Urinary tract infections 590.1x, 590.2, 590.3, 590.8x, 595.0, 599.0 
Pneumonia 481, 482.x, 483.x, 484.x, 485, 486 
Other infections  All codes from 001.0  to 041.9 
Transplants  33.50, 33.52, 33.6, 37.51, 41.94,  46.97, 50.51, 50.59, 52.80, 55.69 
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Table A3   The Medicare Severity Diagnosis Related Groups (MS-DRGs) Composition of the 35 Clinical 
Service Lines   
 
Abbreviations:  BMT = Bone marrow transplant, CC = complications and comorbidities, MCC 
=  major complications and comorbidities, MV = Mechanical ventilation, PDX = principal 
diagnosis, O.R. = operating room procedure, AMI = Acute myocardial infarction, HF = Heart 
failure 
 
CSL Number Clinical Service Line Name MS-DRG Number MS-DRG Clinical Condition 
1 BMT                                                9 Bone marrow transplant (-FY2010)                                                                     
1 BMT                                                14 Allogeneic Bone Marrow Transplant (FY2011+)                                                          
1 BMT                                                15 Autologous Bone Marrow Transplant (FY2011+)                                                          
2 Burns                                              927 Extensive burns or full thickness burns w MV 96+ hrs w skin graft                                    
2 Burns                                              928 Full thickness burn w skin graft or inhal inj w CC/MCC                                               
2 Burns                                              929 Full thickness burn w skin graft or inhal inj w/o CC/MCC                                             
2 Burns                                              933 Extensive burns or full thickness burns w MV 96+ hrs w/o skin graft                                  
2 Burns                                              934 Full thickness burn w/o skin grft or inhal inj                                                       
2 Burns                                              935 Non-extensive burns                                                                                  
3 Cardiology                                         222 Cardiac defib implant w cardiac cath w AMI/HF/shock w MCC                                            
3 Cardiology                                         223 Cardiac defib implant w cardiac cath w AMI/HF/shock w/o MCC                                          
3 Cardiology                                         224 Cardiac defib implant w cardiac cath w/o AMI/HF/shock w MCC                                          
3 Cardiology                                         225 Cardiac defib implant w cardiac cath w/o AMI/HF/shock w/o MCC                                        
3 Cardiology                                         226 Cardiac defibrillator implant w/o cardiac cath w MCC                                                 
3 Cardiology                                         227 Cardiac defibrillator implant w/o cardiac cath w/o MCC                                               
3 Cardiology                                         242 Permanent cardiac pacemaker implant w MCC                                                            
3 Cardiology                                         243 Permanent cardiac pacemaker implant w CC                                                             
3 Cardiology                                         244 Permanent cardiac pacemaker implant w/o CC/MCC                                                       
3 Cardiology                                         245 AICD generator procedures (FY2009+)                                                                  
3 Cardiology                                         246 Perc cardiovasc proc w drug-eluting stent w MCC or 4+ vessels/stents                                 
3 Cardiology                                         247 Perc cardiovasc proc w drug-eluting stent w/o MCC                                                    
3 Cardiology                                         248 Perc cardiovasc proc w non-drug-eluting stent w MCC or 4+ ves/stents                                 
3 Cardiology                                         249 Perc cardiovasc proc w non-drug-eluting stent w/o MCC                                                
3 Cardiology                                         250 Perc cardiovasc proc w/o coronary artery stent or AMI w MCC                                          
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3 Cardiology                                         251 Perc cardiovasc proc w/o coronary artery stent or AMI w/o MCC                                        
3 Cardiology                                         258 Cardiac pacemaker device replacement w MCC                                                           
3 Cardiology                                         259 Cardiac pacemaker device replacement w/o MCC                                                         
3 Cardiology                                         260 Cardiac pacemaker revision except device replacement w MCC                                           
3 Cardiology                                         261 Cardiac pacemaker revision except device replacement w CC                                            
3 Cardiology                                         262 Cardiac pacemaker revision except device replacement w/o CC/MCC                                      
3 Cardiology                                         265 AICD lead procedures                                                                                 
3 Cardiology                                         280 Acute myocardial infarction, discharged alive w MCC                                                  
3 Cardiology                                         281 Acute myocardial infarction, discharged alive w CC                                                   
3 Cardiology                                         282 Acute myocardial infarction, discharged alive w/o CC/MCC                                              
3 Cardiology                                         283 Acute myocardial infarction, expired w MCC                                                           
3 Cardiology                                         284 Acute myocardial infarction, expired w CC                                                            
3 Cardiology                                         285 Acute myocardial infarction, expired w/o CC/MCC                                                      
3 Cardiology                                         286 Circulatory disorders except AMI, w card cath w MCC                                                  
3 Cardiology                                         287 Circulatory disorders except AMI, w card cath w/o MCC                                                
3 Cardiology                                         288 Acute & subacute endocarditis w MCC                                                                  
3 Cardiology                                         289 Acute & subacute endocarditis w CC                                                                   
3 Cardiology                                         290 Acute & subacute endocarditis w/o CC/MCC                                                             
3 Cardiology                                         291 Heart failure & shock w MCC                                                                          
3 Cardiology                                         292 Heart failure & shock w CC                                                                           
3 Cardiology                                         293 Heart failure & shock w/o CC/MCC                                                                     
3 Cardiology                                         296 Cardiac arrest, unexplained w MCC                                                                    
3 Cardiology                                         297 Cardiac arrest, unexplained w CC                                                                     
3 Cardiology                                         298 Cardiac arrest, unexplained w/o CC/MCC                                                               
3 Cardiology                                         302 Atherosclerosis w MCC                                                                                
3 Cardiology                                         303 Atherosclerosis w/o MCC                                                                              
3 Cardiology                                         306 Cardiac congenital & valvular disorders w MCC                                                        
3 Cardiology                                         307 Cardiac congenital & valvular disorders w/o MCC                                                      
3 Cardiology                                         308 Cardiac arrhythmia & conduction disorders w MCC                                                      
3 Cardiology                                         309 Cardiac arrhythmia & conduction disorders w CC                                                       
3 Cardiology                                         310 Cardiac arrhythmia & conduction disorders w/o CC/MCC                                                 
3 Cardiology                                         311 Angina pectoris                                                                                      
3 Cardiology                                         314 Other circulatory system diagnoses w MCC                                                             
3 Cardiology                                         315 Other circulatory system diagnoses w CC                                                              
3 Cardiology                                         316 Other circulatory system diagnoses w/o CC/MCC                                                        
4 Cardiothoracic Surg                                163 Major chest procedures w MCC                                                                         
4 Cardiothoracic Surg                                164 Major chest procedures w CC                                                                          
4 Cardiothoracic Surg                                165 Major chest procedures w/o CC/MCC                                                                    
4 Cardiothoracic Surg                                166 Other resp system O.R. procedures w MCC                                                              
4 Cardiothoracic Surg                                167 Other resp system O.R. procedures w CC                                                               
4 Cardiothoracic Surg                                168 Other resp system O.R. procedures w/o CC/MCC                                                         
4 Cardiothoracic Surg                                216 Cardiac valve & oth maj cardiothoracic proc w card cath w MCC                                        
4 Cardiothoracic Surg                                217 Cardiac valve & oth maj cardiothoracic proc w card cath w CC                                         
4 Cardiothoracic Surg                                218 Cardiac valve & oth maj cardiothoracic proc w card cath w/o CC/MCC                                   
4 Cardiothoracic Surg                                219 Cardiac valve & oth maj cardiothoracic proc w/o card cath w MCC                                      
4 Cardiothoracic Surg                                220 Cardiac valve & oth maj cardiothoracic proc w/o card cath w CC                                       
4 Cardiothoracic Surg                                221 Cardiac valve & oth maj cardiothoracic proc w/o card cath w/o CC/MCC                                 
4 Cardiothoracic Surg                                228 Other cardiothoracic procedures w MCC                                                                
4 Cardiothoracic Surg                                229 Other cardiothoracic procedures w CC                                                                 
4 Cardiothoracic Surg                                230 Other cardiothoracic procedures w/o CC/MCC                                                           
4 Cardiothoracic Surg                                231 Coronary bypass w PTCA w MCC                                                                         
4 Cardiothoracic Surg                                232 Coronary bypass w PTCA w/o MCC                                                                       
4 Cardiothoracic Surg                                233 Coronary bypass w cardiac cath w MCC                                                                 
4 Cardiothoracic Surg                                234 Coronary bypass w cardiac cath w/o MCC                                                               
4 Cardiothoracic Surg                                235 Coronary bypass w/o cardiac cath w MCC                                                               
4 Cardiothoracic Surg                                236 Coronary bypass w/o cardiac cath w/o MCC                                                             
4 Cardiothoracic Surg                                237 Major cardiovasc procedures w MCC or thoracic aortic anuerysm repair                                 
4 Cardiothoracic Surg                                238 Major cardiovascular procedures w/o MCC                                                              
5 Dental/Oral Surgery                                137 Mouth procedures w CC/MCC                                                                            
5 Dental/Oral Surgery                                138 Mouth procedures w/o CC/MCC                                                                          
5 Dental/Oral Surgery                                157 Dental & Oral Diseases w MCC                                                                         
5 Dental/Oral Surgery                                158 Dental & Oral Diseases w CC                                                                          
5 Dental/Oral Surgery                                159 Dental & Oral Diseases w/o CC/MCC                                                                    
6 Dermatology                                        595 Major skin disorders w MCC                                                                           
6 Dermatology                                        596 Major skin disorders w/o MCC                                                                         
6 Dermatology                                        606 Minor skin disorders w MCC                                                                           
6 Dermatology                                        607 Minor skin disorders w/o MCC                                                                         
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7 Gastroenterology                                   368 Major esophageal disorders w MCC                                                                     
7 Gastroenterology                                   369 Major esophageal disorders w CC                                                                      
7 Gastroenterology                                   370 Major esophageal disorders w/o CC/MCC                                                                
7 Gastroenterology                                   371 Major gastrointestinal disorders & peritoneal infections w MCC                                       
7 Gastroenterology                                   372 Major gastrointestinal disorders & peritoneal infections w CC                                        
7 Gastroenterology                                   373 Major gastrointestinal disorders & peritoneal infections w/o CC/MCC                                  
7 Gastroenterology                                   377 G.I. hemorrhage w MCC                                                                                
7 Gastroenterology                                   378 G.I. hemorrhage w CC                                                                                 
7 Gastroenterology                                   379 G.I. hemorrhage w/o CC/MCC                                                                           
7 Gastroenterology                                   380 Complicated peptic ulcer w MCC                                                                       
7 Gastroenterology                                   381 Complicated peptic ulcer w CC                                                                        
7 Gastroenterology                                   382 Complicated peptic ulcer w/o CC/MCC                                                                  
7 Gastroenterology                                   385 Inflammatory bowel disease w MCC                                                                     
7 Gastroenterology                                   386 Inflammatory bowel disease w CC                                                                      
7 Gastroenterology                                   387 Inflammatory bowel disease w/o CC/MCC                                                                
7 Gastroenterology                                   388 G.I. obstruction w MCC                                                                               
7 Gastroenterology                                   389 G.I. obstruction w CC                                                                                
7 Gastroenterology                                   390 G.I. obstruction w/o CC/MCC                                                                          
7 Gastroenterology                                   391 Esophagitis, gastroent & misc digest disorders w MCC                                                 
7 Gastroenterology                                   392 Esophagitis, gastroent & misc digest disorders w/o MCC                                               
7 Gastroenterology                                   393 Other digestive system diagnoses w MCC                                                               
7 Gastroenterology                                   394 Other digestive system diagnoses w CC                                                                
7 Gastroenterology                                   395 Other digestive system diagnoses w/o CC/MCC                                                          
7 Gastroenterology                                   432 Cirrhosis & alcoholic hepatitis w MCC                                                                
7 Gastroenterology                                   433 Cirrhosis & alcoholic hepatitis w CC                                                                 
7 Gastroenterology                                   434 Cirrhosis & alcoholic hepatitis w/o CC/MCC                                                           
7 Gastroenterology                                   438 Disorders of pancreas except malignancy w MCC                                                        
7 Gastroenterology                                   439 Disorders of pancreas except malignancy w CC                                                         
7 Gastroenterology                                   440 Disorders of pancreas except malignancy w/o CC/MCC                                                   
7 Gastroenterology                                   441 Disorders of liver except malig,cirr,alc hepa w MCC                                                  
7 Gastroenterology                                   442 Disorders of liver except malig,cirr,alc hepa w CC                                                   
7 Gastroenterology                                   443 Disorders of liver except malig,cirr,alc hepa w/o CC/MCC                                             
7 Gastroenterology                                   444 Disorders of the biliary tract w MCC                                                                 
7 Gastroenterology                                   445 Disorders of the biliary tract w CC                                                                  
7 Gastroenterology                                   446 Disorders of the biliary tract w/o CC/MCC                                                            
8 Gynecology                                         742 Uterine & adnexa proc for non-malignancy w CC/MCC                                                    
8 Gynecology                                         743 Uterine & adnexa proc for non-malignancy w/o CC/MCC                                                  
8 Gynecology                                         744 D&C, conization, laparoscopy & tubal interruption w CC/MCC                                           
8 Gynecology                                         745 D&C, conization, laparoscopy & tubal interruption w/o CC/MCC                                         
8 Gynecology                                         746 Vagina, cervix & vulva procedures w CC/MCC                                                           
8 Gynecology                                         747 Vagina, cervix & vulva procedures w/o CC/MCC                                                         
8 Gynecology                                         748 Female reproductive system reconstructive procedures                                                 
8 Gynecology                                         749 Other female reproductive system O.R. procedures w CC/MCC                                            
8 Gynecology                                         750 Other female reproductive system O.R. procedures w/o CC/MCC                                          
8 Gynecology                                         757 Infections, female reproductive system w MCC                                                         
8 Gynecology                                         758 Infections, female reproductive system w CC                                                          
8 Gynecology                                         759 Infections, female reproductive system w/o CC/MCC                                                    
8 Gynecology                                         760 Menstrual & other female reproductive system disorders w CC/MCC                                      
8 Gynecology                                         761 Menstrual & other female reproductive system disorders w/o CC/MCC                                    
9 Heart Transplant or Implant of Heart Assist System 1 Heart transplant or implant of heart assist system w MCC                                             
9 Heart Transplant or Implant of Heart Assist System 2 Heart transplant or implant of heart assist system w/o MCC                                           
9 Heart Transplant or Implant of Heart Assist System 215 Other heart assist system implant                                                                    
10 HIV                                                969 HIV w extensive O.R. procedure w MCC                                                                 
10 HIV                                                970 HIV w extensive O.R. procedure w/o MCC                                                               
10 HIV                                                974 HIV w major related condition w MCC                                                                  
10 HIV                                                975 HIV w major related condition w CC                                                                   
10 HIV                                                976 HIV w major related condition w/o CC/MCC                                                             
10 HIV                                                977 HIV w or w/o other related condition                                                                 
11 Kidney/Pancreas Transplant                         8 Simultaneous pancreas/kidney transplant                                                              
11 Kidney/Pancreas Transplant                         10 Pancreas transplant                                                                                  
11 Kidney/Pancreas Transplant                         652 Kidney transplant                                                                                    
12 Liver Transplant                                   5 Liver transplant w MCC or intestinal transplant                                                      
12 Liver Transplant                                   6 Liver transplant w/o MCC                                                                             
13 Lung Transplant                                    7 Lung transplant                                                                                      
14 Med Oncology                                       54 Nervous system neoplasms w MCC                                                                       
14 Med Oncology                                       55 Nervous system neoplasms w/o MCC                                                                     
14 Med Oncology                                       180 Respiratory neoplasms w MCC                                                                          
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14 Med Oncology                                       181 Respiratory neoplasms w CC                                                                           
14 Med Oncology                                       182 Respiratory neoplasms w/o CC/MCC                                                                     
14 Med Oncology                                       374 Digestive malignancy w MCC                                                                           
14 Med Oncology                                       375 Digestive malignancy w CC                                                                            
14 Med Oncology                                       376 Digestive malignancy w/o CC/MCC                                                                      
14 Med Oncology                                       435 Malignancy of hepatobiliary system or pancreas w MCC                                                 
14 Med Oncology                                       436 Malignancy of hepatobiliary system or pancreas w CC                                                  
14 Med Oncology                                       437 Malignancy of hepatobiliary system or pancreas w/o CC/MCC                                            
14 Med Oncology                                       542 Pathological fractures & musculoskelet & conn tiss malig w MCC                                       
14 Med Oncology                                       543 Pathological fractures & musculoskelet & conn tiss malig w CC                                        
14 Med Oncology                                       544 Pathological fractures & musculoskelet & conn tiss malig w/o CC/MCC                                  
14 Med Oncology                                       597 Malignant breast disorders w MCC                                                                     
14 Med Oncology                                       598 Malignant breast disorders w CC                                                                      
14 Med Oncology                                       599 Malignant breast disorders w/o CC/MCC                                                                
14 Med Oncology                                       686 Kidney & urinary tract neoplasms w MCC                                                               
14 Med Oncology                                       687 Kidney & urinary tract neoplasms w CC                                                                
14 Med Oncology                                       688 Kidney & urinary tract neoplasms w/o CC/MCC                                                          
14 Med Oncology                                       834 Acute leukemia w/o major O.R. procedure w MCC                                                        
14 Med Oncology                                       835 Acute leukemia w/o major O.R. procedure w CC                                                         
14 Med Oncology                                       836 Acute leukemia w/o major O.R. procedure w/o CC/MCC                                                   
14 Med Oncology                                       837 Chemo w acute leukemia as sdx or w high dose chemo agent w MCC                                       
14 Med Oncology                                       838 Chemo w acute leukemia as sdx w CC or high dose chemo agent                                          
14 Med Oncology                                       839 Chemo w acute leukemia as sdx w/o CC/MCC                                                             
14 Med Oncology                                       840 Lymphoma & non-acute leukemia w MCC                                                                  
14 Med Oncology                                       841 Lymphoma & non-acute leukemia w CC                                                                   
14 Med Oncology                                       842 Lymphoma & non-acute leukemia w/o CC/MCC                                                             
14 Med Oncology                                       843 Other myeloprolif dis or poorly diff neopl diag w MCC                                                
14 Med Oncology                                       844 Other myeloprolif dis or poorly diff neopl diag w CC                                                 
14 Med Oncology                                       845 Other myeloprolif dis or poorly diff neopl diag w/o CC/MCC                                           
14 Med Oncology                                       846 Chemotherapy w/o acute leukemia as secondary diagnosis w MCC                                         
14 Med Oncology                                       847 Chemotherapy w/o acute leukemia as secondary diagnosis w CC                                          
14 Med Oncology                                       848 Chemotherapy w/o acute leukemia as secondary diagnosis w/o CC/MCC                                    
14 Med Oncology                                       849 Radiotherapy                                                                                         
15 Medicine General                                   75 Viral meningitis w CC/MCC                                                                            
15 Medicine General                                   76 Viral meningitis w/o CC/MCC                                                                          
15 Medicine General                                   77 Hypertensive encephalopathy w MCC                                                                    
15 Medicine General                                   78 Hypertensive encephalopathy w CC                                                                     
15 Medicine General                                   79 Hypertensive encephalopathy w/o CC/MCC                                                               
15 Medicine General                                   94 Bacterial & tuberculous infections of nervous system w MCC                                           
15 Medicine General                                   95 Bacterial & tuberculous infections of nervous system w CC                                            
15 Medicine General                                   96 Bacterial & tuberculous infections of nervous system w/o CC/MCC                                      
15 Medicine General                                   97 Non-bacterial infect of nervous sys exc viral meningitis w MCC                                       
15 Medicine General                                   98 Non-bacterial infect of nervous sys exc viral meningitis w CC                                        
15 Medicine General                                   99 Non-bacterial infect of nervous sys exc viral meningitis w/o CC/MCC                                  
15 Medicine General                                   152 Otitis media & URI w MCC                                                                             
15 Medicine General                                   153 Otitis media & URI w/o MCC                                                                           
15 Medicine General                                   175 Pulmonary embolism w MCC                                                                             
15 Medicine General                                   176 Pulmonary embolism w/o MCC                                                                           
15 Medicine General                                   177 Respiratory infections & inflammations w MCC                                                         
15 Medicine General                                   178 Respiratory infections & inflammations w CC                                                          
15 Medicine General                                   179 Respiratory infections & inflammations w/o CC/MCC                                                    
15 Medicine General                                   186 Pleural effusion w MCC                                                                               
15 Medicine General                                   187 Pleural effusion w CC                                                                                
15 Medicine General                                   188 Pleural effusion w/o CC/MCC                                                                          
15 Medicine General                                   189 Pulmonary edema & respiratory failure                                                                
15 Medicine General                                   190 Chronic obstructive pulmonary disease w MCC                                                          
15 Medicine General                                   191 Chronic obstructive pulmonary disease w CC                                                           
15 Medicine General                                   192 Chronic obstructive pulmonary disease w/o CC/MCC                                                     
15 Medicine General                                   193 Simple pneumonia & pleurisy w MCC                                                                    
15 Medicine General                                   194 Simple pneumonia & pleurisy w CC                                                                     
15 Medicine General                                   195 Simple pneumonia & pleurisy w/o CC/MCC                                                               
15 Medicine General                                   196 Interstitial lung disease w MCC                                                                      
15 Medicine General                                   197 Interstitial lung disease w CC                                                                       
15 Medicine General                                   198 Interstitial lung disease w/o CC/MCC                                                                 
15 Medicine General                                   199 Pneumothorax w MCC                                                                                   
15 Medicine General                                   200 Pneumothorax w CC                                                                                    
15 Medicine General                                   201 Pneumothorax w/o CC/MCC                                                                              
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15 Medicine General                                   202 Bronchitis & asthma w CC/MCC                                                                         
15 Medicine General                                   203 Bronchitis & asthma w/o CC/MCC                                                                       
15 Medicine General                                   204 Respiratory signs & symptoms                                                                         
15 Medicine General                                   205 Other respiratory system diagnoses w MCC                                                             
15 Medicine General                                   206 Other respiratory system diagnoses w/o MCC                                                           
15 Medicine General                                   208 Respiratory system diagnosis w ventilator support <96 hours                                          
15 Medicine General                                   294 Deep vein thrombophlebitis w CC/MCC                                                                  
15 Medicine General                                   295 Deep vein thrombophlebitis w/o CC/MCC                                                                
15 Medicine General                                   299 Peripheral vascular disorders w MCC                                                                  
15 Medicine General                                   300 Peripheral vascular disorders w CC                                                                   
15 Medicine General                                   301 Peripheral vascular disorders w/o CC/MCC                                                             
15 Medicine General                                   304 Hypertension w MCC                                                                                   
15 Medicine General                                   305 Hypertension w/o MCC                                                                                 
15 Medicine General                                   312 Syncope & collapse                                                                                   
15 Medicine General                                   313 Chest pain                                                                                           
15 Medicine General                                   383 Uncomplicated peptic ulcer w MCC                                                                     
15 Medicine General                                   384 Uncomplicated peptic ulcer w/o MCC                                                                   
15 Medicine General                                   539 Osteomyelitis w MCC                                                                                  
15 Medicine General                                   540 Osteomyelitis w CC                                                                                   
15 Medicine General                                   541 Osteomyelitis w/o CC/MCC                                                                             
15 Medicine General                                   551 Medical back problems w MCC                                                                          
15 Medicine General                                   552 Medical back problems w/o MCC                                                                        
15 Medicine General                                   592 Skin ulcers w MCC                                                                                    
15 Medicine General                                   593 Skin ulcers w CC                                                                                     
15 Medicine General                                   594 Skin ulcers w/o CC/MCC                                                                               
15 Medicine General                                   600 Non-malignant breast disorders w CC/MCC                                                              
15 Medicine General                                   601 Non-malignant breast disorders w/o CC/MCC                                                            
15 Medicine General                                   602 Cellulitis w MCC                                                                                     
15 Medicine General                                   603 Cellulitis w/o MCC                                                                                   
15 Medicine General                                   604 Trauma to the skin, subcut tiss & breast w MCC                                                       
15 Medicine General                                   605 Trauma to the skin, subcut tiss & breast w/o MCC                                                     
15 Medicine General                                   637 Diabetes w MCC                                                                                       
15 Medicine General                                   638 Diabetes w CC                                                                                        
15 Medicine General                                   639 Diabetes w/o CC/MCC                                                                                  
15 Medicine General                                   640 Nutritional & misc metabolic disorders w MCC                                                         
15 Medicine General                                   641 Nutritional & misc metabolic disorders w/o MCC                                                       
15 Medicine General                                   642 Inborn errors of metabolism                                                                          
15 Medicine General                                   643 Endocrine disorders w MCC                                                                            
15 Medicine General                                   644 Endocrine disorders w CC                                                                             
15 Medicine General                                   645 Endocrine disorders w/o CC/MCC                                                                       
15 Medicine General                                   682 Renal failure w MCC                                                                                  
15 Medicine General                                   683 Renal failure w CC                                                                                   
15 Medicine General                                   684 Renal failure w/o CC/MCC                                                                             
15 Medicine General                                   685 Admit for renal dialysis                                                                             
15 Medicine General                                   689 Kidney & urinary tract infections w MCC                                                              
15 Medicine General                                   690 Kidney & urinary tract infections w/o MCC                                                            
15 Medicine General                                   698 Other kidney & urinary tract diagnoses w MCC                                                         
15 Medicine General                                   699 Other kidney & urinary tract diagnoses w CC                                                          
15 Medicine General                                   700 Other kidney & urinary tract diagnoses w/o CC/MCC                                                    
15 Medicine General                                   808 Major hematol/immun diag exc sickle cell crisis & coagul w MCC                                       
15 Medicine General                                   809 Major hematol/immun diag exc sickle cell crisis & coagul w CC                                        
15 Medicine General                                   810 Major hematol/immun diag exc sickle cell crisis & coagul w/o CC/MCC                                  
15 Medicine General                                   811 Red blood cell disorders w MCC                                                                       
15 Medicine General                                   812 Red blood cell disorders w/o MCC                                                                     
15 Medicine General                                   813 Coagulation disorders                                                                                
15 Medicine General                                   814 Reticuloendothelial & immunity disorders w MCC                                                       
15 Medicine General                                   815 Reticuloendothelial & immunity disorders w CC                                                        
15 Medicine General                                   816 Reticuloendothelial & immunity disorders w/o CC/MCC                                                  
15 Medicine General                                   862 Postoperative & post-traumatic infections w MCC                                                      
15 Medicine General                                   863 Postoperative & post-traumatic infections w/o MCC                                                    
15 Medicine General                                   864 Fever of unknown origin                                                                              
15 Medicine General                                   865 Viral illness w MCC                                                                                  
15 Medicine General                                   866 Viral illness w/o MCC                                                                                
15 Medicine General                                   867 Other infectious & parasitic diseases diagnoses w MCC                                                
15 Medicine General                                   868 Other infectious & parasitic diseases diagnoses w CC                                                 
15 Medicine General                                   869 Other infectious & parasitic diseases diagnoses w/o CC/MCC                                           
15 Medicine General                                   871 Septicemia or severe sepsis w/o MV 96+ hours w MCC (FY2009+)                                         
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15 Medicine General                                   872 Septicemia or severe sepsis w/o MV 96+ hours w/o MCC (FY2009+)                                       
15 Medicine General                                   915 Allergic reactions w MCC                                                                             
15 Medicine General                                   916 Allergic reactions w/o MCC                                                                           
15 Medicine General                                   917 Poisoning & toxic effects of drugs w MCC                                                             
15 Medicine General                                   918 Poisoning & toxic effects of drugs w/o MCC                                                           
15 Medicine General                                   922 Other injury, poisoning & toxic effect diag w MCC                                                    
15 Medicine General                                   923 Other injury, poisoning & toxic effect diag w/o MCC                                                  
15 Medicine General                                   947 Signs & symptoms w MCC                                                                               
15 Medicine General                                   948 Signs & symptoms w/o MCC                                                                             
15 Medicine General                                   949 Aftercare w CC/MCC                                                                                   
15 Medicine General                                   950 Aftercare w/o CC/MCC                                                                                 
15 Medicine General                                   951 Other factors influencing health status                                                              
16 Neurology                                          52 Spinal disorders & injuries w CC/MCC                                                                 
16 Neurology                                          53 Spinal disorders & injuries w/o CC/MCC                                                               
16 Neurology                                          56 Degenerative nervous system disorders w MCC                                                          
16 Neurology                                          57 Degenerative nervous system disorders w/o MCC                                                        
16 Neurology                                          58 Multiple sclerosis & cerebellar ataxia w MCC                                                         
16 Neurology                                          59 Multiple sclerosis & cerebellar ataxia w CC                                                          
16 Neurology                                          60 Multiple sclerosis & cerebellar ataxia w/o CC/MCC                                                    
16 Neurology                                          61 Acute ischemic stroke w use of thrombolytic agent w MCC                                              
16 Neurology                                          62 Acute ischemic stroke w use of thrombolytic agent w CC                                               
16 Neurology                                          63 Acute ischemic stroke w use of thrombolytic agent w/o CC/MCC                                         
16 Neurology                                          64 Intracranial hemorrhage or cerebral infarction w MCC                                                 
16 Neurology                                          65 Intracranial hemorrhage or cerebral infarction w CC                                                  
16 Neurology                                          66 Intracranial hemorrhage or cerebral infarction w/o CC/MCC                                            
16 Neurology                                          67 Nonspecific cva & precerebral occlusion w/o infarct w MCC                                            
16 Neurology                                          68 Nonspecific cva & precerebral occlusion w/o infarct w/o MCC                                          
16 Neurology                                          69 Transient ischemia                                                                                   
16 Neurology                                          70 Nonspecific cerebrovascular disorders w MCC                                                          
16 Neurology                                          71 Nonspecific cerebrovascular disorders w CC                                                           
16 Neurology                                          72 Nonspecific cerebrovascular disorders w/o CC/MCC                                                     
16 Neurology                                          73 Cranial & peripheral nerve disorders w MCC                                                           
16 Neurology                                          74 Cranial & peripheral nerve disorders w/o MCC                                                         
16 Neurology                                          80 Nontraumatic stupor & coma w MCC                                                                     
16 Neurology                                          81 Nontraumatic stupor & coma w/o MCC                                                                   
16 Neurology                                          82 Traumatic stupor & coma, coma >1 hr w MCC                                                            
16 Neurology                                          83 Traumatic stupor & coma, coma >1 hr w CC                                                             
16 Neurology                                          84 Traumatic stupor & coma, coma >1 hr w/o CC/MCC                                                       
16 Neurology                                          85 Traumatic stupor & coma, coma <1 hr w MCC                                                            
16 Neurology                                          86 Traumatic stupor & coma, coma <1 hr w CC                                                             
16 Neurology                                          87 Traumatic stupor & coma, coma <1 hr w/o CC/MCC                                                       
16 Neurology                                          88 Concussion w MCC                                                                                     
16 Neurology                                          89 Concussion w CC                                                                                      
16 Neurology                                          90 Concussion w/o CC/MCC                                                                                
16 Neurology                                          91 Other disorders of nervous system w MCC                                                              
16 Neurology                                          92 Other disorders of nervous system w CC                                                               
16 Neurology                                          93 Other disorders of nervous system w/o CC/MCC                                                         
16 Neurology                                          100 Seizures w MCC                                                                                       
16 Neurology                                          101 Seizures w/o MCC                                                                                     
16 Neurology                                          102 Headaches w MCC                                                                                      
16 Neurology                                          103 Headaches w/o MCC                                                                                    
16 Neurology                                          123 Neurological eye disorders                                                                           
16 Neurology                                          149 Dysequilibrium                                                                                       
17 Neurosurgery                                       20 Intracranial vascular procedures w PDX hemorrhage w MCC                                              
17 Neurosurgery                                       21 Intracranial vascular procedures w PDX hemorrhage w CC                                               
17 Neurosurgery                                       22 Intracranial vascular procedures w PDX hemorrhage w/o CC/MCC                                         
17 Neurosurgery                                       23 Cranio w major dev impl/acute complex CNS PDX w MCC or chemo implant                                 
17 Neurosurgery                                       24 Cranio w major dev impl/acute complex CNS PDX w/o MCC                                                
17 Neurosurgery                                       25 Craniotomy & endovascular intracranial procedures w MCC                                              
17 Neurosurgery                                       26 Craniotomy & endovascular intracranial procedures w CC                                               
17 Neurosurgery                                       27 Craniotomy & endovascular intracranial procedures w/o CC/MCC                                         
17 Neurosurgery                                       31 Ventricular shunt procedures w MCC                                                                   
17 Neurosurgery                                       32 Ventricular shunt procedures w CC                                                                    
17 Neurosurgery                                       33 Ventricular shunt procedures w/o CC/MCC                                                              
17 Neurosurgery                                       40 Periph & cranial nerve & other nerv syst proc w MCC                                                  
17 Neurosurgery                                       41 Periph/cranial nerve & other nerv syst proc w CC or periph neurostim                                 
17 Neurosurgery                                       42 Periph & cranial nerve & other nerv syst proc w/o CC/MCC                                             
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18 Obstetrics                                         765 Cesarean section w CC/MCC                                                                            
18 Obstetrics                                         766 Cesarean section w/o CC/MCC                                                                          
18 Obstetrics                                         767 Vaginal delivery w sterilization &/or D&C                                                            
18 Obstetrics                                         768 Vaginal delivery w O.R. proc except steril &/or D&C                                                  
18 Obstetrics                                         769 Postpartum & post abortion diagnoses w O.R. procedure                                                
18 Obstetrics                                         770 Abortion w D&C, aspiration curettage or hysterotomy                                                  
18 Obstetrics                                         774 Vaginal delivery w complicating diagnoses                                                            
18 Obstetrics                                         775 Vaginal delivery w/o complicating diagnoses                                                          
18 Obstetrics                                         776 Postpartum & post abortion diagnoses w/o O.R. procedure                                              
18 Obstetrics                                         777 Ectopic pregnancy                                                                                    
18 Obstetrics                                         778 Threatened abortion                                                                                  
18 Obstetrics                                         779 Abortion w/o D&C                                                                                     
18 Obstetrics                                         780 False labor                                                                                          
18 Obstetrics                                         781 Other antepartum diagnoses w medical complications                                                   
18 Obstetrics                                         782 Other antepartum diagnoses w/o medical complications                                                 
19 Ophthalmology                                      113 Orbital procedures w CC/MCC                                                                          
19 Ophthalmology                                      114 Orbital procedures w/o CC/MCC                                                                        
19 Ophthalmology                                      115 Extraocular procedures except orbit                                                                  
19 Ophthalmology                                      116 Intraocular procedures w CC/MCC                                                                      
19 Ophthalmology                                      117 Intraocular procedures w/o CC/MCC                                                                    
19 Ophthalmology                                      121 Acute major eye infections w CC/MCC                                                                  
19 Ophthalmology                                      122 Acute major eye infections w/o CC/MCC                                                                
19 Ophthalmology                                      124 Other disorders of the eye w  MCC                                                                    
19 Ophthalmology                                      125 Other disorders of the eye w/o  MCC                                                                  
20 Orthopedics                                        461 Bilateral or multiple major joint procs of lower extremity w MCC                                     
20 Orthopedics                                        462 Bilateral or multiple major joint procs of lower extremity w/o MCC                                   
20 Orthopedics                                        466 Revision of hip or knee replacement w MCC                                                            
20 Orthopedics                                        467 Revision of hip or knee replacement w CC                                                             
20 Orthopedics                                        468 Revision of hip or knee replacement w/o CC/MCC                                                       
20 Orthopedics                                        469 Major joint replacement or reattachment of lower extremity w MCC                                     
20 Orthopedics                                        470 Major joint replacement or reattachment of lower extremity w/o MCC                                   
20 Orthopedics                                        474 Amputation for musculoskeletal sys & conn tissue dis w MCC                                           
20 Orthopedics                                        475 Amputation for musculoskeletal sys & conn tissue dis w CC                                            
20 Orthopedics                                        476 Amputation for musculoskeletal sys & conn tissue dis w/o CC/MCC                                      
20 Orthopedics                                        477 Biopsies of musculoskeletal system & connective tissue w MCC                                         
20 Orthopedics                                        478 Biopsies of musculoskeletal system & connective tissue w CC                                          
20 Orthopedics                                        479 Biopsies of musculoskeletal system & connective tissue w/o CC/MCC                                    
20 Orthopedics                                        480 Hip & femur procedures except major joint w MCC                                                      
20 Orthopedics                                        481 Hip & femur procedures except major joint w CC                                                       
20 Orthopedics                                        482 Hip & femur procedures except major joint w/o CC/MCC                                                 
20 Orthopedics                                        483 Major joint & limb reattachment proc of upper extremity w CC/MCC                                     
20 Orthopedics                                        484 Major joint & limb reattachment proc of upper extremity w/o CC/MCC                                   
20 Orthopedics                                        485 Knee procedures w pdx of infection w MCC                                                             
20 Orthopedics                                        486 Knee procedures w pdx of infection w CC                                                              
20 Orthopedics                                        487 Knee procedures w pdx of infection w/o CC/MCC                                                        
20 Orthopedics                                        488 Knee procedures w/o pdx of infection w CC/MCC                                                        
20 Orthopedics                                        489 Knee procedures w/o pdx of infection w/o CC/MCC                                                      
20 Orthopedics                                        492 Lower extrem & humer proc except hip,foot,femur w MCC                                                
20 Orthopedics                                        493 Lower extrem & humer proc except hip,foot,femur w CC                                                 
20 Orthopedics                                        494 Lower extrem & humer proc except hip,foot,femur w/o CC/MCC                                           
20 Orthopedics                                        495 Local excision & removal int fix devices exc hip & femur w MCC                                       
20 Orthopedics                                        496 Local excision & removal int fix devices exc hip & femur w CC                                        
20 Orthopedics                                        497 Local excision & removal int fix devices exc hip & femur w/o CC/MCC                                  
20 Orthopedics                                        498 Local excision & removal int fix devices of hip & femur w CC/MCC                                     
20 Orthopedics                                        499 Local excision & removal int fix devices of hip & femur w/o CC/MCC                                   
20 Orthopedics                                        500 Soft tissue procedures w MCC                                                                         
20 Orthopedics                                        501 Soft tissue procedures w CC                                                                          
20 Orthopedics                                        502 Soft tissue procedures w/o CC/MCC                                                                    
20 Orthopedics                                        503 Foot procedures w MCC                                                                                
20 Orthopedics                                        504 Foot procedures w CC                                                                                 
20 Orthopedics                                        505 Foot procedures w/o CC/MCC                                                                           
20 Orthopedics                                        506 Major thumb or joint procedures                                                                      
20 Orthopedics                                        507 Major shoulder or elbow joint procedures w CC/MCC                                                    
20 Orthopedics                                        508 Major shoulder or elbow joint procedures w/o CC/MCC                                                  
20 Orthopedics                                        509 Arthroscopy                                                                                          
20 Orthopedics                                        510 Shoulder,elbow or forearm proc,exc major joint proc w MCC                                            
20 Orthopedics                                        511 Shoulder,elbow or forearm proc,exc major joint proc w CC                                             
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20 Orthopedics                                        512 Shoulder,elbow or forearm proc,exc major joint proc w/o CC/MCC                                       
20 Orthopedics                                        513 Hand or wrist proc, except major thumb or joint proc w CC/MCC                                        
20 Orthopedics                                        514 Hand or wrist proc, except major thumb or joint proc w/o CC/MCC                                      
20 Orthopedics                                        515 Other musculoskelet sys & conn tiss O.R. proc w MCC                                                  
20 Orthopedics                                        516 Other musculoskelet sys & conn tiss O.R. proc w CC                                                   
20 Orthopedics                                        517 Other musculoskelet sys & conn tiss O.R. proc w/o CC/MCC                                             
20 Orthopedics                                        533 Fractures of femur w MCC                                                                             
20 Orthopedics                                        534 Fractures of femur w/o MCC                                                                           
20 Orthopedics                                        535 Fractures of hip & pelvis w MCC                                                                      
20 Orthopedics                                        536 Fractures of hip & pelvis w/o MCC                                                                    
20 Orthopedics                                        537 Sprains, strains, & dislocations of hip, pelvis & thigh w CC/MCC                                     
20 Orthopedics                                        538 Sprains, strains, & dislocations of hip, pelvis & thigh w/o CC/MCC                                   
20 Orthopedics                                        559 Aftercare, musculoskeletal system & connective tissue w MCC                                          
20 Orthopedics                                        560 Aftercare, musculoskeletal system & connective tissue w CC                                           
20 Orthopedics                                        561 Aftercare, musculoskeletal system & connective tissue w/o CC/MCC                                     
20 Orthopedics                                        562 Fx, sprn, strn & disl except femur, hip, pelvis & thigh w MCC                                        
20 Orthopedics                                        563 Fx, sprn, strn & disl except femur, hip, pelvis & thigh w/o MCC                                      
20 Orthopedics                                        906 Hand procedures for injuries                                                                         
21 Otolaryngology                                     11 Tracheostomy for face,mouth & neck diagnoses w MCC                                                   
21 Otolaryngology                                     12 Tracheostomy for face,mouth & neck diagnoses w CC                                                    
21 Otolaryngology                                     13 Tracheostomy for face,mouth & neck diagnoses w/o CC/MCC                                              
21 Otolaryngology                                     129 Major head & neck procedures w CC/MCC or major device                                                
21 Otolaryngology                                     130 Major head & neck procedures w/o CC/MCC                                                              
21 Otolaryngology                                     131 Cranial/facial procedures w CC/MCC                                                                   
21 Otolaryngology                                     132 Cranial/facial procedures w/o CC/MCC                                                                 
21 Otolaryngology                                     133 Other ear, nose, mouth & throat O.R. procedures w CC/MCC                                             
21 Otolaryngology                                     134 Other ear, nose, mouth & throat O.R. procedures w/o CC/MCC                                           
21 Otolaryngology                                     135 Sinus & mastoid procedures w CC/MCC                                                                  
21 Otolaryngology                                     136 Sinus & mastoid procedures w/o CC/MCC                                                                
21 Otolaryngology                                     139 Salivary gland procedures                                                                            
21 Otolaryngology                                     146 Ear, nose, mouth & throat malignancy w MCC                                                           
21 Otolaryngology                                     147 Ear, nose, mouth & throat malignancy w CC                                                            
21 Otolaryngology                                     148 Ear, nose, mouth & throat malignancy w/o CC/MCC                                                      
21 Otolaryngology                                     150 Epistaxis w MCC                                                                                      
21 Otolaryngology                                     151 Epistaxis w/o MCC                                                                                    
21 Otolaryngology                                     154 Nasal trauma & deformity w MCC                                                                       
21 Otolaryngology                                     155 Nasal trauma & deformity w CC                                                                        
21 Otolaryngology                                     156 Nasal trauma & deformity w/o CC/MCC                                                                  
22 Plastic Surgery                                    463 Wnd debrid & skn grft exc hand, for musculo-conn tiss dis w MCC                                      
22 Plastic Surgery                                    464 Wnd debrid & skn grft exc hand, for musculo-conn tiss dis w CC                                       
22 Plastic Surgery                                    465 Wnd debrid & skn grft exc hand, for musculo-conn tiss dis w/o CC/MCC                                 
22 Plastic Surgery                                    573 Skin graft &/or debrid for skn ulcer or cellulitis w MCC                                             
22 Plastic Surgery                                    574 Skin graft &/or debrid for skn ulcer or cellulitis w CC                                              
22 Plastic Surgery                                    575 Skin graft &/or debrid for skn ulcer or cellulitis w/o CC/MCC                                        
22 Plastic Surgery                                    576 Skin graft &/or debrid exc for skin ulcer or cellulitis w MCC                                        
22 Plastic Surgery                                    577 Skin graft &/or debrid exc for skin ulcer or cellulitis w CC                                         
22 Plastic Surgery                                    578 Skin graft &/or debrid exc for skin ulcer or cellulitis w/o CC/MCC                                   
22 Plastic Surgery                                    622 Skin grafts & wound debrid for endoc, nutrit & metab dis w MCC                                       
22 Plastic Surgery                                    623 Skin grafts & wound debrid for endoc, nutrit & metab dis w CC                                        
22 Plastic Surgery                                    624 Skin grafts & wound debrid for endoc, nutrit & metab dis w/o CC/MCC                                  
22 Plastic Surgery                                    904 Skin grafts for injuries w CC/MCC                                                                    
22 Plastic Surgery                                    905 Skin grafts for injuries w/o CC/MCC                                                                  
23 Psychiatry                                         880 Acute adjustment reaction & psychosocial dysfunction                                                 
23 Psychiatry                                         881 Depressive neuroses                                                                                  
23 Psychiatry                                         882 Neuroses except depressive                                                                           
23 Psychiatry                                         883 Disorders of personality & impulse control                                                           
23 Psychiatry                                         884 Organic disturbances & mental retardation                                                            
23 Psychiatry                                         885 Psychoses                                                                                            
23 Psychiatry                                         886 Behavioral & developmental disorders                                                                 
23 Psychiatry                                         887 Other mental disorder diagnoses                                                                      
24 Rehabilitation                                     945 Rehabilitation w CC/MCC                                                                              
24 Rehabilitation                                     946 Rehabilitation w/o CC/MCC                                                                            
25 Rheumatology                                       545 Connective tissue disorders w MCC                                                                    
25 Rheumatology                                       546 Connective tissue disorders w CC                                                                     
25 Rheumatology                                       547 Connective tissue disorders w/o CC/MCC                                                               
25 Rheumatology                                       548 Septic arthritis w MCC                                                                               
25 Rheumatology                                       549 Septic arthritis w CC                                                                                
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25 Rheumatology                                       550 Septic arthritis w/o CC/MCC                                                                          
25 Rheumatology                                       553 Bone diseases & arthropathies w MCC                                                                  
25 Rheumatology                                       554 Bone diseases & arthropathies w/o MCC                                                                
25 Rheumatology                                       555 Signs & symptoms of musculoskeletal system & conn tissue w MCC                                       
25 Rheumatology                                       556 Signs & symptoms of musculoskeletal system & conn tissue w/o MCC                                     
25 Rheumatology                                       557 Tendonitis, myositis & bursitis w MCC                                                                
25 Rheumatology                                       558 Tendonitis, myositis & bursitis w/o MCC                                                              
25 Rheumatology                                       564 Other musculoskeletal sys & connective tissue diagnoses w MCC                                        
25 Rheumatology                                       565 Other musculoskeletal sys & connective tissue diagnoses w CC                                         
25 Rheumatology                                       566 Other musculoskeletal sys & connective tissue diagnoses w/o CC/MCC                                   
26 Substance Abuse                                    894 Alcohol/drug abuse or dependence, left ama                                                           
26 Substance Abuse                                    895 Alcohol/drug abuse or dependence w rehabilitation therapy                                            
26 Substance Abuse                                    896 Alcohol/drug abuse or dependence w/o rehabilitation therapy w MCC                                    
26 Substance Abuse                                    897 Alcohol/drug abuse or dependence w/o rehabilitation therapy w/o MCC                                  
27 Surg Oncology                                      582 Mastectomy for malignancy w CC/MCC                                                                   
27 Surg Oncology                                      583 Mastectomy for malignancy w/o CC/MCC                                                                 
27 Surg Oncology                                      820 Lymphoma & leukemia w major O.R. procedure w MCC                                                     
27 Surg Oncology                                      821 Lymphoma & leukemia w major O.R. procedure w CC                                                      
27 Surg Oncology                                      822 Lymphoma & leukemia w major O.R. procedure w/o CC/MCC                                                
27 Surg Oncology                                      823 Lymphoma & non-acute leukemia w other O.R. proc w MCC                                                
27 Surg Oncology                                      824 Lymphoma & non-acute leukemia w other O.R. proc w CC                                                 
27 Surg Oncology                                      825 Lymphoma & non-acute leukemia w other O.R. proc w/o CC/MCC                                           
27 Surg Oncology                                      826 Myeloprolif disord or poorly diff neopl w maj O.R. proc w MCC                                        
27 Surg Oncology                                      827 Myeloprolif disord or poorly diff neopl w maj O.R. proc w CC                                         
27 Surg Oncology                                      828 Myeloprolif disord or poorly diff neopl w maj O.R. proc w/o CC/MCC                                   
27 Surg Oncology                                      829 Myeloprolif disord or poorly diff neopl w other O.R. proc w CC/MCC                                   
27 Surg Oncology                                      830 Myeloprolif disord or poorly diff neopl w other O.R. proc w/o CC/MCC                                 
28 Surgery General                                    239 Amputation for circ sys disorders exc upper limb & toe w MCC                                         
28 Surgery General                                    240 Amputation for circ sys disorders exc upper limb & toe w CC                                          
28 Surgery General                                    241 Amputation for circ sys disorders exc upper limb & toe w/o CC/MCC                                    
28 Surgery General                                    255 Upper limb & toe amputation for circ system disorders w MCC                                          
28 Surgery General                                    256 Upper limb & toe amputation for circ system disorders w CC                                           
28 Surgery General                                    257 Upper limb & toe amputation for circ system disorders w/o CC/MCC                                     
28 Surgery General                                    264 Other circulatory system O.R. procedures                                                             
28 Surgery General                                    326 Stomach, esophageal & duodenal proc w MCC                                                            
28 Surgery General                                    327 Stomach, esophageal & duodenal proc w CC                                                             
28 Surgery General                                    328 Stomach, esophageal & duodenal proc w/o CC/MCC                                                       
28 Surgery General                                    329 Major small & large bowel procedures w MCC                                                           
28 Surgery General                                    330 Major small & large bowel procedures w CC                                                            
28 Surgery General                                    331 Major small & large bowel procedures w/o CC/MCC                                                      
28 Surgery General                                    332 Rectal resection w MCC                                                                               
28 Surgery General                                    333 Rectal resection w CC                                                                                
28 Surgery General                                    334 Rectal resection w/o CC/MCC                                                                          
28 Surgery General                                    335 Peritoneal adhesiolysis w MCC                                                                        
28 Surgery General                                    336 Peritoneal adhesiolysis w CC                                                                         
28 Surgery General                                    337 Peritoneal adhesiolysis w/o CC/MCC                                                                   
28 Surgery General                                    338 Appendectomy w complicated principal diag w MCC                                                      
28 Surgery General                                    339 Appendectomy w complicated principal diag w CC                                                       
28 Surgery General                                    340 Appendectomy w complicated principal diag w/o CC/MCC                                                 
28 Surgery General                                    341 Appendectomy w/o complicated principal diag w MCC                                                    
28 Surgery General                                    342 Appendectomy w/o complicated principal diag w CC                                                     
28 Surgery General                                    343 Appendectomy w/o complicated principal diag w/o CC/MCC                                               
28 Surgery General                                    344 Minor small & large bowel procedures w MCC                                                           
28 Surgery General                                    345 Minor small & large bowel procedures w CC                                                            
28 Surgery General                                    346 Minor small & large bowel procedures w/o CC/MCC                                                      
28 Surgery General                                    347 Anal & stomal procedures w MCC                                                                       
28 Surgery General                                    348 Anal & stomal procedures w CC                                                                        
28 Surgery General                                    349 Anal & stomal procedures w/o CC/MCC                                                                  
28 Surgery General                                    350 Inguinal & femoral hernia procedures w MCC                                                           
28 Surgery General                                    351 Inguinal & femoral hernia procedures w CC                                                            
28 Surgery General                                    352 Inguinal & femoral hernia procedures w/o CC/MCC                                                      
28 Surgery General                                    353 Hernia procedures except inguinal & femoral w MCC                                                    
28 Surgery General                                    354 Hernia procedures except inguinal & femoral w CC                                                     
28 Surgery General                                    355 Hernia procedures except inguinal & femoral w/o CC/MCC                                               
28 Surgery General                                    356 Other digestive system O.R. procedures w MCC                                                         
28 Surgery General                                    357 Other digestive system O.R. procedures w CC                                                          
28 Surgery General                                    358 Other digestive system O.R. procedures w/o CC/MCC                                                    
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28 Surgery General                                    405 Pancreas, liver & shunt procedures w MCC                                                             
28 Surgery General                                    406 Pancreas, liver & shunt procedures w CC                                                              
28 Surgery General                                    407 Pancreas, liver & shunt procedures w/o CC/MCC                                                        
28 Surgery General                                    408 Biliary tract proc except only cholecyst w or w/o c.d.e. w MCC                                       
28 Surgery General                                    409 Biliary tract proc except only cholecyst w or w/o c.d.e. w CC                                        
28 Surgery General                                    410 Biliary tract proc except only cholecyst w or w/o c.d.e. w/o CC/MCC                                  
28 Surgery General                                    411 Cholecystectomy w c.d.e. w MCC                                                                       
28 Surgery General                                    412 Cholecystectomy w c.d.e. w CC                                                                        
28 Surgery General                                    413 Cholecystectomy w c.d.e. w/o CC/MCC                                                                  
28 Surgery General                                    414 Cholecystectomy except by laparoscope w/o c.d.e. w MCC                                               
28 Surgery General                                    415 Cholecystectomy except by laparoscope w/o c.d.e. w CC                                                
28 Surgery General                                    416 Cholecystectomy except by laparoscope w/o c.d.e. w/o CC/MCC                                          
28 Surgery General                                    417 Laparoscopic cholecystectomy w/o c.d.e. w MCC                                                        
28 Surgery General                                    418 Laparoscopic cholecystectomy w/o c.d.e. w CC                                                         
28 Surgery General                                    419 Laparoscopic cholecystectomy w/o c.d.e. w/o CC/MCC                                                   
28 Surgery General                                    420 Hepatobiliary diagnostic procedures w MCC                                                            
28 Surgery General                                    421 Hepatobiliary diagnostic procedures w CC                                                             
28 Surgery General                                    422 Hepatobiliary diagnostic procedures w/o CC/MCC                                                       
28 Surgery General                                    423 Other hepatobiliary or pancreas O.R. procedures w MCC                                                
28 Surgery General                                    424 Other hepatobiliary or pancreas O.R. procedures w CC                                                 
28 Surgery General                                    425 Other hepatobiliary or pancreas O.R. procedures w/o CC/MCC                                           
28 Surgery General                                    579 Other skin, subcut tiss & breast proc w MCC                                                          
28 Surgery General                                    580 Other skin, subcut tiss & breast proc w CC                                                           
28 Surgery General                                    581 Other skin, subcut tiss & breast proc w/o CC/MCC                                                     
28 Surgery General                                    584 Breast biopsy, local excision & other breast procedures w CC/MCC                                     
28 Surgery General                                    585 Breast biopsy, local excision & other breast procedures w/o CC/MCC                                   
28 Surgery General                                    614 Adrenal & pituitary procedures w CC/MCC                                                              
28 Surgery General                                    615 Adrenal & pituitary procedures w/o CC/MCC                                                            
28 Surgery General                                    616 Amputat of lower limb for endocrine,nutrit,& metabol dis w MCC                                       
28 Surgery General                                    617 Amputat of lower limb for endocrine,nutrit,& metabol dis w CC                                        
28 Surgery General                                    618 Amputat of lower limb for endocrine,nutrit,& metabol dis w/o CC/MCC                                  
28 Surgery General                                    619 O.R. procedures for obesity w MCC                                                                    
28 Surgery General                                    620 O.R. procedures for obesity w CC                                                                     
28 Surgery General                                    621 O.R. procedures for obesity w/o CC/MCC                                                               
28 Surgery General                                    625 Thyroid, parathyroid & thyroglossal procedures w MCC                                                 
28 Surgery General                                    626 Thyroid, parathyroid & thyroglossal procedures w CC                                                  
28 Surgery General                                    627 Thyroid, parathyroid & thyroglossal procedures w/o CC/MCC                                            
28 Surgery General                                    628 Other endocrine, nutrit & metab O.R. proc w MCC                                                      
28 Surgery General                                    629 Other endocrine, nutrit & metab O.R. proc w CC                                                       
28 Surgery General                                    630 Other endocrine, nutrit & metab O.R. proc w/o CC/MCC                                                 
28 Surgery General                                    799 Splenectomy w MCC                                                                                    
28 Surgery General                                    800 Splenectomy w CC                                                                                     
28 Surgery General                                    801 Splenectomy w/o CC/MCC                                                                               
28 Surgery General                                    802 Other O.R. proc of the blood & blood forming organs w MCC                                            
28 Surgery General                                    803 Other O.R. proc of the blood & blood forming organs w CC                                             
28 Surgery General                                    804 Other O.R. proc of the blood & blood forming organs w/o CC/MCC                                       
28 Surgery General                                    853 Infectious & parasitic diseases w O.R. procedure w MCC                                               
28 Surgery General                                    854 Infectious & parasitic diseases w O.R. procedure w CC                                                
28 Surgery General                                    855 Infectious & parasitic diseases w O.R. procedure w/o CC/MCC                                          
28 Surgery General                                    856 Postoperative or post-traumatic infections w O.R. proc w MCC                                         
28 Surgery General                                    857 Postoperative or post-traumatic infections w O.R. proc w CC                                          
28 Surgery General                                    858 Postoperative or post-traumatic infections w O.R. proc w/o CC/MCC                                    
28 Surgery General                                    876 O.R. procedure w principal diagnoses of mental illness                                               
28 Surgery General                                    901 Wound debridements for injuries w MCC                                                                
28 Surgery General                                    902 Wound debridements for injuries w CC                                                                 
28 Surgery General                                    903 Wound debridements for injuries w/o CC/MCC                                                           
28 Surgery General                                    939 O.R. proc w diagnoses of other contact w health services w MCC                                       
28 Surgery General                                    940 O.R. proc w diagnoses of other contact w health services w CC                                        
28 Surgery General                                    941 O.R. proc w diagnoses of other contact w health services w/o CC/MCC                                  
28 Surgery General                                    981 Extensive O.R. procedure unrelated to principal diagnosis w MCC                                      
28 Surgery General                                    982 Extensive O.R. procedure unrelated to principal diagnosis w CC                                       
28 Surgery General                                    983 Extensive O.R. procedure unrelated to principal diagnosis w/o CC/MCC                                 
28 Surgery General                                    987 Non-extensive O.R. proc unrelated to principal diagnosis w MCC                                       
28 Surgery General                                    988 Non-extensive O.R. proc unrelated to principal diagnosis w CC                                        
28 Surgery General                                    989 Non-extensive O.R. proc unrelated to principal diagnosis w/o CC/MCC                                  
29 Trauma                                             183 Major chest trauma w MCC                                                                             
29 Trauma                                             184 Major chest trauma w CC                                                                              
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29 Trauma                                             185 Major chest trauma w/o CC/MCC                                                                        
29 Trauma                                             913 Traumatic injury w MCC                                                                               
29 Trauma                                             914 Traumatic injury w/o MCC                                                                             
29 Trauma                                             955 Craniotomy for multiple significant trauma                                                           
29 Trauma                                             956 Limb reattachment, hip & femur proc for multiple significant trauma                                  
29 Trauma                                             957 Other O.R. procedures for multiple significant trauma w MCC                                          
29 Trauma                                             958 Other O.R. procedures for multiple significant trauma w CC                                           
29 Trauma                                             959 Other O.R. procedures for multiple significant trauma w/o CC/MCC                                     
29 Trauma                                             963 Other multiple significant trauma w MCC                                                              
29 Trauma                                             964 Other multiple significant trauma w CC                                                               
29 Trauma                                             965 Other multiple significant trauma w/o CC/MCC                                                         
30 Urology                                            653 Major bladder procedures w MCC                                                                       
30 Urology                                            654 Major bladder procedures w CC                                                                        
30 Urology                                            655 Major bladder procedures w/o CC/MCC                                                                  
30 Urology                                            656 Kidney & ureter procedures for neoplasm w MCC                                                        
30 Urology                                            657 Kidney & ureter procedures forneoplasm w CC                                                          
30 Urology                                            658 Kidney & ureter procedures for neoplasm w/o CC/MCC                                                   
30 Urology                                            659 Kidney & ureter procedures for non-neoplasm w MCC                                                    
30 Urology                                            660 Kidney & ureter procedures for non-neoplasm w CC                                                     
30 Urology                                            661 Kidney & ureter procedures for non-neoplasm w/o CC/MCC                                               
30 Urology                                            662 Minor bladder procedures w MCC                                                                       
30 Urology                                            663 Minor bladder procedures w CC                                                                        
30 Urology                                            664 Minor bladder procedures w/o CC/MCC                                                                  
30 Urology                                            665 Prostatectomy w MCC                                                                                  
30 Urology                                            666 Prostatectomy w CC                                                                                   
30 Urology                                            667 Prostatectomy w/o CC/MCC                                                                             
30 Urology                                            668 Transurethral procedures w MCC                                                                       
30 Urology                                            669 Transurethral procedures w CC                                                                        
30 Urology                                            670 Transurethral procedures w/o CC/MCC                                                                  
30 Urology                                            671 Urethral procedures w CC/MCC                                                                         
30 Urology                                            672 Urethral procedures w/o CC/MCC                                                                       
30 Urology                                            673 Other kidney & urinary tract procedures w MCC                                                        
30 Urology                                            674 Other kidney & urinary tract procedures w CC                                                         
30 Urology                                            675 Other kidney & urinary tract procedures w/o CC/MCC                                                   
30 Urology                                            691 Urinary stones w esw lithotripsy w CC/MCC                                                            
30 Urology                                            692 Urinary stones w esw lithotripsy w/o CC/MCC                                                          
30 Urology                                            693 Urinary stones w/o esw lithotripsy w MCC                                                             
30 Urology                                            694 Urinary stones w/o esw lithotripsy w/o MCC                                                           
30 Urology                                            695 Kidney & urinary tract signs & symptoms w MCC                                                        
30 Urology                                            696 Kidney & urinary tract signs & symptoms w/o MCC                                                      
30 Urology                                            697 Urethral stricture                                                                                   
30 Urology                                            707 Major male pelvic procedures w CC/MCC                                                                
30 Urology                                            708 Major male pelvic procedures w/o CC/MCC                                                              
30 Urology                                            709 Penis procedures w CC/MCC                                                                            
30 Urology                                            710 Penis procedures w/o CC/MCC                                                                          
30 Urology                                            711 Testes procedures w CC/MCC                                                                           
30 Urology                                            712 Testes procedures w/o CC/MCC                                                                         
30 Urology                                            713 Transurethral prostatectomy w CC/MCC                                                                 
30 Urology                                            714 Transurethral prostatectomy w/o CC/MCC                                                               
30 Urology                                            715 Other male reproductive system O.R. proc for malignancy w CC/MCC                                     
30 Urology                                            716 Other male reproductive system O.R. proc for malignancy w/o CC/MCC                                   
30 Urology                                            717 Other male reproductive system O.R. proc exc malignancy w CC/MCC                                     
30 Urology                                            718 Other male reproductive system O.R. proc exc malignancy w/o CC/MCC                                   
30 Urology                                            722 Malignancy, male reproductive system w MCC                                                           
30 Urology                                            723 Malignancy, male reproductive system w CC                                                            
30 Urology                                            724 Malignancy, male reproductive system w/o CC/MCC                                                      
30 Urology                                            725 Benign prostatic hypertrophy w MCC                                                                   
30 Urology                                            726 Benign prostatic hypertrophy w/o MCC                                                                 
30 Urology                                            727 Inflammation of the male reproductive system w MCC                                                   
30 Urology                                            728 Inflammation of the male reproductive system w/o MCC                                                 
30 Urology                                            729 Other male reproductive system diagnoses w CC/MCC                                                    
30 Urology                                            730 Other male reproductive system diagnoses w/o CC/MCC                                                  
30 Urology                                            984 Prostatic O.R. procedure unrelated to principal diagnosis w MCC                                      
30 Urology                                            985 Prostatic O.R. procedure unrelated to principal diagnosis w CC                                       
30 Urology                                            986 Prostatic O.R. procedure unrelated to principal diagnosis w/o CC/MCC                                 
31 Vascular Surgery                                   34 Carotid artery stent procedure w MCC                                                                 
31 Vascular Surgery                                   35 Carotid artery stent procedure w CC                                                                  
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31 Vascular Surgery                                   36 Carotid artery stent procedure w/o CC/MCC                                                            
31 Vascular Surgery                                   37 Extracranial procedures w MCC                                                                        
31 Vascular Surgery                                   38 Extracranial procedures w CC                                                                         
31 Vascular Surgery                                   39 Extracranial procedures w/o CC/MCC                                                                   
31 Vascular Surgery                                   252 Other vascular procedures w MCC                                                                      
31 Vascular Surgery                                   253 Other vascular procedures w CC                                                                       
31 Vascular Surgery                                   254 Other vascular procedures w/o CC/MCC                                                                 
31 Vascular Surgery                                   263 Vein ligation & stripping                                                                            
32 Ventilator Support                                 3 ECMO or trach w MV 96+ hrs or PDX exc face, mouth & neck w maj O.R.                                  
32 Ventilator Support                                 4 Trach w MV 96+ hrs or PDX exc face, mouth & neck w/o maj O.R.                                        
32 Ventilator Support                                 207 Respiratory system diagnosis w ventilator support 96+ hours                                          
32 Ventilator Support                                 870 Septicemia or severe sepsis w MV 96+ hours (FY2009+)                                                 
33 Spinal Surgery                                     28 Spinal procedures w MCC                                                                              
33 Spinal Surgery                                     29 Spinal procedures w CC or spinal neurostimulators                                                    
33 Spinal Surgery                                     30 Spinal procedures w/o CC/MCC                                                                         
33 Spinal Surgery                                     453 Combined anterior/posterior spinal fusion w MCC                                                      
33 Spinal Surgery                                     454 Combined anterior/posterior spinal fusion w CC                                                       
33 Spinal Surgery                                     455 Combined anterior/posterior spinal fusion w/o CC/MCC                                                 
33 Spinal Surgery                                     456 Spinal fus exc cerv w spinal curv/malig/infec or 9+ fus w MCC                                        
33 Spinal Surgery                                     457 Spinal fus exc cerv w spinal curv/malig/infec or 9+ fus w CC                                         
33 Spinal Surgery                                     458 Spinal fus exc cerv w spinal curv/malig/infec or 9+ fus w/o CC/MCC                                   
33 Spinal Surgery                                     459 Spinal fusion except cervical w MCC                                                                  
33 Spinal Surgery                                     460 Spinal fusion except cervical w/o MCC                                                                
33 Spinal Surgery                                     471 Cervical spinal fusion w MCC                                                                         
33 Spinal Surgery                                     472 Cervical spinal fusion w CC                                                                          
33 Spinal Surgery                                     473 Cervical spinal fusion w/o CC/MCC                                                                    
33 Spinal Surgery                                     490 Back & neck proc exc spinal fusion w CC/MCC or disc device/neurostim                                 
33 Spinal Surgery                                     491 Back & neck proc exc spinal fusion w/o CC/MCC                                                        
34 Injuries/complications of prior care               907 Other O.R. procedures for injuries w MCC                                                             
34 Injuries/complications of prior care               908 Other O.R. procedures for injuries w CC                                                              
34 Injuries/complications of prior care               909 Other O.R. procedures for injuries w/o CC/MCC                                                        
34 Injuries/complications of prior care               919 Complications of treatment w MCC                                                                     
34 Injuries/complications of prior care               920 Complications of treatment w CC                                                                      
34 Injuries/complications of prior care               921 Complications of treatment w/o CC/MCC                                                                
35 Gynecology/Oncology                                734 Pelvic evisceration, rad hysterectomy & rad vulvectomy w CC/MCC                                      
35 Gynecology/Oncology                                735 Pelvic evisceration, rad hysterectomy & rad vulvectomy w/o CC/MCC                                    
35 Gynecology/Oncology                                736 Uterine & adnexa proc for ovarian or adnexal malignancy w MCC                                        
35 Gynecology/Oncology                                737 Uterine & adnexa proc for ovarian or adnexal malignancy w CC                                         
35 Gynecology/Oncology                                738 Uterine & adnexa proc for ovarian or adnexal malignancy w/o CC/MCC                                   
35 Gynecology/Oncology                                739 Uterine,adnexa proc for non-ovarian/adnexal malig w MCC                                              
35 Gynecology/Oncology                                740 Uterine,adnexa proc for non-ovarian/adnexal malig w CC                                               
35 Gynecology/Oncology                                741 Uterine,adnexa proc for non-ovarian/adnexal malig w/o CC/MCC                                         
35 Gynecology/Oncology                                754 Malignancy, female reproductive system w MCC                                                         
35 Gynecology/Oncology                                755 Malignancy, female reproductive system w CC                                                          
35 Gynecology/Oncology                                756 Malignancy, female reproductive system w/o CC/MCC                                                    
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